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ABSTRACT 
                                                
In Nigeria most of the populace relies heavily on medicinal plants for the treatment of 
malaria.  This thesis describes the investigation of the antiplasmodial properties of seven 
plants used in the traditional treatment of malaria in Nigeria.  The seven plants include 
Mangifera indica L., Citrus limon L. Burm.f, Musa sapientum L., Psidium guajava L., Carica 
papaya L., Cymbopogon citratus Staph, and Vernonia amygdalina Delile.  These plants are 
widely distributed in Nigeria and are used in Nigerian folk medicine to treat malaria and 
febrile illnesses.  After the initial screening of the antiplasmodial properties of these plants, 
two out of the seven plants were screened out due to poor activity.  In this study, 
investigation of plants which showed antiplasmodial activities ≥10µg/ml was not taken 
further. The two plants screened out were Mangifera indica and Musa sapientum while the 
five plants selected include Carica papaya, Citrus limon, Cymbopogon citratus, Psidium 
guajava, and Vernonia amygdalina. The in vitro antiplasmodial screening of these plants 
with selected solvents showed equipotent activity against the chloroquine sensitive (D10) 
and the chloroquine resistant (DD2) strains of P. falciparum and no in vitro cytotoxicity 
against the Chinese Hamster Ovarian cell line (CHO).   The selected five plants were 
further tested singly and in combination.  Bioassay-guided fractionation of C. papaya ethyl 
acetate fraction using a combination of solid phase extraction and HPLC yielded two 
polyunsaturated fatty acids.  GC-MS and NMR spectroscopic methods identified and 
characterized these compounds as 9,12,15-Octadecatrienoic acid (Compound 1) and 9,12- 
Octadecadienoic acid (Compound 2).  Both compounds showed IC50 <10 µg/ml against the 
D10 and DD2 strains of P. falciparum, but were not as potent as the parent ethyl acetate 
crude extract. 
   
Oral administration of 9,12,15-Octadecatrienoic acid (linolenic acid) and 9,12-
Octadecadienoic acid (linoleic acid) in vivo to mice infected with P. berghei using the 4-
day suppressive test showed an enhancement in parasite suppression when the two 
compounds were combined.  9,12,15- Octadecatrienoic acid was more potent (70% 
growth inhibition) but showed rapid recrudescence post treatment.  A bioavailability study 
using the methyl ester of 9,12,15- Octadecatrienoic acid (which has identical in vitro and 
 vii 
in vivo antimalarial activity) was performed to investigate its elimination rate from plasma.  
The results showed poor oral bioavailability and rapid elimination or metabolism.   
Evaluation of the elimination rate of 9, 12,15-Octadecatrienoic acid from plasma using 
the intravenous data showed a fast elimination from plasma with a half life of 
approximately 1 hour. Determination of in vivo antimalarial activity after intravenous 
administration of the compound is consistent with this finding.   In vivo experiments using 
dichloromethane extracts of C. citratus and V. amygdalina gave parasite inhibition of 
87.2% and 95.8%, respectively on day four post treatment.  A combination of these two 
extracts cured mice infected with P. berghei.   
      
It is apparent that experimental evaluation of herbal drugs for the treatment of malaria is 
rather impressive, however, only few are in the market and very few have reached 
clinical trials.  For instance quinine and artemisinin are products of medicinal plants used 
in the treatment of malaria.  Researchers need to take more active interest in the 
investigation and standardization of herbal drugs with potent antimalarial activity so as to 
be clinically effective and globally competitive. This study provided information on the 
efficacy and safety of selected Nigerian medicinal plants used in the traditional treatment of 
malaria. Since majority of the African populace patronize the traditional healers, the information 
from this study could serve as a guide to the antiplasmodial and toxicity properties of these plants.  
The information can also be used in the development of herbal remedies or for sources of lead 
compounds that can be developed into more favourable antimalarial compounds.  Studies using 
the murine model of PbA in (BALB/C x 57BL/6) have shown several features in common 
with human cerebral malaria. However findings from the use of these models may not be 
directly extrapolated to humans since the ideal animal model that could display precise 
clinical characteristics of human malaria is not yet available. The results can only be 
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TRADITIONAL MEDICINES, AND THE 








Malaria is one of the major infectious diseases responsible for the high rate of 
mortality and morbidity in developing countries. Malaria is caused by 
apicomplexan protozoan parasites which belong to the genus Plasmodium (Miller 
et al., 1994), and are known to contain apicoplast which is an indispensable 
organelle for the parasites‟ metabolic processes. The double membranous wall of 
this organelle evolved from a cyanobacterium through a secondary 
endosymbiotic process (McFadden et al., 1996).  Four species of Plasmodium 
parasites are known to cause infection in humans; Plasmodium falciparum, 
Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.  Plasmodium 
knowlesi, previously known to infect monkeys has been implicated in human 
infection as well (Singh et al., 2004).  Plasmodium falciparum is the most virulent 
parasite, and is highly incriminated in the global mortality rate.  It is the most 
common human parasite in Africa, and is seen in all malaria endemic regions of 
the world (WHO, 2005).  P. vivax is not common in Africa, and is mostly seen 
outside Africa (Mendis et al., 2001).  The prevalence of P. malariae is low, even 
in malaria endemic areas, while morbidity due to P. ovale is rarely reported 
(Mims et al., 2004, Mueller et al., 2007).   
 
Clinical manifestations of this disease include anaemia, and numerous 
complications, such as hypoglycaemia, cerebral malaria, metabolic acidosis, and 
respiratory distress. Common symptoms and complaints include fever, chills, 
convulsion, headache, nausea, loss of appetite, diarrhea, weakness, vomiting 
and malaise (English et. al., 1996, Biersmann et al., 2007, Legros et al., 2007).  
An annual global estimate of 300-500 million cases of malaria has been reported 
with a mortality of 2-3 million deaths, and children account for 1 million of these 
deaths (WHO, 1997; WHO, 2003). Children especially those less than five years 
old, and pregnant women, are at high risk to malaria (Desai et al., 2007).  Malaria 
during pregnancy can result in low birth weight thus affecting the chances of 
survival (Rowe and Kyes, 2004).  Anaemia and jaundice induced by malaria may 
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occur as a result of the rupture and lyses of red blood cells.  The disease can be 
fatal if not adequately treated in good time, and may also create room for 
opportunistic infections (Snow et al., 2005; WHO, 2005).   
 
1.1.1 History of Malaria 
 
Malaria has been noted for more than 4,000 years and it is believed that this 
disease has greatly influenced human populations and history (CDC, 2010). 
An earlier assumption was that malaria arose from fetid marshes, suggesting 
„mal aria‟ which means bad air.  This belief that malaria fevers were caused by 
miasmas rising from swamps persisted, and it is widely held that the word 
malaria comes from the Italian mal‟aria meaning bad air.  The Italians used this 
term to describe the relationship between intermittent fever and exposure to 
marsh air (CDC, 2010). The name is traceable to the belief that the accumulation 
of bad stagnant water initiates infection (Kondrasen et. al., 2004).  Prior to this 
time, the disease was thought to be of supernatural origin, as those infected were 
said to have offended their gods.  The first person to correct this erroneous 
assumption was Hippocrates (CDC, 2010).  He related the infection and its 
manifestations to seasonal and geographical differences (CDC, 2010).  
  
Malaria incidences date back to 6000 years in Egypt and China and 1600 BC in India 
(WHO, 1986).  Malaria is geographically specific, however, the mass movements of 
migrant workers, refugees and non-immune travellers across borders have largely 
contributed to the global spread of the disease (Rooth, 1992).  Available records stated 
that between 2,500 and 2,000 years ago, malaria reached the shores of the Mediterranean 
sea, while its presence in northern Europe  was about 1,000 to 500 years ago (Carter and 
Mendis 2002).  It is believed that the Europeans and the West Africans were 
incriminated for introducing malaria into the new world at the end of the 15
th
 century 
AD.  P. falciparum was likely to have reached the Americans through the African slaves 
who were brought in by the Spanish colonial masters (Carter and Mendis 2002). More 
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than one-half of the world‟s population was at risk of malaria by the 19th century, 
and the mortality rate was also increasing at an alarming rate.  
 
The search for the cause of malaria was however heightened by the discovery of 
bacteria by Antoni van Leeuwenhoek in 1676.  This search was further intensified 
by the development of the germ theory of infection, by Louis Pasteur and Robert 
Koch in 1878-1879, and the incrimination of microorganisms as the causative 
agent of infectious diseases (Cox, 2010).  Laveran, a military doctor, in his work 
in Algeria in 1889, identified the etiologic agent as a protozoan parasite (CDC, 
2004). Eight years later, the female Anopheles mosquito was identified as the 
vector of these protozoan parasites by Ross (CDC, 2004; CDC, 2010).  In 1898 
the Italian malariologists, Giovanni Battista Grassi, Amico Bignami, Giuseppe 
Bastianelli, Angelo Celli, Camillo Golgi and Ettore Marchiafava demonstrated 
conclusively that human malaria was also transmitted by anopheline mosquitoes 
(CDC, 2010).  Two years after, Giovanni Batista Grassi and Raimondo Filetti 
were the first to introduce the names of two human malaria parasites as 
Plasmodium vivax and P. malariae (CDC, 2010).  In 1948 Henry Shortt and Cyril 
Garnham discovered that malaria parasites undergo pre-erythrocytic stages in 
the liver before entering the blood stream.  Wojciech Krotoski in 1982 reported 
the presence of the dormant stages in the liver as the final stage in the life cycle 
of the parasite (Cox, 2010; CDC, 2010) 
 
At this juncture, a clearer picture of the causative agent and transmission pattern 
started unfolding.  This understanding enhanced the development and 
implementation of malaria control measures. Efforts were made to control the 
vectors by draining the swamps and water bodies where they breed, and also by 
using kerosene or oil to destroy their developmental stages (Burton, 1967).  
Spreading kerosene on mosquito breeding sites was one the first strategy 
adopted in the control of malaria (Burton, 1967). Preventive measures were 
advocated such as the use of insecticide-treated bednets, repellents and protective 
clothing. Unfortunately, total prevention of malaria has been set back, due to the 
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development of resistance by vector species to insecticides such as 
dichlorodiphenyltrichloroethane (DDT) (Subbarao, 1988; Baird, 2000; Corbel et al., 
2007).  
 
The earliest recorded treatment for malaria dates back to 1600.  This was 
traceable to the native Peruvian Indians who used the bitter bark of the 
Cinchona tree to treat fever (CDC, 2010).  The quinine from Cinchona tree 
extracts was the mainstay of treatment until the Chinese developed another 
potent drug from the worm wood Artemisia annua L. (CDC, 2010).  Artemisinin 
(Qinghaousin) was first isolated in 1971 from the aerial parts of Artemisia 
annua L., which is a Chinese herb used in the traditional treatment of fever and 
malaria (Klayman, 1985; Li and Rieckmann, 1992).  
 
The therapeutic effectiveness of artemisinin is limited by a number of factors 
such as short half-life, neurotoxicity, and low solubility which affects its 
bioavailability (Balint, 2001). However, attempts to improve the pharmacokinetic 
parameters of artemisinin have led to the development of several semi-synthetic 
derivatives; dihydroartemisinin, artemether, arteether and artesunate, which are 
less toxic and have shown greater potency with enhanced stability (Van Agtmael 
et al., 1999).   
 
There was a recorded success in eradication of malaria in Europe and North 
America (WHO, 2005). However, the issue of „imported malaria‟ from migrant 
workers and tourists from a number of endemic regions is still an issue of 
concern.  The emergence of drug resistant parasites has further heightened 
this fear.  Resistance of parasites to chloroquine was first reported in East 
Africa in 1978 (Fogh et al., 1979).  Huong et al., (2001) reported a decrease in 
the sensitivity to artemisinin.  WHO recommended the use of artemisinin 
combination therapies as a way to fight parasite resistance to already existing 
antimalarials (WHO, 2006). 
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1.1.2 Transmission of malaria 
Transmission of the parasite to man is achieved by the intravenous inoculation of 
sporozoites from an infected female anopheles mosquito. These sporozoites are 
themselves not pathogenic, but are rather a transient phase, whose survival and 
development are necessary for the completion of the parasite‟s life cycle and 
subsequent transmission.   The sporozoites invade the hepatocytes where they 
multiply rapidly for about a week or two, releasing thousands of merozoites.  
Every successful sporozoite has the potential of producing about 20,000 
merozoites (Ménard, 2000).  The merozoites rupture the hepatic cells and invade 
the erythrocytes where they undergo proliferation and invade more erythrocytes.  
This process of replication asexually continues, but some differentiate into 
gametocytes.  These gametocytes are the stages ingested by the female 
anopheles mosquito in the course of its blood meal.  The parasite develops in the 
mosquito vector for about 2 weeks.  The ingested gametocytes form gametes 
which fuse in the midgut giving rise to zygotes.  The zygotes in turn develop into 
ookinetes which penetrate the gut wall to develop into a form known as the 
oocysts.  The oocytes burst and releases sporozoites which migrate to the 
salivary gland of the mosquito vector. As the mosquito takes a blood meal which 
is necessary for its reproductive process, the sporozoites are injected into the 
new host thereby maintaining transmission.  
 
An effective and efficient transmission requires the presence of the parasite and 
human host, and an anthropophylic (bite humans) vector. The species A. 
gambiae have a unique anthropophilic tendency. Effective transmission requires 
endophagic or exophagic (indoor and outdoor biting) and an exophilic (rest 
outside) female Anopheles mosquito (WHO, 2004).  Female mosquitoes need a 
blood meal to produce eggs (Moorthy et al., 2004).  Occasionally, malaria can be 
transmitted congenitally or through blood transfusion, organ transplantation, or 
through shared needles and these transmission routes do not require a vector 
since the transmission is direct.  The parasite extrinsic cycle shortens in a 
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warmer environment, while temperatures below 16ºC adversely affect the 
extrinsic cycle of malaria parasites and the biting activity of vector species 
(Colluzi, 1999).  This may partly explain the fact that the disease is endemic in 
tropical and warmer regions of the world.  The concern about global warming and 
its consequences as regards malaria prevalence and distribution may not be 
unconnected to the observed temperature effects. Hot weather could also cause 
people to sleep outdoors, without bed nets, and even to expose their skin to 
mosquitoes (CDC, 2010).  The rate of transmission in humans could be 
determined by genetic composition of the populace, for instance carriers of sickle 
cell anaemia are usually not prone to malaria attack (Carter and Mendis 2002).  
Some innate, inborn or acquired immunity may also cause variations in a given 
population.  The vectoral capacity and preferences for biting and resting are also 
contributing factors to these variations (WHO, 2004; CDC, 2010).   
 
1.1.3 Life Cycle of malaria parasite 
The life cycle of malarial parasites involves the asexual and the sexual stages 
of development.  The parasites have obligatory phases in the human host and 
the mosquito vector (Stanley, 1997).  The pre-erythroctic and the erythrocytic 
stages are basically the two phases in the parasites life cycle (Fig: 1.1.3.1)                    
                               
 
 





                  
Fig 1.1.3.1 Life cycle of malaria parasite  
(Source:http//www.dpd.cdc.gov/dpdx) 
 
1.2 Malaria Epidemiology 
Epidemiology may be defined as that branch of science which studies the state 
of health or health related incidence and distribution in a given population and 
the application of the unraveled information to control health problems (Last, 
2001).  Malaria epidemiology is geared towards an in-depth understanding of 
the disease distribution and transmission patterns which are relevant to the 
control of malaria.  Malaria is said to be endemic in Africa due to the observed 
consistency in the pattern of Plasmodium transmission in humans over a 
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number of years.  The global epidemiology spectrum of malaria as recorded in 
several studies showed varying transmission intensities and patterns (Snow et 
al., 2005).  It is evident from these studies that the intensity of transmission 
differs within continents and within countries (Snow et al., 2005, Guerra et al., 
2006).   Stable malaria, as is the case in sub-tropical and tropical regions is 
characterized by a genetically diverse parasite surface antigen (Bull et al., 
1998).  
 
 The rate at which parasites develop resistance to the already existing 
antimalarial drugs is daunting. The genetic diversity and mutations of these 
parasite populations could be some factors contributing to parasite resistance 
(Jianbing et al., 2003).  Genetic diversity is inevitable in regions of high 
Plasmodium transmission such as Africa and Papua New Guinea (PNG) where 
multiple infections are the order of the day (Babiker et al., 1994; Paul et al., 
1995). This provides more avenues for the spread of alleles which favour the 
parasite‟s population (Babiker et al., 1994; Paul et al., 1995).   Areas such as 
PNG experience local variations in malaria epidemiology between villages and 
even between households within the same village (Cattani et al., 1986).  The 
varying patterns of malaria epidemiology across the globe could be attributed to 




1.3 Malaria Pathogenesis 
The human hosts, as well as the parasite species, have evolved various 
physiological characteristics and behavioural traits that seem to favour the 
disease pathology (CDC, 2010,).  An in-depth understanding of these variations 
in man and parasite is vital for the control and subsequently eradication of 
malaria.  The parasite‟s life cycle gives a good idea of the transmission process 
in the human host.  The exo-erythrocytic stage is not responsible for infection 
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(Miller et al., 1994).  The mosquito infective stage is a product of the 
erythrocytic cycle.  The size of the parasite population is to a large extent 
amplified, resulting in differentiation into gametocytes.   Over 20 merozoites are 
produced by a single mature parasite of P. falciparum within a time frame of 48 
hours (Miller et al., 2002).  This Plasmodium parasite, as an apicomplexan 
parasite, possesses three organelles; the rhoptries, micronemes and dense 
granules on the apical or invasive end of the parasite.  The secretions from the 
apical organelles, post contact with the red blood cells, induce their exposure to 
antibodies (Miller et al., 2002).  The receptors located in the micronemes, 
rhoptries and cell surface initiate the invasion of the liver by the sporozoites and 
red blood cells by the merozoites (Adams et al., 1990).   Some complications 
associated with P. falciparum include anaemia, hypoglycaemia, cerebral 
malaria, renal failure, and noncardiac pulmonary edema (Miller et al., 1994).  
The most frequent complaints and symptoms include fever, chills, nausea, 
headache, and weakness, loss of appetite, diarrhea, vomiting and malaise 
(English et al., 1996., Biersmann et al., 2007., Legros et al., 2007).  In various 
organs, like the heart, lungs, liver, kidney, subcutaneous tissues, brain and 
placenta, parasite sequestrations have been observed, and cerebral malaria 
could occur as a result of the parasites sequestered in the brain, which may 




1.4 Global Malaria situation 
Malaria has been one of the world‟s most devastating parasitic diseases, and 
the parasite incriminated is Plasmodium falciparum (Fisher and Bialek, 2002).  
Malaria is an issue of global public health concern.  More than 40% of the 
world‟s population lives in malaria endemic regions.  An estimated 300-500 
million new clinical cases are reported annually (Snow et. al., 2005). Those at 
risk of malaria each year are about 3.2 billion people.  
 
 




Fig 1.4.1 Map showing the malaria risk countries. World malaria report 
2005: Global distribution of malaria transmission risk. 
Source:   http://www.rollbackmalaria.org/wmr2005/html/map1.htm 
 
 The devastation caused by this disease is alarming, particularly in sub-Saharan 
Africa where more than 90% of deaths occur (WHO, 2005).  Globally, the two 
regions with the highest malaria transmission intensity are Oceania and sub 
Saharan Africa.  In sub-Saharan Africa, a child dies of malaria every second 
(Snow et al., 2005).  This is a death toll which exceeds the mortality rate from 
AIDS.  It also constitutes a severe threat in some regions of South–East Asia, 
Oceania, Haiti, the Amazon basin of South America, and the Dominican Republic 
(CDC, 2010).  P. vivax is mostly prevalent in Central America, the Middle East, 
and India (CDC, 2010).     
 
Among the high risk individuals are children less than 5 years old (Breman, 
2001).  They are chronic victims of this pandemic. The debilitating effect of 
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malaria in the very young populace is disheartening.  That many children die 
from the disease is not questionable, but it is also important to realize that even 
in those surviving, a lot may have been damaged, altered or malfunctioning due 
to hypovitaminosis arising from the several bouts of infection in this populace.  It 
has also been observed that malaria infection causes poor school attendance 
and impairs the physical and intellectual development of affected individuals 
(Sachs and Malaney 2002).  Though a host of other factors contribute to the 
endemicity of this disease, the regions mostly affected are the poorer regions of 
the world.  It is also important to realize that the low immunity of this age group to 
infection, as well as the compromised immunity of pregnant women, further 
aggravates the situation.  Pregnant women, especially those in their first 
trimester or the primigravidae and the unborn foetus are adversely affected as 
parasites are sequestered in their placenta (Rowe and Kyes, 2004).  Another 
group of individuals at high risk are non-immune travelers, refugees and migrant 
workers entering endemic regions (Rooth, 1992).  The movements of refugees, 
migrant workers and non-immune travellers across borders have also 
encouraged the global spread of the disease (Rooth, 1992). 
 
The global transmission pattern of malaria some decades ago highlighted the 
success of antimalarial control measures in the temperate regions of the world 
and the increased prevalence of the disease burden in the tropics.  However, the 
current global warming is threatening the stability of these temperate regions.   
 
 
1.5 State of the pandemic in Nigeria 
Malaria is endemic in Nigeria.  Malaria is common usually in malnourished 
populations, especially children and low class populations (Sanjoaquin and 
Molyneux 2009). It is recorded that the dominant parasite incriminated is P. 
falciparum, and on rare occasions P. vivax (Mendis et al., 2001; Carter and 
Mendis 2002).  The dominant vector is the Anopheles gambiae, and to a less 
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extent A. funestus (WHO, 2004).  According to WHO (2007) statistical data, the 
Nigerian population is about 149,000,000, and the number at risk is about 
144,600,000.  About 97% of the population lives in areas at risk of malaria.  
Nigeria records an annual death rate of 300,000 due to malaria, and of this 
number 25% are infant-related mortality, 30% child-related mortality and 11% 
maternal mortality.  In health facilities, about 60% of the outpatient cases are 
due to malaria (WHO statistics, 2007).  It was estimated that an individual can 
suffer from as many as four bouts of malaria annually (WHO, 1995).  The 
frequency is rapidly increasing due to onset of resistance by parasite species to 
existing antimalarial drugs (WHO, 2000).  Nigeria recorded a progressive 
increase in the incidence throughout the country, ranging from 1.12 million in 
1990 and 2.25 million by 2000 and 2.61 million in 2003 (WHO, 2005).  The 
economic burden of the disease in Nigeria is disheartening.  Work 
performance, effectiveness and commitment are compromised.  School 
attendance records a high level of truancy due to malaria. Increase in medical 
expenditures and bills are alarming.  This generally leaves the populace 
illiterate, poorer, weaker and less productive. 
 
 
1.6 Traditional medicinal practices in Nigeria 
Nigeria is made up of diverse cultural entities that embody different ethnic 
groups.  These locations are geographically described as the north; where the 
Hausas and the Fulanis concentrate, the southwest is made up of the Yorubas 
and the southeast the Igbos.  There are also other sizable groups that live in 
these locations.  They include the Kanuri in the north, the Edo, Efik, and 
Urhobo in the south, and the Tiv in the center.  The oldest component of the 
health system in Nigeria is made up of traditional healers and birth attendants.  
They are the major providers of primary health care.  The practices of these 
healers culturally meet the needs and the expectations of the patients (Iwu, 
1994).  A good number of Nigerians hold on tenaciously to the belief that the 
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remedies used by the traditional healers are safe and more tolerated by the 
body (De Smet, 1991).   They emphasize the availability, affordability, 
effectiveness and reproducibility of these herbal remedies.   
 
Traditional medicine, as it is popularly called, is a cultural heritage (Kaou et al., 
2008) of various communities in most countries of the world.  It encompasses 
different kinds of folk medicine, unconventional medicine, and indeed any kind 
of treatment regimen that is acknowledged and practiced by a community or 
ethnic group. It embraces the totality of indigenous knowledge, attitudes, beliefs 
and practices, of a locality or region which they apply in diagnosis, prevention 
and treatment of diseases. This depends absolutely on practical experiences 
and observations which run across the generations, whether acquired, learnt, 
or by instinct.  
 
Nigeria is a multi-cultural country with diverse flora, fauna, and traditions to take 
care of its teeming population. Herbal remedies and preparations are used by 
traditional healers in the treatment of disease conditions, including malaria 
(Farnsworth and Morris, 1976).  The traditional healers and birth attendants in 
Nigeria have a great diversity of plants to explore in their practice.  Nigeria has 
two major seasonal variations; the rainy and dry season.  The distribution of 
plants in Nigeria vary because of the diverse ethnic groups with their diverse 
geographical locations and because of seasonal variations. Differences also 
exist in the method of using or applying these herbal remedies. Such 
diversities, however, are traceable to the cultures and traditions of the various 
locations.  The diversity of plants used in traditional medicine varies with culture 
and tradition (Farnsworth and Morris, 1976).  
 
The traditional medicinal practitioners use plants singly or in combination in 
their formulations (Igoli et al., 2005).  Decoctions, infusions, macerations and 
inhalations are some of the ways these herbal remedies are taken (Igoli et al., 
2005).  Public health education and community enlightenment programmes 
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could help to reduce the level of illiteracy in Nigeria and may, in the long run 
convince the traditional healers on proper dosage formulations.  It could be 
possible to reduce the number of individuals who are carriers of the disease, 
but who are asymptomatic, through the synergistic application of control 
methods.  
 
1.7 Malarial Control Strategies 
1.7.1 Targets to vectors 
 
Vector control is an effective way to prevent malaria transmission (WHO, 2004). 
Indoor residual spraying (IRS), insecticide treated nets (ITN), ultra-low volume 
sprays and the screening of houses are ways to fight the vectors.  Combination 
of IRS and ITN could be of immense help in the management of insecticide 
resistance. However, effective application of IRS depends on adequate 
professional vector control services, good planning and a good understanding of 
the activities of the vector species (Rowland, 1999; WHO, 2006). There is no 
doubt that a certain degree of success has been recorded through these control 
mechanisms.  However, this requires that the vectors feed and rest indoors.  The 
disadvantages inherent in these approaches include the fact that exophagic 
vectors are selectively excluded, spraying may adversely affect humans, since 
adequate information on the best insecticide is insufficient.  Moreso, there 
availability of human and financial resources to sustain control effort is limited 
(WHO, 2004).  Significant increase in parasite resurgence could be linked to a 
decrease in the indoor residual spraying for vector control.  
 
Larvicides can be effective by killing larvae, or blocking their breathing trumpets 
as is observed when kerosene is poured on the stagnant water surfaces (CDC, 
2010).  The challenge here is all too obvious since the kerosene is not supplied 
free of charge.  There is a limit to which method could be sustained.  This is also 
the situation with using DDT, insecticide treated nets (ITNs), pyrethroids and 
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organophosphates (WHO, 2004).  Most of the populace often resorts to domestic 
sanitation, water drainage and naturally-induced biological control measures 
which, though necessary, are grossly inadequate to control vectors.  The oil 
extracted from Citrus limon L. Burm.f. has been shown to be effective against 
mosquito larva (Zayed et al., 2009).  This is in line with the recommendations in 
favour of plants as alternative sources to control mosquito vector due to their 
bioactive chemical composition (Park et al., 2002).  The introduction of 
genetically- modified mosquitoes has been proposed, but the speed of replication 
and distribution may be inadequate to counterbalance the naturally existing 
vector species (WHO, 2004).  The speed of replication could be hindered by 
adaptation and survival of the fittest.  A new population will have to develop a 
special means of survival for sustainability.  This more often than not is met with 
challenges. Health education and community involvement are indispensable 
tools for an effective use and application of existing control measures. 
 
1.7.2 Targets to Humans 
This approach is aimed at reducing human vector contact (Rowland et al., 
2004a).  Use of insecticide treated nets (ITNs), repellents, protective clothing, 
house screening or larval control are some of the ways to achieve this. Insect 
repellants such as DEET (N,N-diethyl-3-toluamide) are also effective (Rowland 
et al., 2004a, Rowland et al., 2004b).  Public health education, community 
involvement and enlightenment campaigns are vital tools to achieving the set 
objective.  The difficulties observed in such a method include the issue of 
keeping individuals indoors, due to hot weather and since these are people 
engaged in work which necessitates leaving the temporary comfort of their 
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1.7.3 Targets to parasites 
This aims at destroying or killing the parasites.  One major way of doing this is 
by the use of chemotherapeutic agents (Dorsey, 2000).  In the case of malaria, 
antimalarial or antiplasmodial agents are administered.  Most of the populace in 
Nigeria and Sub-Saharan Africa depend solely on the herbal preparations from 
the traditional healers in the treatment of various ailments, including malaria 
(Igoli et al., 2005).  Only very few of the populace visit a local health centre for 
treatment. 
 
1.8 Challenges to Malaria Control Efforts 
1.8.1 Environmental factors 
There are inherent factors prevalent in a community or region.  Such factors 
include climatic factors and geographical locations or locality, the type of soil, 
the pattern of rainfall, speed of wind, temperature, altitude, water salinity and 
vegetation.  These, in one way or the other, affect control measures and are 
natural factors which humans are unable to alter, for instance temperature 
variation which is a factor in explaining the geographical distribution of malaria 
(Sachs and Malaney 2002). 
 
1.8.2 Factors attributable to vectors 
This refers to the vectoral capacities and their longevity.  Plasmodium falciparum 
sporogony fails to occur at low temperatures, while high temperatures favour 
their transmission (Abeku et al., 2003).  Optimal temperature conditions between 
20ºC-30ºC are required for effective transmission of the Plasmodium parasites.  
Below this temperature, transmission is delayed or altered, as parasites do not 
develop at temperatures below 16ºC (Sachs and Malaney 2002).  Some vector 
species suspend biting activity at very low temperatures (Colluzi, 1999) while 
others have, over time, developed some adaptations to survival.  Some are 
endophagic, while others are exophagic (WHO, 2004).  Endophilic and 
endophagic habits are genetically induced measures to vectoral survival.  The 
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success of indoor residual spraying (IRS) relies heavily on the mosquitoes 
feeding and resting indoors (WHO, 2004).  However, this is not the habit of most 
mosquitoes and the pyrethroid used in spraying sooner or later wards them off.  
Factors that are favourable to vectors encourage transmission of parasites to 
humans. Vectoral resistance and behaviour adversely affect control measures 
(WHO, 2004; CDC, 2010).  Resistance may be due to detoxification of insecticide 
by enzymes or by mutation on its target site; sodium channels for DDT and 
pyrethroids and acetylcholinesterase for organophosphates (CDC, 2010).   
Similarly, the exophilic species which prefer to rest outdoors are less likely to 
acquire lethal doses of insecticides sprayed on the walls, when comared to the 
endophillic species which rest inside (CDC, 2010). 
 
1.8.3 Factors attributable to Humans 
Human activities in a given area are also important factors that oppose control 
efforts, e.g. deforestation, reforestation. Agricultural practices, such as dams, 
canals and irrigation contribute to the heavy burden of malaria in affected 
regions.  Land cover and land use play a great role in malaria transmission 
(Hay et al., 2000). Global warming, urbanization and its consequences, 
especially in developing countries, pose challenges to control mechanisms.  
Knowledge, attitudes and perceptions of the populace could make control 
feasible or difficult.   Non-compliance with adequate treatment modalities 
sustains prevalence and encourages resistance.  It heightens the epidemiology 
and pathogenicity of infection.  Lack of an adequate and sustained supply of 
DDT and ITN to the populace poses its hindrance (CDC, 2010).  Poverty is a 
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1.8.4 Factors attributable to parasites 
The major concern in this regard is the resistance of parasites to existing 
antimalarial drugs (Jianbing et al., 2003).  .  The rate at which these parasites 
develop resistance is alarming.  Chloroquine, which was the mainstay of 
treatment, has met with parasite resistance (Jianbing et al., 2003).  The relief 
from artemisinin, its derivatives and combinations are seriously threatened by 
several treatment failures recorded in some regions.  The first case of treatment 
failure of artemether-lumefantrine has been documented in a Japanese traveler 
(Mizuno et al., 2009). Reduced sensitivity to artemisinin has been reported in 
China and Vietnam (Huong et al., 2001, Yang et al., 2003).  There is therefore 
an urgent need for new and effective antimalarials. 
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1.8.5 The urgent need for new antimalarials 
The need to employ new, effective and sustainable strategies in the 
development of new antimalarials is of utmost importance.  Chloroquine 
resistance was first documented in East Africa as far back as 1978 among non-
immune travelers (Fogh et al., 1979). Subsequently, similar reports emanated 
from the rest of tropical Africa (Trape, 2001) where chloroquine has been the 
first line treatment for malaria (Trape et al., 2002).  Sulphadoxinepyrimithamine 
(SP) is another widely used antimalarial.  It is relatively cheap and available, 
but has, unfortunately, been met with resistance.  There have been cases 
reported on the therapeutic failures of SP in many areas in Asia, South America 
and Africa (Plowe, 2003). Treatment failures have been recorded with 
artemisinin combination treatments (ACTS) in various regions (Jambou et al., 
2005; Rogers et al., 2009).   
 
 The conditions that favour the development of drug resistance by parasites 
include the absence of a variety of drug treatment options, high migration levels 
of population, significant under dosing, the presence and usage of adulterated 
drugs, prescription delivery by non-qualified personnel and non- compliance 
with treatment.  Little wonder that the endemicity of malaria, and the resistance 
to existing drugs, affects the poorer, underdeveloped, and illiterate regions of 
the world.  There is a need to identify effective antimalarials to which the 
parasites are unlikely to develop resistance.  One of the best ways of achieving 
this is by the application of combination therapy for malaria. 
 
1.9 Malaria combination therapy 
The use of combination therapy to fight drug resistance was proposed in 1955 
(Covell et al., 1955). This was further advocated and emphasized by Peters in 
1970, and was also reinforced by White and Olliaro (1996).  Recently, the 
World Health Organization (WHO, 2001) has recommended the use of 
artemisinin combination treatments (ACTs) to fight the issue of resistance, and 
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as a first line treatment in countries where parasite resistance has severely 
compromised the therapeutic efficacy of drugs already in use (WHO, 2007). 
The combination of artesunate (AS) + amodiaquine (AQ) has currently been 
adopted as a first line treatment in 15 African countries (WHO, 2006). Excellent 
clinical responses and tolerability were recorded in Senegal through the use of 
AS+AQ, AS+ mefloquine (MQ) and AQ+SP in the treatment of uncomplicated 
falciparum malaria (Faye et al., 2007).  However, a further study in children 
from Burkina Faso reported the onset of minor discomforts which disappeared 
at the completion of dosage (Barennes et al., 2004).  Combination therapy is an 
effective means to the optimal control of malaria in developing countries 
(Guerin et al., 2002).   Further studies recommended the use of combination 
treatment with rapid elimination rates to reduce drug resistance pressure in 
Africa (Watkins et al., 1988, Watkins and Mosobom, 1993).   
 
Combination treatment has several advantages over monotherapies.  It is a 
good anti-plasmodial strategy and is effective in preventing or delaying 
resistance (White et. al., 1996; White, 1998) and it effectively slows down 
selection pressure since each component is target specific.  Combination 
therapy extends the useful therapeutic life of the component agents and 
reduces treatment times.  It has shown proven efficacy in treating tuberculosis 
and HIV/AIDS (Nyunt and Plowe, 2007).  Combination therapy also has the 
advantage of increasing patient compliance with treatment, (Nosten et al., 
1994).  It lowers the total cost of production, transport and dispensing, 
especially in a fixed dose regimen.  Importantly, also, it reduces the risk of 
patients taking the wrong dosage especially when prescribed by the unqualified 
drug dealers seen in most underdeveloped countries. It also plays a vital role in 
simplifying patient counseling and education.   It prevents and delays the 
progression of resistance and augments cure rates (Price et al., 1997).  The 
concept of drug combination treatment is based on the premise that parasite 
resistance is delayed when it has to mutate in several sites with independent 
mechanism of action.   The essence of a good drug combination relies on the 
 
Chapter 1 – Malaria, Traditional Medicines, Role of Natural Products in Malaria Treatment  
 
 22 
fact that at least one of the agents in the combination will be clinically active 
even in the onset of resistance (White, 1998).  Since our environment is richly 
blessed with diverse natural products, they should be utilized where possible, to 
address our health problems and challenges.  There is need for new, 
integrated, and multivalent treatment strategies to delay the progression of 
resistance, especially now that treatment failures, even with ACTs, have been 
recorded in the Thai-Cambodian border and Thailand (Jambou et al., 2005; 
Vijaykadga et al., 2006, Wongsrichanalai and Meshnick, 2008, Rogers et al., 
2009).  This has challenged scientists to search for new drug combinations by 
exploring further our natural resources. 
 
 
1.9.1 ROLE OF NATURAL PRODUCTS IN MALARIA 
TREATMENT 
1.9.1.1 Antiplasmodial agents from natural products  
Nature continues to be an ever-evolving source for substances and compounds 
of great medicinal value.  Diverse groups of natural products have offered 
tremendous help in the treatment of various illnesses.  Most of these natural 
products are taken in their natural states in the traditional medicinal practices.  
The extraction, purification, isolation and characterization of compounds from 
natural sources with good medicinal values have caught the interest of 
industrialized societies and scientists to explore the flora and fauna of our rich 
ecosystem to identify their medicinal uses and properties.  Natural products can 
offer new and novel scaffolds for development of new antimalarial drugs. They 
contain several classes of antimalarial compounds including; alkaloids, 
terpenoids, flavonoids, chalcones, peptides xanthones, quinones, coumarins 









1.9.1.2 Antiplasmodial agents from plants 
Plants have been good sources of antimalarial agents (Farnsworth and Morris, 
1976).  The activities of herbal remedies and extracts from plants are traceable 
to the medicinal properties of natural products in them.  The quinolines and 
artemisinins are antimalarial drugs from plant products which have contributed 
immensely to the fight against malaria (CDC, 2010).  Various classes of 
compounds with antimalarial activity have been isolated from plants and other 
natural sources.  These are discussed in detail below (section 1.9.2). 
 
Unsaturated hydrocarbons are also a class of compounds which could be 
derived from plant products and food supplements.  The antimalarial activities 
of this class of hydrocarbons have been documented. Kurmaratilake et al., 




1.9.1.3 Antiplasmodial agents from marine organisms and 
microorganisms 
 
More than 70% of the earth‟s surface is occupied by the marine environment.  
The marine body is a potential source of diverse medicinal products, new 
compounds, nutritional food supplements, cosmetics and agrochemicals (Blunt 
et al., 2006).  The diverse medicinal potential of the marine body is not 
unconnected to the wealth of diverse resources, both biological and chemical 
that abound in it.  Diverse marine life forms such as algae, sponges, corals, 
ascidians and fungi which inhabit the marine environment have been studied to 
reveal their medicinal values (Faulkner, 2001, 2002).  Such explorations of the 
flora and fauna of the marine environment have revealed that the marine 
environments are rich sources of potent compounds of diverse medicinal 
importance, however no isolated or synthesized drug from the marine 
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environment has yet made its way to clinical application (Newman and Cragg 
2004). Their antimicrobial, anti- inflammatory, antitumur, antibiotic and 
antimalarial properties have been documented (Hill, 2006; Laurent et al., 2006; 
Nakao and Fusetani, 2007; Carbelleira, 2008; Loset, 2008).  A survey of 
different marine invertebrates by Mendiola et al., (2006) showed the in vitro and 
in vivo antiplasmodial activity of seven extracts from chordates, porifera, 
echinoderms and cnidarians.  The chordates antimalarial activity was traceable 
to the major metabolites like alkaloids and polypeptides.  Fresh water 
organisms, e.g. cyanobacteria, with promising antiplasmodial properties have 
been found in the marine environment (Gademann and Kobylinska 2009).   
They have been washed out into the oceans from their fresh water habitats e.g. 
streams, and rivers (Gademann and Kobylinska 2009).   Recently, six pure 
metabolites and some complex mixtures of fatty acids which exhibited 
promising PfFabI inhibitory and antiplasmodial activity were isolated from the 
Turkish marine sponge Agelas oroides (Tasdemir et al., 2007). 
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Alkaloids are one of the most important groups of natural products.  This class 
of natural products has been of great medicinal value.  Alkaloids have been 
used in the treatment of parasitic infections.  The popular antimalarial drug 
quinine is an indole alkaloid from Cinchona succirubra Pav. ex Klotzsch of the 
family Rubiaceae.  Quinine was the mainstay of malaria treatment for more 
than three centuries.  Indole alkaloids isolated from natural sources has shown 
promising antiplasmodial activity in both in vitro and in vivo systems (Frederich 
et al., 2008) Alkaloids showing antimalarial activity could be further classified 
as; naphthylisoquinolines, bisbenzylisoquinolines, protoberberines, aporphines, 
indoles, and manzamines.  These, have been isolated from extracts of natural 
products and have exhibited promising anti-plasmodial activity against different 
strains of malaria parasites.   
 
Extracts of Triphyophyllum peltatum (Hutch. and Dalziel) Airy Shaw, of the 
family Dioncophyllaceae which were identified as containing 
naphthylisoquinoline alkaloids, exhibited high antiplasmodial activity in P. 
berghei infected mice (Francois et al., 1997). Korupensamine a monomeric 
naphthylisoquinoline alkaloid (IC50=2.0 µg/ml) (Hallock et al., 1997) and 
korundamine A, a heterodimeric naphthylisoquinoline alkaloid with 
antiplasmodial activity (IC50=1.1 µg/ml) (Hallock et al., 1998) were obtained 
from Ancistrocladus korupensis D.W. Thomas and Gereau, of the family 
Ancistrocladaceae. The antiplasmodial and cytotoxic activities of 53 
bisbenzylisoquinoline alkaloids were recorded by Angerhofer et al. (1999).  
These alkaloids showed activity against the D6 clone and W2 clone of P. 
falciparum in the IC50 range of 29-1500nM and 59-4030nM respectively.  
Antiplasmodial activity of compounds from the stem bark of Isolona 
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qhesquierenina of the family Annonaceae has been reported by Mambu et al. 
(2000).  The promising antiplasmodial activities of the protoberberine alkaloids 
were shown by Wright et al. (2000).  Recently, the antiplasmodial activities from 
three ascidians have been reported by Mendiol et al. (2006).  Rao et al. (2006) 
reported the antimalarial activities of manzamine alkaloids isolated from an 
Indonesian Acantho strongylophia sponge.  Previous studies also documented 




This class comprises a large group of structurally diverse natural products 
(Zwenger and Basu, 2008).  They are further divided into other groups which 
include sesquiterpenes, diterpenes, triterpenes, and miscellaneous terpenes.  
Sesquiterpene lactones abound in the genus Vernonia.   Numerous 
researchers have also recorded the antimlarial activity of the sesquiterpenes, 
from Distephanus angulifolius (DC.) H.Rob. & B.Kahn  of the family Asteraceae 
(Pedersen et al., 2009), Tithoma diversifolia A.Gray of the family Asteraceae 
(Goffin et al., 2002), Drechslera dematioidea (Bubák & Wróbl.) Subram. & B.L. 
Jain of the family Pleosporaceae (Osterhage et al., 2002), and the Red algae 
Laurencia obtusa (Topcu et al., 2003).  Novel cembradiene diterpenoids with 
antimalarial activity (IC50 15.0 µg/ml) were isolated from the Caribbean 
gorgonian octocoral Eunice species (Wei et al., 2004).  Five antimalarial 
labdane diterpenoids from Aframomum zambesiacum K.Schum. seeds of the 
family Zingiberaceae were isolated and tested against an FCBI chloroquine 
resistant strain (Kenmogne et al., 2006). Moderate antiplasmodial activity was 
recorded from novel furanoterpenoids isolated from the ethyl acetate fraction of 
Siphonochilus aethiopicus (Schweinf.) B.L.Burtt of the family Zingiberaceae 
(Lategan et al., 2009).  Artemisinin and its derivatives are sesquiterpene 
trioxane lactones and their antimalarial activity is traceable to the endoperoxide 
bridge present in this group (Martinelli et al., 2008). 
 




1.9.2.3 Quassinoids and limonoids 
The activities of two quassinoids reported by Okunade A.L., (2003) include 
ailanthone (IC50=0.03 µg/ml) and 6α-tigloloxychaparrinone (IC50=0.06 µg/ml).  
These were isolated from Ailanthus altissima (Mill.) Swingle, in the family 
Simaroubaceae. Pasakbumin B, pasakbumin C and eurycomanone with 
antimalarial activity of (IC50 22.6 ng/ml, 93.3 ng/ml and 40.0 ng/ml) respectively 
were isolated from Eucalyptus longifolia Link of the family Myrtaceae (Kuo et 
al., 2004; Chan et al., 2004).  Quassinoids from the roots of Simaba orinocensis 
Kunth of the family Simaroubaceae showed antiplasmodial activity (IC50 3.0 
and 3.67 ng/ml vs. 3.2 and 8.5 ng/ml respectively) (Muhammad et al., 2004) 
against the D6 and W2 strains.  However, quassinoids have shown in vivo 
toxicity which could be attributed to protein synthesis inhibition and efforts to 
develop selective inhibitors of parasite and host cell ribosomes has been faced 
with the challenge of differentiating between the two.  This could possibly 
suggest that the recorded antimalarial activity of the quassinoids may be due to 
its toxicity to the host cells. Limonoids with in vitro antimalarial activity have 
been reported from Cedrela odorata L. of the family Meliaceae (Bray et al., 
1990), Khaya senegalensis A.Juss. of the family Meliaceae (Khalid et al., 1998) 
and Khaya grandifoliola C.DC. of the family Meliaceae (Bickii et al., 2000).  
Azadirachta indica A.Juss. (Neem) belonging to the family Meliaceae which has 
been widely used as an antiplasmodial agent belongs to this group.   
 
 
1.9.2.4 Flavonoids and Chalcones 
Promising antimalarial activities have been recorded for flavonoids.  A good 
number of biflavones have been documented to possess moderate to good 
antiplasmodial activity as shown in Wikstroema indica (L.) C.A.Mey. of the 
family Thymelaeaceae, cikokianin B and C (IC50 0.53 and 0.56 µg/ml) (Nunome 
et al., 2004) respectively.  Isolates from Ochna integerrima (Lour.) Merr. of the 
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family Ochnaceae (IC50 80 ng/ml) (Ichino et al., 2006) and Garcinia livingstonei 
T. Anderson of the family Clusiaceae (IC50 6.7 µM) (Mbwambo et al., 2006). 
Licochalcone A, isolated from Glycyrrhiza inflata Batalin belonging to the family 
Leguminosae has shown good antiplasmodial activity.  This is traceable to its 
ability to inhibit the protease activities of Plasmodium (Chen et al., 1994).  
Nyasol a chalcone, isolated from Asparagus africanus Lam. Of the family 
Asparagaceae showed weak antiplasmodial activity with IC50 = 49 1M (Oketch-




A number of compounds with antiplasmodial activities have been identified from 
this group.  Two antiplasmodial compounds exhibiting moderate activity against 
K1 strain (EC50=1.60 and 12.0 µg/ml) were isolated from an insect pathogenic 
fungus Paecilomyces tenuipes.  These compounds, beuvericin and beuvericin 
A, belong to the group known as the cyclodepsipeptides (Nilanonta et al., 
2000).  A cyclic peptide from a marine sponge showed good antiplasmodial 
activity against P. falciparum.  The recorded activity is traceable to the apical 
protrusion which seems to interfere with the invasion of the erythrocytes by the 
merozoites (Mizuno et al., 2002).  The antimalarial activity of a peptide 
microtubule inhibitor, dolastatin 10 isolated from the sea hare D. auricularia was 
reported by Fennel et al., (2003).   Venturamide A and venturamide B (IC50=8.2 
and 5.6 µM, respectively) are two cyclic hexapeptides isolated from the marine 
Cyanobacterium oscillatoria with antimalarial activity against the W2 strain and 
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1.9.2.6 Xanthones, quinones and coumarins 
Antiplasmodial activities have been recorded for cowaxanthone (IC50=1.5 
µg/ml), calothwaitesixanthone (IC50 2.7 µg/ml) and mangostin (IC50= 17.0 µM) 
which were isolated from Garcinia cowa Roxb. of the family Clusiaceae, 
Calophyllum caledonicum Vieill. ex Planch. and Triana of the family Clusiaceae, 
and Garcinia mangostana L. of the family Clusiaceae respectively (Hay et al., 
2004, Mahabusarakam et al., 2006).   Isolates from the roots of Salasia kraussii 
Harv. of the family Celastraceae known as quinone methides A and B showed 
high antiplasmodial activity (IC50= 94.0 and 27.6 ng/ml respectively) (Figueiredo 
et al., 1998).  Antiplasmodial activity of compounds isolated from Vernonia 
brachycalyx O.Hoffm. of the family asteraceae, 2΄-epicycloisobrachy-
coumarinone epoxide (IC50=54 µM) against the Dd2 strain has been reported. 
Clausarin and dentatin isolated from Clausena harmandiana Pierre ex 
Guillaumin of the family Rutaceae showed antiplasmodial activity (IC50=0.1 and 
8.5 µg/ml), respectively (Yenjai et al., 2000). The phenylcoumarins isolated 
from the ethyl acetate extract of Hintonia latiflora Sessé and Moc. ex DC. of the 
family Rubiaceae stem bark showed complete suppression of parasitemia and 
the development of P. berghei schizonts in infected mice (Argotte-Ramos et al., 
2006).   
 
Clearly plants still hold considerable promise for producing new antimalarial 
lead compounds, and plant extracts themselves, used either singly or in 
combination may be effective against the parasites.  In this regard, the 
antiplasmodial activities of seven Nigerian plants were investigated in this 
study.  The details of these plants and the justification for their study are 
discussed in the next chapter. 
                                                       
 











LITERATURE REVIEW OF PLANTS INVESTIGATED 














2.0 INTRODUCTION  
                       The seven plants used in this study were collected based on their traditional 
medicinal uses in the treatment of febrile conditions and other related ailments 
in Nigeria.  The traditional healers in Nigeria make use of medicinal plants in 
the management of several body disturbances (Igoli et al. 2005).  Of interest is 
the observation that the fruits and the leaves of the plants investigated are used 
as food for humans and livestock in Nigeria and other tropical parts of the 
world. 
                                                             
                                         2.1 Description and medicinal uses of Vernonia amygdalina 
 
                                
                                   Fig 2.1.1 V. amygdalina plant 
                                 Source: http://www.thetaug.org/vernoniaamygdalina.html 
 
                        Vernonia amygdalina Delile, commonly known as bitter leaf, is a shrub or small 
tree belonging to the family Asteraceae.  It grows to a height of about 3 meters 
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(Gresham et al., 2008).  V. amygdalina is a popular African vegetable which 
grows in several parts of tropical and subtropical Africa (Oleszek et al., 1995; 
Farombi 2003; Erasto et al., 2006). In southwestern Uganda it is locally known 
as “omubirizi”, and is traditionally used for analgesia and in the treatment of 
malaria infections (Anoka et al., 2008).  The greenish powder formulations of 
this species are sold as AM (anti-malaria) by the Medical Traditional Healers 
Association in Rukararwe, Bushenyi district, Uganda (Anoka et al., 2008).   In 
Nigeria, it is locally known as “ewuru” in Yoruba, “onugbu /olugbu” in Igbo, and 
“shiwaka/chukwuaka” in Hausa (Ajebesone and Aina, 2004; Igoli et al. 2005).  
  
 The genus Vernonia consists of about 200 species in Brazil, where some are 
ingested to treat gastrointestinal disorders (Monteiro et al, 2001).  Vernonia 
species are found to thrive well at temperatures slightly below 30ºC and 
altitudes at of between 600 m-3000 m.  It enjoys loose and moist soil rich in 
humus and a rainfall range between 750-2000 mm annually.  Despite its 
characteristic bitter taste, V. amygdalina is used as a vegetable in the western 
and central parts of Africa (Ajebesone and Aina, 2004; Igile et al., 1995).  For 
instance, in Nigeria it is used as a vegetable and herb for soup.  It is used to a 
large extent in tropical Africa for its culinary and medicinal purposes, it is also 
used in the traditional treatment of malaria, diabetes, diarrhea, veneral disease, 
hepatitis, gastrointestinal problems, skin disorders, cough, constipation and in 
the treatment of wounds (Bullogh and Leary, 1982; Aka and Ekekwe, 1995; 
Igile et al., 1995; John et al., 1995; Hamil et al., 2000; Otshudi et al., 2000; 
Kambizi and Afolayan, 2001; Ajebesone and Aina, 2004). Traditionally, in 
Ethiopia the decoctions of V. amygdalina are used to control tick in cattle 
(Regassa, 2000).  It is also used as an anthelmintic by a good percentage of 
livestock farmers in Nigeria (Nwude and Ibrahim, 1980; Kudi and Myint 1999).   
 
 Most of the livestock farmers in Nigeria use herbal remedies to treat their 
animals.  Further studies documented its use in various folk medicines as an 
anthelmintic, antiprotozoal and antibacterial agent (Burkill, 1985; Tadesse, et 
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al., 1993; Huffman et al., 1996a).  The bitter pith from young shoots of V. 
amygdalina helps in the control of intestinal nematode infection when ingested 
by chimpanzees (Huffman, 2003).  Several investigations have reported the 
nutritional composition of the bitter pith from the young shoots to contain high 
levels of vitamin A and C, as well as a high level of protein (Ajebesone and 
Aina, 2004; Igile et al., 2005).  Phytochemical analysis of V. amygdalina has 
shown the presence of several bioactive principles, which include bitter 
sesquiterpene lactones, vernolide, vernolepin, vernodalin and vernomydin 
(Kupchan et al., 1969).  
 
  The antitumour and antimicrobial properties of V. amygdalina have been 
traced to its bioactive principles (Kupchan et al., 1969, Jisaka, et al., 1993 
Koshimizu, et al., 1994). V. amygdalina is known to contain steroids, saponins 
and flavonoids (Rwangabo et al., 1986; Ohigashi et al., 1991; Igile et al., 1994). 
Flavonoids, sesquiterpenes and triterpenes isolated from V. amygdalina have 
been shown to possess anti-ulcer properties (Arrieta et. al., 2003, Giordano et. 
al., 1990, Havsteen, 2002).  The lipid composition of V. amygdalina was shown 
to contain 12 fatty acids and amounts to 74.1% of the lipid content (Erasto et 
al., 2007a; Erasto et al., 2007b).  The most abundant is palmitic acid, (22.2%).  
The essential fatty acids (EFA) α-linolenic and linoleic acid were present at 
21.55 and 15.8%, respectively.  Dietary foods remain a good source of EFA 
since they cannot be manufactured in the body.  V. amygdalina has been 
reported by some researchers to show antioxidant activity (Erasto et al., 2007a, 
2007b), hypoglycemic, antineoplastic, antibacterial and antioxidant properties 
(Akah and Okafor, 1992; Izevbigie et al., 2004; Taiwo and Lee, 1999; Iwalewa 
et al., 2003). V. amygdalina has shown antiplasmodial properties, which has 
been attributed to the sequesterpene lactones isolated from the leaves 
(Masaba, 2000; Abosi and Raseroka, 2003; Tona et al., 2004).  Previous 
studies have shown that V. amygdalina may possess anticancer activity (Opata 
et al., 2006; Izevbigie et al., 2004). 
 
 




                    2.2 Description and medicinal uses of Psidium guajava 
 
                     
 
                    
                      Fig 2.2.1 P. guajava plant 




 Psidium guajava L. belongs to the family Myrtaceae and is a native to tropical 
America (Begum et al., 2002).  It grows in the central and northern parts of 
America, several European and African countries and has long been 
naturalized in southeast Asia (Begum et al., 2002).  P. guajava is a small tree 
that grows to a height of about 10 m and has a smooth, but patchy, peeling 
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bark (Stone, 1970).  The leaves are opposite and have a short petiole with 
prominent veins in the blade (Stone, 1970).  Psidium guajava thrives in tropical 
and subtropical regions of the world, however it thrives well in dry climates 
(Stone, 1970). The common name is guava.  It is a popular plant, and most of 
the local names are very close to its common name in pronunciation or spelling, 
for instance guave, goyave, or goyavier in French, guavenbaum, guayave in 
German, goiaba, goiabeiro in Portuguese, guiaba in Brazil, guayaba in Spanish 
and guava in English. It is also known as ugova, ugwuoba, gurofa and 
gwaabaa in Nigeria.  Its ethnomedical use is wide (Killion, 2000).     
 
 A previous report documented the use of guava leaf decoction to treat digestive 
disorders due to diarrhea (Heinrich et al., 1998).  Further investigation into its 
traditional uses showed the different ways in which the leaves are used.  They 
are applied topically on wounds and ulcers, used to treat rheumatic pain, and 
could be chewed as a palliative measure for toothache (Heinrich et al., 1998).  
A decoction of the leaves and bark given to pregnant women after delivery 
helps to expel the placenta and serves as a vaginal and uterine wash, 
especially in leucorrhoea (Conway, 2002).  In South Africa, infusions or 
decoctions of these species are used traditionally to control or treat ailments 
such as diabetes mellitus and hypertension (Oh et al., 2005; Ojewole, 2005).  
The anti-inflammatory and analgesic effects of this species have been reported 
(Ojewole, 2006; Murugananda et al., 2001).  In Brazil, the ripe fruit, flowers and 
leaves are traditionally used as a decoction to treat anorexia, cholera, diarrhea, 
digestive problems, dysentery, gastric insufficiency, skin problems, sore throat, 
ulcers, vaginal discharges and laryngitis (Holetz et al., 2002; Cybele et al 
1995).  In West Africa, Latin America and the Caribbean, decoctions of these 
species are used in the treatment of diarrhea and problems associated with 
indigestion (Mitchell and Ahmad, 2006b).  The decoctions which serve as a 
diuretic are also used in the treatment of sore throat, laryngitis and mouth 
swelling.  The ethanol and aqueous extracts of P. guajava at a concentration of 
80 µg/ml showed significant antidiarrhoeal activity (using morphine as the 
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reference standard) due to their ability to inhibit 70% of the solution-induced 
contractions of isolated guinea pig ileum (Lutterodt, 1992; Tona et al., 1999).  
P. guajava species have also shown antibacterial, antimicrobial (Coutino et al., 
2001, Arima and Danno, 2002; Chah et al., 2006), and antifungal activity 
against Arthrinium sacchari M001 and Chaetomiu funicola M002 strains (Sato 
et al., 2000). Its potency against Propionibacterium acnes has also been 
reported (Qadan et al., 2005).   
 
 The aqueous extract of P. guajava showed-dose dependent in vitro cytotoxic 
activity (at a dose of 1.0 mg/ml) against the cancer cell line D4-145 (Chen et al., 
2007).    It was noted that the viability of the D4-145 cell lines after incubating 
them with the extract for 48 and 72 hours was reduced to 36.1% and 3.6%, 
respectively (Chen et al., 2007).  It has further been shown that the essential 
oils from the leaves of these species showed activity against human epidermal 
carcinoma of the nasopharynx (KB) and the murine leukemia (P388) cell lines 
at a concentration range of 0.019 mg/ml to 4.96 mg/ml. It was documented in 
this report that the IC50 value recorded on P388 cell lines was four times 
greater than the potency of vincristine (Manosroi et al., 2006). This effect was 
attributed to the presence of monoterpenes in the essential oil of P. guajava 
(Cito` et al., 2003).  Subsequently, P. guajava was reported to show significant 
activity on myocardial injury (Conde et. al., 2003).  In India, the leaves of this 
species are used to treat cough (Khan and Ahmad, 1985), and extracts from 
the leaves have also shown good hepatoprotective effects at a dose of 
500mg/kg (Roy et. al., 2006).  Guava leaf extracts are good sources of natural 
antioxidants (Ojan and Nihorimbere, 2004).  A further study documented the 
anti-allergic activity of the leaf extract on T cell immunity in mice (Seo et al., 
2005).  The work of Mukhtar et al., (2004) has shown the potent hypoglycaemic 
activity of the water extract at a dose of 250 mg/kg.  Anti-diabetic activity of 
ethanol fractions of this species has been reported in a further study (Mukhtar 
et al., 2006).   Other researchers previously reported the hypoglycaemic activity 
in mice and humans (Cheng and Yang, 1983). An anti-hyperglycemic effect of 
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the butanol-soluble fraction from P. guajava leaves was shown in mouse 
models with type 2 diabetes (Oh et al., 2005).   It showed an analgesic effect 
against thermally and chemically induced nociceptive pain (Ojewole, 2006).  
Guava leaf extract significantly reduced dysmenorrhea in a double-blind and 
randomized clinical trial, and proved more effective when compared to the 
group which received conventional treatment and placebo (Vldislavona et al., 
2007; Svetlana et al., 2007). The species has shown antiplasmodial properties 
(Nundkumar and Ojewole, 2002).   
 
 The bioactivity guided isolation of compounds showed the presence of 
quercetin, quercetin-3–arabinoside (Lutterodt, 1989) and asiatic acid (Conde et 
al., 2003).  Other compounds including flavonoids, saponins, and oleanolic 
acids were shown to be present in the leaves (Arima and Danno, 2002).  A 
further study reported the presence of nerolidol, ß-sitosterol and ursolic, 
crategolic and guayavolic acids. Triterpenoids were isolated from the leaves 
(Begum et al., 2002).  Ascorbic acid is the most abundant constituent of the 
skin of P. guajava fruit; it is also present in the fleshy part and central pulp 
(Charles et al., 2006).  The unripe fruit is reported to have a high concentration 
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Fig 2.3.1 C. papaya plant 
Source: http://www.drosera.pl/papaja-p-42.html 
 
Carica papaya L. of the family Caricaceae is a soft-stemmed perennial plant.  It 
is usually unbranched and can grow to a height of about 20m (De Maria et al., 
2006).  It is believed to originate from the Caribbean coast of Central America 
and over the years has found its way into many tropical and subtropical 
climates (Ei Moussaoui et al., 2001). C. papaya can grow in male, female or 
hermaphrodite forms.  It is found growing wild in many parts of the tropics, and 
is cultivated because of its sweet juicy fruit which serves as a nutritious food 
with rich medicinal value, and also because of the ease with which it digests.  It 
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commonly features in breakfasts, cooked in diverse ways, and as ingredients in 
jellies beverage and juice (Oloyede, 2005) 
 
The fruits, leaves and latex of this species are traditionally used in different 
parts of the world to treat diverse disease conditions.  It is used various places 
in the treatment of asthma, rheumatism, fever, diarrhea, boils, hypertension and 
to increase the production of milk in lactating individuals (Zakaria et. al., 2006).  
The fruit and seed extracts of C. papaya have shown significant bactericidal 
activity against Staphylococcus aureus, Bacillus cereus, Escherischia coli, 
Pseudomonas aeruginosa and Shigella flexneri (Emeruwa, 1982).  The unripe 
fruit contains glycine, phenylalanine and tryptophan, which have shown 
antisickling properties (Igbal and Kazi, 1980).  The compounds isolated from 
the methanol and ethanol fractions of C. papaya seeds (MCP1 and ECPI), 
respectively have shown contraceptive activities in male albino rats (Nirmal et 
al., 2005).  A dose-dependent antimalarial activity of the petroleum ether 
fractions of the pulp and rind of C. papaya (IC50=18.09 and 15.19 µg/ml, 
respectively) delayed the development of the ring stages of the parasite after 
24 hours incubation with the extract, and a noticeable morphological distortion 
of the trophozoites was reported (Bhat and Surolia, 2001).  Further studies 
have shown that this species has promising antifungal (Giordani et al., 1991), 
antibacterial (Osato et al., 1993) and anthelminthic (Satrija et al., 1994) 
properties.  C. papaya ameliorates vaginal disturbances due to Trichomonas 
vaginalis (Calzada et al., 2007).   It has been reported to show anti-
inflammatory and immunomodulatory properties (Mojica-Henshaw et al., 2003).  
The anthelminthic activity of C. papaya is traceable to the presence of carpain 
(alkaloid), carpasemine (benzylthiourea) and benzylisothiocyanate (Kermanshai 
et al., 2001).  The latex of C. papaya at a dose of 8g/kg has been found to be 
84.5% effective against Heligmosomoides polygyrus (in mice) and Ascaris 
suum in pigs (Satrija et al., 1994).   These researchers reported a dose 
response activity of papaya latex and stated that the calculated ED100 of 
papaya latex against adult Heligmosomoides polygyrus was 12g/kg using probit 
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analysis (Satrija et al., 1994).  Papain which is a major component of this 
species, is used in tenderizing meat and production of bubble gum.  C. papaya 
has also shown hypoglycaemic effects (Olagunju et al., 1995).  It has been 
reported as accessible, non-toxic, prophylactic and to be a promising 
monotherapy against intestinal parasitosis in tropical countries (Okeniyi, 2007).   
 
Scientific studies have shown the potency and cost effectiveness of the fruit 
when applied topically in the treatment of chronic ulcers in Jamaica (Hewitt  et 
al., 2002).  A further study attributed this mechanism of action to the activity of 
the proteolytic enzymes chymopapain and papain, as well as the antioxidant 
and antimicrobial activities of the species (Anuar et al., 2008).  Another study 
reported the use of the fruit from this species in the treatment of burns, as 
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 2.4 Description and medicinal uses of Cymbopogon citratus 
 
 
Fig 2.4.1 C. citratus plant 
Source: http://www.floridata.com/ref/c/images/cymb-ci10.jpg 
 
Cymbopogon citratus Staph is a tall perennial grass which belongs to the family 
Poaceae.  It is a genus of about 55 species.  It originated from the warm 
temperate and tropical regions of the world.  It is commonly known as lemon 
grass.  It has a simple leaf with a central margin, very distinct from its parallel 
venation running through the entire length of the leaf. Its traditional applications 
in Nigeria include use in the treatment of fever, jaundice, hypertension, as 
analgesic, in soap making and as an insect repellant (Onabanjo et al., 1993).  
This study also reported the presence of alkaloids, saponins, tannins and 
simple sugars in the aqueous extracts from the leaves.  It has a wide 
application in the traditional medicinal practices in tropical Africa (Tortoriello 
and Romero, 1992). A further study also indicated its traditional medicinal 
values in tropical and subtropical countries and in producing a pleasant aroma 
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in their herbal teas (Cheel et al., 2005).  C. citratus has a characteristic 
pleasant flavour, which may explain the wide usage of its essential oils in the 
production of perfumes, cosmetics and as a flavouring ingredient in a good 
number of food beverages and confectionaries (Guynot et al., 2003, Pandey et 
al., 2003).   The essential oil of C. citratus is documented to have antibacterial, 
as well as antifungal, activity (Suhr and Nielsen, 2003; Wilkinson and 
Cavanagh, 2005).   
 
Cymbopogon citratus is widely used in Brazilian traditional medicine to 
ameliorate nervous and gastrointestinal abnormalities (Melo et al., 2001).  A 
further study documented its use in Brazilian folk medicine as a tea to relieve 
anxiety, and this was shown by the activity of the essential oils in a mouse model 
(Blanco et al., 2009).  Its sedative and anticonvulsant properties as well as its 
use as an anxiolytic agent has been documented (Blanco et al., 2009).  This 
study compared the anxiolytic activity of the essential oils from this species to 
that of diazepam in mice.  The oils were shown to have significant activities in 
mice.  Some researchers have proposed herbal extracts with recorded activity in 
the central nervous system as a better option in the treatment of anxiety, 
depression, headache or epilepsy than the conventional drugs (Phillipson, 2001; 
Carlini, 2003).  Further studies recorded the antinociceptive activity of the 
essential oils from C. citratus (Viana, 2000).  The extracts from the tea have been 
reported to show analgesic, diuretic, sedative, antispasmodic and anti-
inflammatory properties (Carlini et al., 1986).  Five C-glycosylflavonoids from; 
orientin, isoorientin, isoscoparin, swertiajaponin and isoorientin 2˝-O-rhamnoside 
have been isolated from C. citratus and have shown potent antioxidant activity by 
significantly inhibiting lipid peroxidation in erythrocytic membranes (Orrego et al., 
2009).   Citral, myrcene and limonene have been isolated from C. citratus (Ha et. 
al., 2008).  Previous studies have also isolated and identified cymbopogonol and 








2.5 Description and medicinal uses of Citrus limon      
 
 
Fig 2.5.1 C. limon plant 
Source: http://www.bambusarium.de/exoten/citrus/citrus.htm 
 
Citrus limon L. Burm.f. plants are small trees which belong to the family 
Rutaceae.  They have a characteristic spiny shoot and conspicuously green 
leaves.  The species has a wide usage of its fruit in the commercial production 
of lemonade or to garnish drinks.  Several drinks are served with a slice of 
lemon decoratively placed on the rim of the cup or in the glass of juice.  In 
Nigeria it is used to tenderize meat and the fruit juice is used to wash and clean 
molluscs before cooking (Igoli et al., 2005).  Some useful components such as 
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citric acid, ascorbic acid, minerals and flavonoids are contained in this species 
(Rio et al., 2004).  Some researchers have attributed the activity of this species 
to the presence of flavonoids which have diverse biological and health-related 
functions (Middleton and Kandaswami, 1992, Elangovan and Govindasamy, 
1994). Flavonoids have shown antiviral, antimutagenic (Iwase et al., 2001) and 
antimicrobial properties (Cushinie and Lamb, 2005).  The hexane extract of C. 
limon was active against Trichophyton mentagrophytes and Microsporum canis 
(Johann et al., 2007).   
 
Further studies on the flavonoids from Citrus species have described their anti-
hemorroidal, anti-oxidant, anti-inflammatory and anti-lipid peroxidation 
properties (Galley and Thillet, 1993; Da Silva et al., 1994).  The oil extracted 
from C. limon effectively killed mosquito larvae (Zayed et al., 2009).  This 
suggests that plants could be used to control the mosquito vector due to their 
bioactive chemical composition (Park et al., 2002).  Limonoids are a group of 
triterpene derivatives found in the Rutaceae and Meliaceae families (Bennett 
and Hasegawa, 1982; Hashinaga et al., 1990).  It has been recorded that most 
of the natural limonoids are from citrus plants of the family Rutaceae (Ohta et 
al., 1992).  Further studies reported that limonin and nomilin are the most 
abundant Citrus limonoids and have shown anti-carcinogenic properties in 
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2.6 Description and medicinal uses of Musa sapientum      
 
Fig 2.6.1 M. sapientum plant 
Source: http://www.stripes.com/08/may08/GTMO 
 
Musa sapientum L. belongs to the family Musaceae. This family comprises 
bananas, plantains, and ornamental bananas.  Plantain leaves are similar to 
banana leaves but are larger and stronger.  Plantains tend to be firmer and lower 
in sugar content than desert bananas and are used either when green or under 
ripe (starchy) or ripe (sweet).  Plantains are a staple food in the tropical region of 
the world for instance in Nigeria (Igoli et al. 2005), it could be processed in the 
same way as potatoes.  Propagation is by suckers.  
 
The juice of the Musa sapientum flowers has been reported to show 
hypoglycemic effects (Pari and Maheswari, 1999).  The methanolic extract of 
banana has shown anti-oxidant effect in vitro (Goel et al., 2001).  Researchers 
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have reported the anti-ulcerogenic activity of dried powder of banana pulp 
against ulcers in guinea pigs and in rats (Sanyal et al., 1963).  Further work 
confirmed the anti-ulcerogenic activity of banana against histamine induced 
gastric ulcers in mice (Elliot and Heward, 1976) and aspirin-induced gastric 
ulcers in rats (Best et al., 1984). The anti-ulcerogenic activity of 
sterylaclyglycosides, sitoindosides I-IV isolated from Musa paradisiaca Linn. has 
been demonstrated in rats and humans (Ghosal and Saini, 1984; Ghosal, 1985; 
Bhattacharya and Ghosal, 1987). The antiulcer activity of a flavanoid, 
leucocyanidin isolated from unripe plantain banana pulp has been reported (lewis 
et al., 1999). 
 
2.7 Description and medicinal uses of Mangifera indica 
 
Fig 2.7.1 M. indica plant  
Source: Djatmiko W.A., (Wie146)  
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Mangifera indica L. of the family Anacardiaceae is a perennial tree with 
evergreen leaves.  The leaves are simple with alternate arrangement.. The 
fruit is a drupe, and hangs from the tree on long stems when it matures.  It 
has various shapes and sizes. The ripe fruit is variably coloured yellow, 
orange and red, green colour usually indicates that the fruit is not yet ripe, 
however, this depends on the species (Igoli et al. 2005).  In the center of the 
fruit is a single flat, oblong seed.  This seed depending on the species can be 
fibrous or hairless on the surface. 
 
Native from tropical Asia, and thrives well in many parts of tropics and subtropics 
(Ross, 1999).  M. indica has naturalised in most tropical biotopes in India, 
Southeast Asia, Malaysia, Himalayan regions, Sri Lanka, Africa, America and 
Australia (Kirtika and Basu 1993; Sahni, 1998).  It is common in different parts of 
the world where it is given vernacular names such as in Brazil: Manga, Mango, 
Mangueira, Skin Mango; Canary Islands: Mango; China: An Lo Kuo, Mangguo, 
Mango; Egypt: Mango; Fiji: Aam, Mango; Germany: Mango; Mango; Guatemala: 
Mango; Sudan: Mango; Tanzania: Embe, Mango, Mwembe; Tonga: Mango; 
United States: Bowen mango; Venezuela: Mango (Kirtikar and Basu 1993; Ross, 
1999). M. indica has hundreds of cultivars which are distributed throughout the 
world. 
 
Different parts of Mangifera indica are used in the traditional herbal remedies 
across the globe (Ross, 1999). The aqueous extract of M. indica L. is reported to 
have antioxidant, anti-inflammatory, analgesic and immunomodulatory 
properties, which helps to prevent disease progress and dermatological 
disorders, AIDS, cancer and asthma (Guha et al., 1996, Nuñez-Selles, 2005). 
 
Ross (1999) reported the chemical constituents of the different organs of M. 
indica L.  Mangiferin, is a major C-glucosylxanthone isolated from various parts 
of M. indica.  Mangiferin is widely distributed in the Anacardiaceae and 
Gentianaceae families, especially in the leaves and the bark (Yoshimi et al., 
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2001). The natural C-glucoside xanthone mangiferin [2-C-β-Dgluco- pyranosyl-
1,3,6,7- tetrahydroxyxanthone; C19H18O11; Mw, 422.35; melting point, 
anhydrous 271°C (Muruganandan et al. 2002). Researchers have reported the 
presence of this compound in various parts of M. indica: leaves (Desai et al. 
1966), fruits (El Ansari et al., 1971), stem bark (Bhatia et al., 1967), heartwood 
(Ramanathan and Seshadri 1960) and roots (Nigam and Mitra 1964). 
 
Mangiferin is a vital ingredient of a natural extract from Mangifera indica known 
as Vimang and has shown diverse pharmacological uses such as, antioxidant 
(Muruganandan et al. 2002; Leiro et al., 2003), immunomodulatory (Garcia et al., 
2002, 2003), lipolytic (Yoshikawa et al. 2002), anti-allergic (Rivera et al., 2006), 
anti-inflammatory and anti-nociceptive (Beltran et al. 2004; Garrido et al., 2004), 
antitumor (Yoshimi et al., 2001), antidiabetic (Muruganandan et al. 2005), and 
antiparasitic activities (Perrucci et al. 2006). Mangiferin showed In vitro activity 
against 7 bacterial species, Bacillus pumilus, B. cereus, Staphylococcus aureus, 
S. citreus, Escherichia coli, Salmonella agona, Klebsiella pneumoniae, 1 yeast 
(Saccharomyces cerevisiae) and 4 fungi (Thermoascus aurantiacus, 
Trichoderma reesei, Aspergillus flavus and A. fumigatus) (Stoilova et al., 2005). 
 
2.8   Scope of this study 
Researchers have shown keen interest to investigate African medicinal plants 
to identify possible potential sources of antimalarial compounds (Saidu, et al., 
2000; Orafidiya et al., 2001; Orafidiya, et al., 2002; Noor et al., 2007; 
Odugbemi, et al., 2007; Frederich et al., 2008).  This study aims to investigate 
scientifically, the antiplasmodial activities of five Nigerian plants singly or in 
combination. The escalating challenge posed by parasite resistance, to existing 
antimalarial drugs emphasized the urgent need for drugs with different mode of 
action (Ridley, 2002).  Several reports stated the advantages of combination 
treatment (White and Olliaro, 1996; White, 1998; 1999; White et al., 1999)   It 
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became necessary therefore to explore the antiplasmodial activities of these 
plants singly or in combination. 
 
2.8.1 Why Nigerian plants? 
Nigeria is a tropical rain forest country in an endemic malaria region with a 
great diversity of natural products yet to be explored.  The tropical rain forest 
natural products are potential sources of biologically active compounds (Noor et 
al., 2007).  Traditionally these plants are used in treating malaria in Nigeria.  
Majority of the African populace depend on these plants used by traditional 
healers. They are accessible, cheap, affordable, available and sustainable. 
African medicinal plants have demonstrated diverse potentials as possible 
sources of promising antiplasmodial compounds (Saidu, et al., 2000; Okokon et 
al., 2006; 2007; Philippe et al., 2007).  However, little work has been done on 
the antiplasmodial and toxicity properties of similar or related species 
naturalized in Nigeria.   Moreso, most of the herbal preparations used to treat 
malaria in Nigeria are without scientific evidence on efficacy.   
 
2.8.2 Rationale for plant collection    
 Used in the Nigerian traditional medicinal practices to treat malaria. 
 Availability all through the year, hence supply will not be interrupted, 
since it is not seasonal.  
 They are readily grown, accessible and quite easy to maintain since they        
are also found growing in the wild, thus it poses little or no difficulty in 
propagation. 
 Their leaves are used as food in Nigeria. 
 Lack of research output on the scientific information concerning the 
safety, and efficacy of these plants naturalized in Nigeria, in the 





Chapter 2 – Literature Review of Plants Investigated and Study Objectives  
 
 50 
Details of the in vitro cytotoxicity and in vivo toxicity properties of these Nigerian 
plants, as well as their activity against Plasmodium parasites are either scanty 
or lacking.  
 
This information is vital so as to confirm if their antiplasmodial activity is specific 
to Plasmodium parasites or due to cytotoxicity of the components. It is 
necessary therefore, that the species that occur in Nigeria be tested for activity 
since the activity of same species of plants could vary due to soil composition, 
geographical and climatic conditions (Massotti et al., 2003; Angioni et al., 
2006).  
 
The traditional healers in Nigeria make use of these plants singly or in 
combination to treat malaria.  These plants have been collected to scientifically 
investigate their antiplasmodial properties singly and when combined. Several 
studies have shown that the challenges posed by the resistance of parasites to 
already existing drugs could be averted by drug combination treatments (White, 
1998; White et al., 1999; Guerin, 2002; Faye et al., 2007). The WHO 
recommended the use of Artemisinin combination therapies (ACT‟s) for the 
treatment of malaria (WHO, 2005; WHO, 2007).   
  
These plants have been used singly or in combination with other plants in the 
traditional treatment of malaria in Nigeria.  They are used in the form of 
decoctions, infusions, tinctures or macerations (Igoli et al., (2005). The majority 
of the populace makes use of plant remedies, and anecdotal reports suggest 
that combining the plants is more effective than using them singly. The 
traditional recipes of combinations of five of these plants as used in Nigeria 











Table 2.8.1 Tabular representation of some Nigerian medicinal plants that 
are used in combination in the traditional treatment of malaria  
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 Source: http://www.bioline.org.br/showimage?tc/photo/tc07026t2.jpg and 




2.9 General objectives 
 To scientifically establish the in vitro and in vivo effectiveness of these 
plants singly and in combination against the plasmodium parasites and 
the bioavailability study of an active compound.   
 
2.9.1 Specific objectives 
 To use an in vitro system to determine the antiplasmodial activity of 
extracts from selected plants against the chloroquine sensitive and 
chloroquine resistant strains of Plasmodium falciparium. 
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 To determine the in vitro cytotoxicity properties of these plants singly and 
in combination using the CHO cell line. 
 To identify and trace the activity of the most active extract in vitro 
through a bioactivity guided fractionation.  
 To investigate the bioavailability of an isolated compound with 
antimalarial activity in an in vivo mouse model.   
 To use mice models to screen extracts that showed promising 
antiplasmodial activity in vitro for efficacy and safety in vivo. 
 To identify the synergistic combination of the plant extracts that will cure 
malaria in a mouse model. 
 
 
The methods involved in the collection of these plants, and the details of the 
experimental processes are described in the next chapter.  
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3.1 In vitro antiplasmodial experiment 
The in vitro antiplasmodial studies involved a continuous culturing of both 
strains of the parasite.  The parasites received in their frozen state were thawed 
and continuously cultured as described below. 
 
3.1.1 Cultivation of P. falciparum parasites  
The strains used for this experiment have adapted to in vitro experimental 
conditions.  The D10 strain of the parasites, which was donated by Dr A. 
Cowman, Walter and Eliza Hall Institute of Medical Research, Melbourne, 
Australia was derived from FCQ-27 Papua New Guinea (Ekong et al., 1993).  
The Chloroquine resistance (CQR) DD2 strain was derived from Indochina 
(Wiesner et al., 2001).  The asexual erythrocytic stages of these parasites were 
maintained in a continuous culture using a modified method of Trager and 
Jensen (1976).  The in vitro assay procedure was done in the hood under 
sterile conditions.  Continuous culturing of the erythrocytic stage necessitates 
the addition of red blood cells in the in vitro set up.  The O+ human blood was 
obtained from the Groote Schuur Hospital, Cape Town and washed before use, 
as described below. 
 
 
3.1.2 Washing of blood  
Blood samples usually at normal state contain both red blood cells (RBC) and 
the white blood cells (WBC).  Washing gets rid of a proportion of the WBC.  The 
RBC remaining are used to culture the malarial parasites in vitro.  The washing 
process was started by transferring an aliquot of blood into sterile tube.  An 
equal volume of complete medium (CM) was added to it.  This was centrifuged 
at 1200rcf for 5 minutes.  After spinning, the supernatant was aspirated.  An 
equal volume of CM as used previously was added and the procedure was 
repeated.  The supernatant was aspirated and the pellet containing RBC was 
stored in the fridge at 4ºC for eventual usage.  The medium used in the in vitro 
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continuous culturing of parasites and washing of blood were prepared as 
described in section 3.1.3.  
 
3.1.3 Preparation of medium 
Three media were used for the in vitro culture of the parasites: complete 
medium (CM), incomplete medium, and wash medium. 
  
3.1.3.1 Complete medium 
This medium is used to maintain the parasites in culture.  It is made up of 10.4 
g/l RPMI 1640 with gluthamine (but no NaHCO3), (Bio Whittaker), 4 g/L 
glucose, 6 g/lHepes (N-[2-hydroxyethyl]-Piperazine-N1-[2-ethnsulphric acid]) 
(Sigma-Aldrich), 0.088g/L Hypoxanthine enriched with 5 g/L Albumax and 1.2 
ml/L (0.05 g/L) gentamycin (Sigma-Aldrich).  At the desired PH the colour 
indicator in the RPMI appears orange.  The medium was filtered twice.  The 
first is a pre-filtration under pressure using 0.45 µm to remove impurities or 
contaminants.  The second stage was filter sterilization through 0.22 µm filter.  
The addition of 5% sodium bicarbonate (8.4 ml) to 200 ml medium gave rise to 
a complete medium (CM). 
 
3.1.3.2 Incomplete medium 
This is the same as the complete medium, but does not contain 5% sodium 
bicarbonate. 
 
3.1.3.3 Wash medium   
This is prepared and filtered the same way as CM, but without albumax.  It 
contains the same amount of sodium bicarbonate solution.  The complete 
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 3.1.4 Feeding or synchronization of parasites in continuous 
culture. 
Parasites were grown and maintained in tissue culture flasks (Greiner Bio-
One). The continuous culturing of the parasites involved three steps which 
included changing of the medium, feeding the parasites with RBC in the late 
trophozoite stage, and synchronization of the parasites with sorbitol in the early 
trophozoite stage (ring stage). Feeding and synchronization was usually not 
done on the same day since the phases of the parasites alternate every 24 
hours. The medium was changed by centrifuging the entire content of the flask 
(CM, RBC, PRBC) at 750 rpm for 5 minutes and the supernatant was removed.  
Smears are made from the pellets to ascertain the diagnostic stage of the 
parasite and the parasitemia.  The blood smear was allowed to air dry, fixed 
with methanol and stained with 10% Giemsa for about 10 minutes before 
viewing under the light microscope.  It was at this juncture that the decision to 
feed or synchronize or to change the medium was taken.   The parasites at the 
ring stage were synchronized by the addition of 20 ml of sorbitol to the pellets.  
This was allowed to stand for 10 minutes in a water bath (37ºC).   Thereafter, it 
was centrifuged at 700 rpm for 3 minutes.  The supernatant was aspirated and 
10 ml of CM was added to the desiccant and placed back in culture.  After the 
routine feeding or synchronization of the parasites, the culture flask was flushed 
with gas (3%O2 4% CO2), for about 1 minute and incubated at 37ºC for 24 
hours. The parasitemia was maintained at 1% for the antiplasmodial assay.     
 
3.1.5 Cryostorage and thawing of parasites 
3.1.5.1 Cryostorage of parasites 
Cryostorage involves freezing and storing the parasites in cryotubes.  At one 
stage it became necessary to replenish the parasite stock which had been used 
up due to continuous culturing of the parasites.  At a desired parasitemia and 
phase, the parasites were frozen and transferred to cryotubes which were 
stored in liquid nitrogen.  Parasites were frozen in their ring stages since their 
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membranes are more robust than that of the later stages. The freezing medium 
was made up of 1.6 g sodium lactate, 30 mg potassium chloride, 1.38 g sodium 
dihydrogen phosphate and 57 g glycerol in 100 ml Millipore water (mH2O).   
Glycerol disrupts crystal formation of the water which can damage the 
parasites.  The freezing medium was filtered using a 0.22 µm filter. The filtrate 
was slowly added (5 volumes to 3 volumes PRBC) and allowed to stand for 5 
minutes.  They were transferred to cryotubes and kept at -80ºC overnight, and 
subsequently transferred to liquid nitrogen the next day. 
 
3.1.5.2 Thawing of parasites 
Three thawing solutions were used to thaw the parasites.  Solution A contained 
12% sodium chloride (NaCl), solution B contained 1.8% NaCl, while solution C 
contained 0.9% NaCl plus 0.2% glucose.  Thawing of parasites using these 3 
solutions was done step-wise and as fast as possible.  The cryotubes taken 
from liquid nitrogen were placed in a water bath at 37ºC to thaw.  Solutions A 
and B were added sequentially and were centrifuged at 400 rcf for 5 minutes.  
The supernatant was removed, and solution C was added to the pellet and 
allowed to stand for 5 minutes.  Thereafter the PRBC was cultured as already 
described (3.1.4). 
 
3.1.6 Preparation of samples for antiplasmodial assay   
The preparation was the same for all of the extracts and fractions tested.  
Initially, a stock solution of 2 mg/ml of sample was prepared in 10% methanol 
(MeOH) (in deionised water).  This was further diluted in complete medium to 
attain a final concentration of 200 µg/ml in 1% MeOH which is the desired 
concentration for the antiplasmodial assay.  The stock solutions were prepared 
on the assay day.  Chloroquine (CQ) (Sigma) was used as the standard 
reference drug (control).  Two mg/ml stock of CQ (Sigma) was constituted in 
deionised water and further diluted in complete medium to a concentration of 
200 µg/ml.  DL-α- Dipalmitoylphosphatidylcholine (DPPC) (Sigma) served as a 
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vehicle for the unsaturated hydrocarbons investigated in this study. Fatty acids 
were dissolved in chloroform (2 mg/ml).  Mixed fatty acids and DPPC micelles 
were prepared by adding DPPC four-fold the amount of fatty acid.  Solvents 
were evaporated under nitrogen and 1 ml of complete medium (RPMI 1640) 
was added to the mixture.  The mixture was sonicated for 2 minutes and 
thereafter used for assay.   
 
3.1.7 In vitro experimental plate set up and procedure 
  
Fig 3.1.7 A diagrammatic representation of the 96-well microtitre plate set 
up used in this study. 
 
 KEY: Red = Column 1(Blank), Violet = Column 2(negative control), Light yellow = 
Column 3 (Positive control + drugs in duplicate), Orange =Column 12 
 
A flat-bottomed, 96-well microtitre plate (Greiner Bio-One) was used for this 
assay as shown in fig 3.1.7.  The suspension were dispensed into the wells in 
this order; column 1 was used as blank (100 µl 1% hematocrit + 100 µl 
complete medium (CM)), and column 2 was the negative control (100 µl 1% 
parasite suspension + complete medium) while columns 3-12 contained the 
different concentrations of plant samples (100 µg/ml serially diluted two-fold in 
complete medium up to 0.195 + 100µl 1% parasite suspension in each well).  
Columns 3 and 12 had the highest (100 µg/ml) and the lowest (0.195 µg/ml) 
concentrations, respectively.  A volume of 100 µl CM was added to all the wells 
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except those in column 3 containing 200 µl of drugs which had already been 
diluted in CM.  CQ (Sigma) which is the positive control compound was tested 
at a starting concentration of 100 ng/ml or 1000 ng/ml for the sensitive (D10) 
and resistant (DD2) strains of P. falciparum respectively.  Each column has 
eight wells.  The drugs in column 3 were arranged in duplicate and could 
contain a maximum of 4 drugs (CQ inclusive) in one plate.  A two fold-serial 
dilution of the initial or starting concentration was done using the multi-channel 
pipette from columns 3-12 and the last 100 µl after column 12 was squirted out.  
This leaves each row in columns 3-12 with 100 µl of different drug 
concentrations in CM.  Unparasitised erythrocyte (RBC) was added to column 1 
(blank) which had no drugs, while parasitized red blood cells (pRBC) were 
added to columns 2-12.  Column 2 (negative control) had the parasitized red 
blood cells but no drugs.  Columns 3-12 had parasites and drugs at different 
concentrations. The plate was covered with a lid (Greiner Bio-One) and placed 
in a gassing chamber, gassed for 2 minutes (93% N2, 4% CO2 and 3% O2) and 
incubated for 48 hours.  A final hematocrit and parasitemia of 2% was used for 
all experiments.  The IC50 recorded in this study is the mean of at least two 
independent experiments.   
 
3.1.8 Parasite lactate dehydrogenase (PLDH) assay  
Quantitative assessment of in vitro antiplasmodial activity in this study was 
determined by using a modified method of parasite lactate dehydrogenase 
assay as described by Makler et al.(1993).  This is a colorimetric enzymatic 
method.  A unique feature of this technique is its ability to distinguish parasite 
pLDH activity from the host LDH activity by making use of 3-acetyl pyridine 
adenine dinucleotide (NAD).  Lactate is converted to pyruvate by pLDH using 
APAD as a co-enzyme.  In the presence of the reduced APADH, the yellow 
coloured nitro blue tetrazolium (NBT) is converted to a purple formazan salt.  
The percentage of the parasites that survived and the concentration causing 
50% growth inhibition (IC50) was determined by measuring the conversion of 
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NBT by P. falciparum.  This procedure is reliable (Basco et al., 1995) and does 
not consume time. 
 
3.1.9 Developing plates 
The assay plate (plate A) was incubated for 48 hours.  After the incubation, the 
plate was resuspended and 15 µl of the suspension was transferred to 
corresponding wells in another plate (plate B) already containing 100 µl 
Malstat.  This was followed by the addition of 25 µl of NBT into each well of 
plate B.  A hair dryer was used to remove any air bubbles that might be present 
in the plate.  This was placed in a dark cupboard to develop, since NBT is light 
sensitive.  The absorbance of each well was read after 5 minutes or as soon as 
a colour change from yellow to purple was observed, using a microplate reader 
at 590 nm. 
 
3.1.9.1 Details of reagents used to develop plates 
Malstat is made up of a solution of 400 µl Triton X 100, 4g of L-lactate, 1.32 g 
Tris- buffer and 22 mg APAD in 200 µl of mH2O.  Malstat helps to disrupt the 
red blood cell membrane, exposing the parasites to NBT.  NBT consists of a 
solution of 160 mg NBT and 8 mg phenazine ethosulphate in 100 ml of mH2O.  
NBT changes from yellow to purple in the presence of living parasites.  
 
3.1.9.2 Preparation and storage of reagents used to develop 
plates 
To prepare Malstat, 400 µl Triton X 100 was heated gently to dissolve, 4 g L-
lactate and 1.32 g Tris buffer in 200 µl of mH2O was added.  The resultant 
mixture was stirred to dissolve and allowed to cool.  Then 22 mg of APAD was 
added and the pH adjusted to 9.  The solution was transferred into a bottle and 
covered with foil to reduce exposure to light since NBT is light sensitive. All the 
reagents were stored at 4ºC.  
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3.1.10 Data analysis 
The absorbance of each well was read when the colour changes from yellow to 
purple, using a microplate reader at 590 nm. The percentage parasite survival 
and the concentration that inhibits the growth of parasites by 50% were 
determined by measuring the conversion of NBT by P. falciparum. This was 
achieved by analyzing the readings from the microplate reader using Microsoft 
Excel® 2002, and the IC50 value which is the concentration at which the growth 
of the parasite was inhibited by 50% was determined using a non-linear dose 
response curve fitting analysis in Graph Pad Prism version 4.  In this study the 
IC50 values are mean of 2 or more independent experiments. 
 
3.2 In vitro Cytotoxicity experiment 
Cytotoxicity testing of samples was carried out using the following media as 
listed below. 
Complete medium: This is made up of 10% FCS, 45% DMEM and 45% 
HAMS 
Thawing medium:  This solution consists of 30% FCS, 35% DMEN and 35% 
HAMS 
Freezing medium:  Solution of 90% FCS, 10% DMSO (filter sterilized) 
 
3.2.1 Preparation of medium and reagents for cell culture 
 
Dulbecos Modified Eagles Medium (DMEM) (Highveld Biological, South 
Africa) is made up of 13.53 g/L DMEM and 3.7 g/L NaHCO3 in an acid clean 
volumetric flask and pH of 7.1.  The solution was stirred for about 30 minutes, 
pre-filtered and supplemented with gentamycin (500 µl/L or 0.05 g/L) into sterile 
bottles and stored in the fridge at 4ºC. 
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Nutrient Mixture F-12 HAM (HAMS) (Sigma) contains 10.7 g/L HAMS and 
1.17 g/L NaHCO3 in an acid-clean flask at a pH of 7.1.  This is filter sterilized, 
decanted into sterile bottles, and stored in the fridge at 4ºC. 
 
Foetal Calf Serum (Highveld Biological, South Africa) was heat inactivated and 
stored at -20ºC.  The cells were cultured and maintained in complete medium 
(CM), thawed in a thawing medium and frozen in a freezing medium. 
 
Trypsin (Highveld Biological, South Africa) contains 0.10 g in 100 ml PBS.  
This was stirred for about 30 minutes, filter sterilized and stored at 4ºC. 
 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
salt contains 5 mg/ml in Millipore water.  The aliquot is filter sterilized before 
use and stored in a bottle at 4ºC. 
Emetine was used as the positive control for the cytotoxicity assay (Clarkson et 
al., 2004, Chukwugekwu et al., 2009, Lategan et al., 2009)..  The stock was 
made up with 2 mg/ml Millipore water and stored at 4ºC.   
 
3.2.2 Subculturing Cells 
The cells were cultured in the flask with vented caps (Greiner Bio-one) and 
incubated at 37ºC.  They were maintained as a monolayer and subcultured as 
soon as they became confluent.  To subculture the cells in the flask, all the 
medium used in culturing them earlier was removed and the cells rinsed twice 
with 10 ml each of sterile phosphate buffer saline (PBS).  This was followed by 
the addition of 5 ml of 10% sterile trypsin (Highveld Biological, South Africa).  It 
was placed in an incubator for 2 minutes and agitated slightly to lift cells.  Long 
exposure to trypsin was avoided. To inhibit the activity of the trypsin, 5 ml of 
complete medium (CM) was added.  The cell suspension was transferred to a 
sterile tube and centrifuged at 750 rpm for 5 minutes.  The supernatant was 
poured off completely.  The pellet was resuspended in 5 ml CM, and 1 ml of the 
cell suspension was transferred into a new flask containing 9 ml CM.  This was 
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placed back into the incubator at 37ºC.  However, if the cells were to be frozen, 
the method below was applied. 
 
3.2.3 Freezing and cryostorage of cells 
 The freezing medium consist of 90% FCS and 10% DMSO (filter 
sterilized).The confluent cells were harvested and resuspended in 5ml CM as 
described above.  The resultant cell suspension was slowly mixed with freezing 
medium (2 x volume of cells) while swirling on ice.  They were decanted into 
cryotubes, swabbed thoroughly with webcol, sealed and stored in liquid 
nitrogen at -80ºC.  Thawing the cells involved the procedure described below. 
 
3.2.4 Thawing cells 
The thawing solution was made up of 30% FCS, 35% DMEN and 35% HAMS.  
The frozen cells in the cryotubes were placed in a beaker with ice to thaw.  
They were allowed to thaw completely in a cold thawing medium.  The contents 
were centrifuged at 750 rpm for 5 minutes and the supernatant was poured off.  
The pellets were resuspended in thawing medium and 1 ml of this suspension 
was transferred to flasks containing 9 ml of thawing medium.  This was 
incubated at 37ºC (5% CO2) and left to attach for 48 hours.  If the cells had not 
reached confluency, then the medium was changed as stated in section 3.2.5. 
 
3.2.5 Changing medium 
The flasks containing the cells were viewed under the microscope to confirm if 
they were confluent or not.  Half of the medium (5 ml) was changed and 
replaced with a fresh CM (5 ml) if they were not confluent. They were placed 
back into the incubator.  These procedures were performed under sterile 
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3.2.6 Cytotoxicity assay 
The mammalian Chinese hamster ovarian (CHO) cell line was used to 
investigate the cytotoxicity activity of all extracts, fractions and compounds.  
The CHO cell line was obtained from S. Schwager in the Department of 
Medical Biochemistry, University of Cape Town, South Africa.  This cell line 
was chosen because of its wide acceptance and the little or no difficulty 
experienced in culturing and maintaining it in vitro (Clarkson et al., 2004).  The 
cytotoxicity assay used in this study was the modified method described by 
Mossman et al. (1983).  This is a rapid colorimetric assay method for 
determining cellular growth and chemosensitivity. It makes use of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) salt.  There is a 
cleavage of the tetrazolium ring in active mitochondria showing that only viable 
cells are able to reduce the yellow coloured, water-soluble MTT to purple 
coloured, water-insoluble formazan (Sieuwerts et al., 1995). 
 
3.2.7 Preparation of samples for cytotoxicity assay      
The preparation was the same for all of the extracts and fractions tested as 
described earlier (3.1.6).  Briefly, a stock solution of 2 mg/ml of sample was 
prepared in 10% MeOH (in deionised water).  This was further diluted in 
complete medium to attain a final concentration of 200µg/ml in 1% MeOH.  
Owing to the high lipophilic nature of compounds investigated in this study, DL-
α-dipalmitoylphosphatidylcholine (DPPC) (Sigma) served as a vehicle for these 
compounds. Fatty acids were dissolved in chloroform (2 mg/ml).  Mixed fatty 
acids and DPPC micelles were prepared by adding DPPC four-fold the amount 
of fatty acid.  Solvents were evaporated under nitrogen and 1 ml of complete 
medium (RPMI 1640) was added to the mixture.  The mixture was sonicated for 
2 minutes and thereafter used for assay.  The stock solutions were prepared on 
the assay day. Emetine (Sigma) was used as the standard reference drug 
(control) to establish the cytotoxicity of the sample against the CHO cell lines 
(Clarkson et al., 2004; Chukwugekwu et al., 2009; Lategan et al., 2009). Two 
 
Chapter 3 – Materials and Methods 
 
 65 
mg/ml stock of emetine was constituted in deionised water and stored at 4ºC.  
A 10% dilution of stock solution in CM was made in complete medium to give 
the highest concentration of 200 µg/ml and the lowest concentration of 0.002 
µg/ml.  These concentrations were tested to determine the cytotoxicity of test 
samples against the CHO cells, as well as the IC50 by comparing with the 
reference drug emetine.   
 
3.2.8 Cytotoxicity assay  
This assay method could be grouped into two phases; the first is plating the 
cells and the second is addition of drugs. 
 
3.2.8.1 Plating cells 
A 96-well microtitre plate (Greiner-Bio one) was used.  The cell suspension was 
prepared as explained during subculturing (3.2.2).  Row H was used as blank 
and contained 200 µl CM only (with no cell suspension), while 100 µl of cell 
suspension + 100 µl CM were added from rows G-A.  The plate was incubated 
for 24 hours.  After 24 hours, cells became exponential and drugs were added 
at this juncture. 
 
3.2.8.2 Addition of drug 
After 24 hours, the CM was aspirated off.  Row H was the blank (200 l CM) 
Row G which served as the negative control received 200 µl CM with no drug, 
while rows F-A contained 100 µl of drug concentrations in triplicate + 100 µl 
CM.  Thus each well had a final volume of 200 l.  The plate was covered with 
a sterile lid (Greiner Bio-One) and incubated for 48 hours at 37ºC (5%CO2). 
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3.3 Developing plates 
After incubation for 48hours, 25µl of MTT was added to each well and 
incubated for a further 4 hours.  The plate was centrifuged at 200 rpm for 10 
minutes.  The medium was carefully aspirated off and 100 µl DMSO was added 
to dissolve the resultant purple formazan crystals.  The cell survival was 
determined using a microplate reader at 540 nm wavelength.  The data was 
analyzed using Microsoft Excel® 2002 and Graph Pad Prism, version 4 was 
used for the non-linear dose response curve analysis.  The IC50 values were 
given as a mean of 2 or more independent experiments. 
 
3.3.1 Selectivity index (SI) 
The selectivity index, which is the cytotoxicity: antiplasmodial ratio, was 
calculated to determine if the recorded activity was due to the antiplasmodial 
activity of the test samples or due to cytotoxicity to CHO cells.  The formula 
below was used to calculate selectivity index (Attioua et al., 2007; Kaou et al., 
2008; Chukwujekwu et al., 2009,). 
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3.4 In vitro drug combination experiment 
3.4.1 Combination therapy  
 
3.4.1.1 Plate Preparation for drug combination assay 
The plate set up was the same as described in 3.1.7. The checkerboard 
method used in this study was adapted from Berenbaum (1978).  The in vitro 
combination studies involved two extracts a and b.  One extract (component a) 
with a predetermined concentration needed to inhibit parasite growth by 50% 
(IC50) was kept constant, while the other extract also with a pre-determined IC50 
(component b) was added at different concentrations to determine the 
antiplasmodial effect of the two extracts in combination.  The same experiment 
was repeated, this time with component b constant while component a was 
varied.  The combination experiment used a 96-well microtitration plate.  The 
first column was the blank with complete medium and unparasitised 
erythrocytes (100 µl complete medium (CM) +100 µl RBC), while the second 
column contained complete medium with parasitized erythrocytes (100 µl 
CM+100 µl pRBC). The wells in columns 4-12 contained 100 µl of complete 
medium. Wells in column 3 contained 100 µl of [50 µg] concentration of 
component a in CM, except for the first duplicate rows (3A and 3B) which had 
the concentration of component a alone (200 µl).  The rest of the rows in 
duplicate (rows C to H) containing 100 µl of CM received additional 100 µl 
aliquots of 50%, 25% and 5% of the IC50 of component b, respectively. Serial 
dilutions of these concentrations were made from columns 3 to 12 using a 
multichannel pipette with a volume of 100 µl transferred after resuspending 
thoroughly.  The last 100 µl from column 12 was discarded.  A volume of 100 µl 
pRBC was added to wells in columns 3-12 halving the drug concentrations. The 
final volume in each well was 200 µl.  Plates were gassed for 2 minutes 
(93%N2, 4% CO2 and 3% O2) and incubated for 48 hours, as carried out in the 
in vitro monotherapy experiment.  The plates were developed using the pLDH 
assay method (3.1.8), and read using the microplate reader at 590 nm.  The 
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results were analyzed using Microsoft Excel® 2002 and the Graph pad prism, 
version 4.  This method was used initially for studying drug interactions with 
bacteria (Hall et al., 1993).  However, the principles are easily applied to P. 
falciparum (Fivelman et al., 2004).  
 
3.4.1.2 Plate preparation for drug combination cytotoxicity test  
The combined drugs were tested for cytotoxicity, as already described, using 
the CHO cell lines.  This was done to determine if the activity of the combined 
drugs was due to cytotoxicity to the CHO cell lines or to the selectivity for 
Plasmodium falciparum. The plates were analyzed in the same way, as 
explained in the monotherapy experiments.  
 
3.4.1.3 Method used to measure synergism, additivity or 
antagonism of combined extracts 
 Fractional inhibitory concentrations (FIC) as described by Berenbaum (1978) 
were used to determine the interactions between the plants in combination. 
This method has been used by other researchers including Canfield et al. 
(1995) and Fivelman et al. (2004)).   
                                                                             
The formula used in calculating the sum of the fractional inhibitory 
concentrations (FIC) is: 
 
              IC50 (µg/ml) of extract (a) in combination 
              IC50 (µg/ml) of extract (a) alone 
                                  + 
             IC50 (µg/ml) of extract (b) in combination 
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3.5 Procedures for the bioassay guided fractionation, isolation 
and identification of compounds from C. papaya ethyl acetate 
fraction. 
 
3.5.1 Solid phase extraction (SPE) 
The solid phase extraction (SPE) procedure was carried out with reverse phase 
octadecyl C18 Isolute cartridges (2.6x13.0 cm, 10 g sorbent, IST Ltd, Anatech, 
South Africa).  Samples of the ethyl acetate extract from the leaves of C. 
papaya were dissolved in methanol.  This mixture was diluted to a 
concentration of 5mg/ml with a 60% acetonitrile concentration in water 
(60%ACN:40%mH2O).  The C18 isolute cartridge was pre-moistened with 20 
ml of mH2O and preconditioned with 20 ml of the 60% acetonitrile.   A volume 
of 3 ml of this solution was layered on the top of this cartridge.  Samples 
retained on the sorbent beds were rinsed with 20 ml of mH2O to elute 
unretained material. Samples retained on the sorbent beds were eluted under 
vacuum through a step-wise gradient with 40 ml of ACN:H2O (20%-100%) at an 
increasing concentration of 20%.  The eluates were collected in a fitted bottle.  
The vacuum pressure was set to control the flow at the rate of 15 ml/min.  At 
the end of each run, the cartridge was washed with 100 ml acetone to wash out 
any remaining material.  The collected fractions were concentrated under 
pressure by rotary evaporation at 40ºC and freeze-dried.  The freeze-dried 
samples were placed in vials and stored at -20ºC.  The 100% ACN fraction was 
transferred to pre-weighed vials, dried in the fume hood and stored at -20ºC. 
The in vitro antiplasmodial activities of these fractions were determined using 
the pLDH method described earlier (3.1.8). The SPE fraction, with promising 
antiplasmodial activity and good selectivity index (P63 100% acetonitrile), was 
further purified using high pressure liquid chromatography (HPLC), and 
structurally elucidated using NMR and GC-MS spectroscopic methods, as 
described below.  
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3.5.2 High Pressure Liquid Chromatography (HPLC) 
The SPE fraction selected for further purification was fractionated on a 
Shimadzu LC 10AS high pressure gradient system.  This was equipped with a 
desktop PC which runs Shimadzu control software via a Shimadzu CBM10A 
communication bus module.  Other components of the HPLC instrument 
included an automatic sample injector, two solvent delivery systems (LC10AS 
pumps) and a diode array detector (Shimadzu SPDM10A).  Compounds were 
detected by UV spectra at 210 nm, 240 nm and 260 nm as acquired by the 
diode array detector.  The solvents used include methanol (Scharlau) and 
acetonitrile (Scharlau), each of analytical grade.  Purified deionized water 
(Millipore, milli-Qwater system) was also used. The conditions are stated 
section 3.5.3. 
 
3.5.3 Semi-preparative HPLC conditions  
A semi-preparative HPLC C18 column (Discovery®, 25cm x 10mm, 5µm, 
56924-U Supelco) was used.  Samples were chosen based on their in vitro 
antiplasmodial activity, as well as their cytotoxicity values.  Samples were 
centrifuged in a micro-centrifuge (Abbott, Germany) at 1000 rpm in 5 minutes.  
The injection volume was 50 µl with a flow rate of 2 ml/min over a 30 min run 
time and a solvent gradient of 20%-100% acetonitrile in water.  The elution time 
of the peaks was observed, noted, and set up for further collections following 
multiple injections.  The fractions collected were concentrated using the rotary 
evaporator and freeze-dried.  Dried samples were tested in vitro against 
Plasmodium parasites, and the active peaks were run on analytical HPLC.  The 
concentrated and dried samples of the two peaks were tested for purity using 
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3.5.4 Analytical HPLC conditions 
The purity of the compounds was monitored by an analytical HPLC using an 
octadecyl Silica column (Agilent Eclipse, XDB-C18, 4.6x150mm, 5µm, USA).  
Separations were accomplished at 29.7ºC with a solvent gradient of 20%-100% 
acetonitrile in water for 30 minutes at a flow rate of 1 ml/min.  Pure compounds 
were identified and structurally elucidated using GC-MS and NMR 
spectroscopic methods. 
  
3.5.5 Nuclear Magnetic Resonance (NMR) 
The NMR spectra were performed on a Varian Unity Inova 600 MHz system 
available at the University of Stellenbosch, Stellenbosch). The compounds were 
dissolved in methanol at a concentration of 3 mg/ml. NMR spectroscopy made 
use of 1-D NMR and 2-D NMR techniques.  The 1D NMR; 1H and 13C were used 
and the 2-D NMR techniques used in this study included HSQC, HMQC, and 
COSY.   
                
3.6 GC-MS conditions  
The HPLC samples were analyzed on a Waters GCT premier spectrometer, 
model HP5.  The column specification was 30 m, 0.25 mm ID, 0.25 µm film 
thickness.  The carrier gas was helium, with a constant flow of 1 ml/min.  The 
injection split was 1:5, the injector temperature and the transfer temperature 
were 280ºC.  The EI ionization energy was 70eV, the scanning mass range 
was m/z 40 to 400 with a solvent hold of 6 minutes.  The peaks of the two 
compounds were identified by comparison with the retention times of reference 
standards.   
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3.7 In vivo Bioavailability and Activity methods 
    
3.7.1 Animals and diet 
This study was approved by the Animal Research Ethics Committee of the 
University of Cape Town, South Africa in 2007.  All animal procedures were 
carried out in accordance with the suggested ethical guidelines for care of 
laboratory animals by the Animal Care and Use Committee of the University of 
Cape Town, as adapted from the recommendations of the Medical Research 
Council of South Africa (MRC 2004).  The test animals were wild strains of C57 
BL6 mice.  Mice were obtained from the animal unit of the University of Cape 
Town (South Africa) at the ages between 7-10 weeks old.  The animals were 
transferred to the animal facility of the Division of Pharmacology, University of 
Cape Town. As soon as they arrived at the facility they were housed in 
standard cages in groups of five and placed on a pelleted custom diet. They 
were maintained under conventional conditions with controlled temperature 
(22±4ºC) and illumination (12h; 6:00 am to 6:00 pm) and had free access to 
standard diet and water ad libitum. 
 
 
3.7.1.1 Plasma Preparation for bioavailability study 
 
Whole blood samples (O+) were obtained from the Western Province Blood 
Transfusion Service, Groote Schuur Hospital, Cape Town, South Africa.  Blood 
was centrifuged at 1300 rpm for 5 minutes. Plasma (supernatant) was stored at 
-20ºC.  This was used in the preparation of standards for method development 
and evaluation. 
 
3.7.1.2 Sample formulation and treatment of animals 
The average weight of each group of mice in a particular cage was calculated 
and 100 mg/kg of compound was given to groups A, B and C.  Group A was 
dosed orally, group B and group C received subcutaneous and intravenous 
dosage, respectively.  Fatty acid methyl ester (FAME) micelles were prepared 
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according to the method of Kumaratilake et al., (1992).  This method was used 
in preparing all of the fatty acids and their FAME used in both the in vitro and in 
vivo experiments. Solutions were freshly prepared before treatment.   The 
unsaturated fatty acids and their esters are insoluble in water. DL-α-Dipalmitoyl 
phosphatidylcholine (DPPC) (Sigma) was served as a vehicle to these 
compounds due to their lipophilic nature. Fatty acids were dissolved in 
chloroform (10-50 mg/5 ml).  Mixed fatty acids and DPPC micelles were 
prepared by adding DPPC at four-fold the amount of the fatty acid.  Solvents 
were evaporated under nitrogen and 1 ml of complete medium (RPMI 1640) 
was added to the mixture.  Thereafter, the mixture was sonicated for 2 minutes 
and used for the in vivo experiments.  A volume of 200µl of the resultant 
solution was given to each mouse in the three routes of administration using a 
calibrated syringe.  The same dose was given to the 3 groups for a better 
comparison.  The subcutaneous injection was administered just behind the ears 
in between the two fore arms.  For the intravenous dosage (i.v), mice were 
anesthetized with ketamine 15 minutes before dosing.  All groups were given 
free access to food and water immediately after dosing. 
 
 
3.7.1.3 Blood collection and sample preparation for analysis 
Venous blood (50µl) was collected through the base of the eye using 
heparinized tubes (Lasec 200 capillary tubes; 75mm, 1.40-1.60mm, 80µl; for 
micro-hematocrit determination) from the Laboratory and Scientific Equipment 
Company (Lasec), Cape Town, South Africa. Blood samples were taken from 
experimental animals at four time points (t1 to t4) after administration.  Blood 
samples were immediately transferred to pre-labeled (group A) Eppendorfs in 
an ice pack and centrifuged at 1300 rpm for 5 minutes.  A volume of 20 µl of 
the plasma was transferred into pre-labeled Eppendorfs in group B.  The group 
B Eppendorfs, now with 20 µl plasma, were kept in a -20ºC freezer for 
subsequent extraction.   
 




3.7.1.4 Preparation of Standards 
An initial stock solution (SS1) of 1 mg/ml concentration of compound 1 was 
prepared in methanol. Seven standards (STD 1-7; stock solution of standards) 
from the initial stock solution (SS1) of compound 1 were prepared by two-fold 
serial dilutions in plasma with a starting concentration of 20 µg/ml to 0.3125 
µg/ml.   The seven standards STD 1 to STD7 were labeled in decreasing order 
of concentration such that the highest is STD1=20µg/ml while the least 
concentrated STD7=0.3125µg/ml. Blank plasma was also included to serve as 
a control.  Samples were stored at -20ºC for short term storage and at -80ºC for 
longer durations.  However, before analyzing the samples, the LC/MS/MS 
spectrometer and the chromatographic conditions were developed and 
optimized. 
 
3.7.1.5 Extraction from plasma 
The test samples and the standards (STDI-STD7) were extracted.  These 
standards and fatty acid methyl ester were extracted using a modified method 
of Aleryani et al. (2005).  A volume of 100 µl of acetone was added into 20µl of 
spiked plasma (20µg/ml) in labeled Eppendorfs (Group B).  Acetone was added 
to precipitate protein.  The solution was vortexed for a minute and placed in ice 
for ten minutes.  It was then centrifuged at 1120 rcf for 5 minutes.  The resultant 
supernatant was transferred to labeled Eppendorfs (Group C).  Hexane (150 µl) 
was added to group C Eppendorfs, vortexed for a minute, placed in ice for ten 
minutes and centrifuged at 200 rcf for 5 minutes.  The hexane layer was 
transferred to group D Eppendorfs and dried under nitrogen.  After drying was 
completed, 100 µl of mobile phase (acetonitrile: 0.1% formic acid; 50:50) was 
added to these Eppendorfs.  The mixture was vortexed for 30 seconds and 
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3.7.1.6 LC/MS/MS Analytical and Chromatographic conditions  
The LC-system (Agilent 1200 series HPLC) equipped with an API 3200 
quadrupole mass spectrometer detector (Applied Biosystems) was used in the 
experiment.  This was carried out by direct injection of 2 µl at a flow rate of 0.5 
ml/min using a Phenomenex C18 (5 cm x2 mm i.d., 5 µm) column.  The mobile 
phase (MP) was acetonitrile: 0.1% formic acid (50:50) which was run 
isocratically for 1.9 minutes.  The stability of the eluent system was efficient for 
identifying the retention times of compounds. Further in vivo study was carried 
out as shown in section 3.7.2. 
 
3.7.2 In vivo antiplasmodial experiments 
3.7.2.1 Test animals and diet 
The test animals and their diet were the same as outlined earlier (3.7.1). 
 
3.7.2.2 In vivo toxicity study of crude extracts 
The in vivo toxicity testing of extracts was investigated at a dose of 800 mg/kg 
for 4 days.  The extracts dissolved completely in 200 µl ethanol, 20µl Tween 80 
and 780 µl phosphate buffered saline (PBS).  The dosage was administered 
orally.  The test animals were monitored for 4 weeks to ascertain if there were 
any adverse events.  The same formulation was used for the in vivo 
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3.7.2.3 Parasite strain 
The parasites used for this experiment were of the cryopreserved P. berghei 
(ANKA) strain.  This parasite strain was donated by the Swiss Tropical Institute, 
Basel, Switzerland.  Parasite stock was preserved in liquid nitrogen at -80ºC in 
the Division of Clinical Pharmacology, University of Cape Town.  Parasite stock 
was sustained by serial passage of blood from infected mice to uninfected 
mice.  Parasitemia was monitored regularly.  At a desired parasitemia, the mice 
were bled and euthanized.  Blood samples collected were frozen in cryotubes 
and stored in liquid nitrogen at -80ºC. 
 
3.7.2.4 Infection of experimental animals 
The parasite stock which was frozen in cryotubes was thawed.  The thawed 
parasites were diluted in phosphate buffered saline.  The inoculum was injected 
intra-peritoneally into two mice which received 200 µl each.  After a period of 6 
days, the parasitemia was determined.  An incision was made in the tail vein 
and a drop of blood was placed on the slide.  Thin smears were made and fixed 
in methanol and stained in 10% giemsa stain for 25 minutes.  This is ten 
minutes longer than the duration of staining slides of in vitro experiments.    
After the staining, a drop of immersion oil was placed on the slide and viewed 
under a light microscope.  The parasitemia was determined.  A volume of 200 
µl of 1x106 parasitized cells/ml was used to infect each mouse.  The number of 
cells/ml was calculated using a haemocytometer and was diluted to a 
suspension of 5x106 using phosphate buffered saline (PBS).  All animals used 
in the in vivo antiplasmodial study were each infected with 200 µl of 1x106 
parasitized cells/ml.  The percentage growth inhibition was determined 
according to Tona et al. (2001) as follows; 
 
% growth inhibition=   Parasitemia of negative control- Parasitemia of test sample X 100 
                                                    
                                                          Parasitemia of negative control                                             
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3.7.2.5 Treatment of experimental animals 
The in vivo testing of crude extracts and compounds against Plasmodium 
berghei was done using the 4-day suppressive test described by Peters et al. 
(1993).  Each experiment had a positive control group and a negative control 
group.  The positive control group received 200 µl of CQ (reference drug) at a 
dose of 10 mg/kg in Millipore water.  The negative control group received 200 
µl Millipore water only.  Solvent control test fot the formulation (200 µl ethanol, 
20µl Tween 80, and 780µl phosphate buffered saline) used in dissolving the 
extracts showed no antiplasmodial activity.  Test groups and control groups 
were grouped as five animals in separate cages. Mice and cages were 
distinctively marked and labeled, respectively with permanent marker.  The test 
animals were uniformly treated with different doses of extracts, singly or in 
combination. The extracts dissolved completely in 200 µl ethanol, 20µl Tween 
80, and 780µl phosphate buffered saline.  The extract was dissolved first in 
ethanol and Tween 80 before adding PBS. Extracts were administered orally.  
Each mouse in the test group received 200µl of drug formulation 24 hours post 
infection.  The mice were monitored on a daily basis and physical appearance 
and weights were noted.  Parasitemia was determined 3 days post-infection 
and this was regularly monitored.  The length of time prior to the mice being 
sacrificed was subject to the parasitemia, mouse disposition and general well-
being of animal, as recommended by the animal care and use committee. 
 
3.7.2.6 4-day suppression test 
The four-day suppression test used in all in vivo antiplasmodial experiments 
was as described by Peters et al. (1993).  Animals were infected on day 0, (D0) 
while treatment started 24 hours after infection (D1).  The parasitemia of each 
group was determined and the standard deviation values taken as the mean 
value for the group.  Mice were sacrificed day 9 post infection, except on 
occasions where mice were very sick before day 9, or still showing no 
parasitemia on day 9.  Mice with no parasitemia on day 9 were left for 28-days 
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post infection in accordance to WHO, 2006 specifications for determining cure 
of infected mice.  During this period, in order to establish cure, mice were 
monitored daily and parasitemia determined two to three times a week. 
 
3.7.2.7 In vivo data analysis  
Parasitemia of all groups was monitored, and growth inhibition calculated, as 
shown earlier (3.7.2.4).  The standard deviation values of parasitemia and 
weight were determined using the Microsoft Excel® 2002.  The percentage 
parasitemia relative to the number of days post infection was evaluated using 
the Graph Pad Prism 4 version. 
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Seven plants were collected in this study based on their traditional use to treat 
malaria in Nigeria.  They were sequentially extracted using solvents of different 
polarities (Petroleum ether, Dichloromethane, Ethyl acetate, Methanol and 
Millipore water). Fractions from each plant were screened for in vitro 
antiplasmodial activity singly.  Selected fractions with IC50 ≤10 µg/ml were 
further tested in combination.  The figure 4.1.1 schematically illustrates the 










Purification, isolation and structural elucidation
 
 
Fig 4.1.1: Schematic representation of phytochemical screening to 
isolate antiplasmodial compounds.  Extraction solvents include; 
Petroleum ether (PET), Dichloromethane (DCM), Ethyl acetate (EA) 
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4.2 Plant collection, extraction and yield 
4.2.1 Study Site  
   Nigeria is a West African country located at latitude 10º00´ north of the equator 
and longitude 8º00´ east of Greenwich.  It is a tropical country with 
characteristic hot and wet conditions.  These conditions are due to the two 
major seasonal variations, the rainy season and the dry season.  However, the 
south eastern part of Nigeria, where the plants were collected, has an 
additional shorter version of each season coming between the two major 
seasons.  This is not the case in the northern part of Nigeria where the two 
major seasons prevail.  The two major seasons with their shorter versions at 
the collection site are: the long rainy season, the short dry season, the short 
rainy season, and the long dry season.  The plants were collected during the 
long rainy season.  The long rainy season starts in March and continues to the 
end of July.  The peak of this season is in June. Malaria transmission reaches 
its peak during the rainy season (Falade et al., 2007).  The long rainy season is 
followed by what is commonly known as August break which is the short dry 
season.  As the name suggests, it is indeed a short, dry period experienced in 
August for about 2-3 weeks.  A short rainy season commences after the August 
break. It starts in early September and runs to mid-October, with its peak 
usually at the end of September.  The rains in the short rainy season are 
usually not as heavy as those experienced during the long rainy season.  Last, 
but not the least, is the long dry season which spans through October and early 
March.  The peak of this period is between early December and late February.  
This is also commonly known as the harmattan period and is usually dry with 
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4.2.2 Collection of Plants 
A total of seven plants, each from a different plant family, were collected from 
Okigwe, Imo state in Nigeria.  These plants were collected during the long rainy 
seasons in Nigeria.  The choice of these plants for investigation was made due 
to their popularity in Nigerian folk medicine (Igoli et al., 2005).  These plants 
were commonly used by traditional healers in the diverse ethnic regions of the 
country for the treatment of febrile illnesses and related ailments (Igoli et al. 
2005).  The plants collected for this study are available all through the year and 
there is little or no difficulty in their propagation.  The plants used for this study 
were collected and identified by the Plant Science and Biotechnology 
Department, Abia State University, Uturu, Nigeria.  These plants were air dried 
at room temperature and voucher specimens (Table 4.2.2.1), were deposited in 
the herbarium of Abia state University, Uturu, Nigeria.   The air dried plant 
materials were packaged and couried to the University of Cape Town in South 
Africa.  Collection of these plants in Nigeria was met with no difficulty or 
restraint, since the plants are used as food, and are found growing in homes. 
This study established collaboration between University of Cape Town in South 
Africa and the Abia state University in Nigeria.  The Division of Pharmacology in 
the University of Cape Town requested for the importation of these plants from 
Nigeria.  The Nigerian custom services granted the demand of the Abia State 
University to export these materials to the University of Cape Town South 
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    Table 4.2.2.1 Voucher specimen numbers of collected plants 
Botanical Names Voucher specimen numbers 
Mangifera indica PM/ABSU/06-20 
Citrus limon PM/ABSU/06-32 
Musa sapentium PM/ABSU/06-40 
Psidium guajava PM/ABSU/06-52 
Carica papaya PM/ABSU/06-63 
Cymbopogon citratus PM/ABSU/06-72 
Vernonia amygdalina PM/ABSU/06-82 
 
      
 
Table 4.2.2.2: Names and dry weight (g) of plants collected 




Part used Dry 
weight of 
plants (g) 
1 Mangifera indica Mango Mango Leaves 115.6 





3 Musa sapentium Plantain Plantain Leaves 48.4 
4 Psidium guajava Guava Ugofa/ 
uguava 
Leaves 84.4 







Achara Leaves 43.7 
7 Vernonia 
amygdalina 
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4.2.3 Solvent extraction of plant material 
The dry plants were reduced into smaller pieces using a plant blender (Waring, 
Connecticut, USA).  They were sequentially extracted using various solvents of 
different polarities.  This sequential extraction started with petroleum ether, 
which helps in reducing the chlorophyll pigment in these green leaves.  This 
was followed by dichloromethane extraction, thereafter ethyl acetate, methanol 
and water in that order.  Each solvent was repeatedly used to extract each 
plant for 4-5 times.  Plants were extracted for 24 hours, and during the process 
the plant material and the solvent were continuously shaken for adequate 
mixing on a horizontal orbit shaker (Labcon, California, USA).  The resultant 
mixture was filtered and the filtrate concentrated under pressure in a Büchi 
Rotavapor R-205 (Büchi Labortechnik AG Switzerland), at 24ºC.  The 
concentrated extracts were transferred to pre-weighed vials, dried in the hood 
at room temperature and stored at -20 ºC.  The water extracts were 
concentrated by freeze drying using a DURA-DRY ΙΙ instrument (FTS Systems, 
NY, USA) under a reduced pressure at -82ºC.  The freeze-dried extracts were 
stored at -20ºC.  This procedure was carried out for the seven plants collected.  
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1260.4 868.9 631.3 8633.6 121.3 10.0 
Citrus limon 1162.9 366.9 91.2 2894.8 1223.5 11.9 
Musa 
sapentium 
1699.8 106.7 42.5 1634.4 650.7 8.5 
Psidium 
guajava 
1617.2 791.6 536.6 7965.8 91.7 13.0 
Carica 
papaya 
1432.7 839.4 187.8 6563.1 7.0 23.4 
Cymbopogon 
citratus 
1060.5 506.7 84.0 4790.7 1307.9 17.8 
Vernonia 
amygdalina 




4.3 In vitro activity testing 
4.3.1 In vitro antiplasmodial activity of the plants collected  
Each extract was screened for antiplasmodial activity against the chloroquine 
sensitive (CQS D10) strain of P. falciparum.  The method used to measure 
parasite viability was the parasite lactate dehydrogenase activity (pLDH) 
method of Makler et al. (1993).  This is a colorimetric enzymatic method which 
distinguishes parasite LDH (pLDH) from host LDH activity.  Lactate is converted 
to pyruvate by pLDH and APAD is reduced to APADH in the presence of living 
parasites.  The percentage of living parasites was determined by measuring the 
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conversion of NBT by P. falciparum.  Details of this method are described in 
section 3.1.8.   
 
4.3.2 Screening criteria 
Of the seven plants collected, two plants, M. indica and M. sapientum, showed 
little antimalarial activity (Table 4.3.2.1), and work with these two was not taken 
further.  In this study, plants with in vitro activities of ≤10 µg/ml were chosen.  
Chloroquine used during this screening showed an IC50 of 8.55±2.81ng/ml in 
the CQS D10 strain The five plants selected (Table 4.3.2.2) all contained 
fractions with in vitro activity ≤10 µg/ml in the chloroquine sensitive (CQS D10) 
and chloroquine resistant (CQR DD2) strains of the parasite (Table 4.3.3.1). 
The CQ used in the DD2 strain showed IC50 value of 98.5±26.1ng/ml 
 
 
Tables 4.3.2.1: The in vitro antiplasmodial activity of the seven plants 
extracted with the various solvents using the CQS D10 strain. 
 










M. indica 17.5 49.8 39.3 14.6 >50.0 
M. sapientum 27.0 52.2 >50.0 >50.0 >50.0 
P. guajava 15.5 6.0 21.6 >50.0 >50.0 
C. limon 37.2 5.0 >50.0 12.0 >50.0 
C. papaya 16.4 12.8 2.6 10.8 >50.0 
C. citratus 9.1 7.6 12.1 15.9 >50.0 
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4.3.2.1 Results and Discussion 
Water extracts showed no activity with all IC50 values >50µg/ml.  Irungu et al. 
(2007) recorded similar results in work with 14 plants.   Bhat and Surolia (2001) 
recorded no activity of the water extracts of C. papaya.  The petroleum ether 
extracts of the rind and pulp of the unripe fruit of C. papaya demonstrated 
antiplasmodial activities with IC50 values of 15.19 µg/ml and 18.09 µg/ml 
respectively (Bhat and Surolia, 2001).  Their observations using FCK 2 (a local 
strain of P. falciparum from Karnataka state, India) were similar to the IC50 
value of 16.36 µg/ml from the petroleum ether extracts of the leaves of C. 
papaya investigated in this study usin the D10 of P. falciparum (Table 4.3.2.1). 
Stronger antiplasmodial activities with IC50s of <10 µg/ml were seen mostly in 
the dichloromethane extracts, except C. papaya which showed the highest 
activity in the ethyl acetate fraction.  The IC50 values of the five selected 
extracts which had IC50 <10µg/ml compare favourably with those reported for 
extracts of Artemisia annua (3.9 µg/ml) and Azadirachta indica (≤10 µg/ml), 
against P. falciparum (Maria do Ceu de et al., 2002).  Methanol, as well as 
petroleum ether, extracts recorded activities of >10 µg/ml in most of the plants.  
The high activity recorded in the dichloromethane (DCM) extracts over extracts 
from other solvents, like water and methanol, was also reported by Koch et al. 
(2005).  This may be traceable to the absence of tannins, polysaccharides and 
other water- soluble molecules which do not have antiplasmodial properties.  
 
A second batch of the 5 selected plants was further collected and identified by 
the Botany department of the Abia State University Uturu, Nigeria.  The 
procedures for the second batch were carried out as was done in the first 
batch. The selected plants in the second batch were also sequentially 
extracted, as was carried out in the first batch, and the yields from the selected 
solvents were noted.  The HPLC profile, and the in vitro antiplasmodial 
activities, of the selected plants in the second batch, compares favourably with 
the corresponding plants in the first batch. Samples from the two batches were 
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pooled together.  The total yields from the first and second batch, as well as the 
total yield of the pooled samples are shown (Table 4.3.2.3). 
 
Table 4.3.2.2: Names and parts of selected plants after screening (second 
batch) 










2 Psidium guajava Guava Ugofa/ 
uguava 
Leaves 
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Table 4.3.2.3: The total weights and yields of the two batches and the pooled 
samples of each extract.  
 
Botanical 







































Citrus limon DCM 48.3 366.9 746.0 5665.3 794.3 6.0 0.8 
Psidium 
guajava 
DCM 84.4 791.6 1264.6 11860.8 1349.0 12.7 0.9 
Carica 
papaya 
EA 38.6 187.8 1950.6 9492.3 1989.2 9.7 0.5 
Cymbopogon 
citratus 
DCM 43.7 506.7 726.5 8424.0 770.2 8.9 1.2 
Vernonia 
amygdalina 
DCM 122.5 3430.7 201.5 5643.0 324.0 9.1 2.8 
            
            Key: DCM= Dichloromethane 
                      EA= Ethyl acetate 
 
 
The extract of interest from Carica papaya leaves was the ethyl acetate.  The 
percentage yield of the ethyl acetate fraction was lower compared to the 
dichloromethane fractions of the other four plants. The in vitro antiplasmodial 
and cytotoxicity activities of the selected extracts are shown in Table 4.3.3.1  
The extracts showed little or no cytotoxicity against the CHO cell line with 
selectivity indices ranging from 9.35-185.37 (Table 4.3.3.1). The control drug 
for the in vitro antiplasmodial experiment was chloroquine while that for 
cytotoxicity experiment was emetine (Clarkson et al., 2004, Chukwugekwu et 
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4.3.3. In vitro activity of selected plants after screening 
 
Table 4.3.3.1 In vitro antimalarial activity of the selected extracts on 



















C. limon DCM 5.01±0.32 5.99±0.39 247±2.94 49.30 41.23 1.19 
P. guajava DCM 3.38±1.16 4.60±1.00 85.64±2.14 25.33 18.61 1.36 
C.papaya EA 2.96±0.14 3.98±0.42 737.8±0.28 249.25 185.37 1.34 
C.citratus DCM 6.85±0.56 9.44±1.02 331±0.70 48.32 35.06 1.37 
V.amygdalina DCM 3.98±1.21 4.12±0.39 38.54±0.97 9.68 9.35 1.03 
 
IC50 values are given as the mean of three independent experiments 
Key:   DCM= Dichloromethane   EA= Ethyl acetate    
    SI=selectivity index=Cytotoxic antiplasmodial ratio (IC50 CHO/IC50 P.falciparum 




4.3.3.1 Results and Discussion 
For the five selected plants after screening the D10 strain used in the 
experiment was found to be CQ- sensitive with 50% inhibitory concentration 
(IC50) value of 9.21±3.01ng/ml while the DD2 strain showed IC50 value of 
98.5±26.1ng/ml. The representative IC50 values of the selected extracts in the 
cytotoxicity experiments are shown (Fig 4.3.3.3). The activity of the extracts 
against the chloroquine sensitive (D10) and chloroquine resistant (DD2) strains 
of P. falciparum did not differ significantly.  The strongest antiplasmodial activity 
was observed in the ethyl acetate fraction of C. papaya.  C. papaya showed a 
high selectivity for P. falciparum with a selectivity index of 249.25 and 185.37 
against the D10 and DD2, strains respectively.   
 
In general, an SI ≥10 signifies that biological efficacy is not the result of in vitro 
cytotoxicity (Attioua et. al., 2007, Chukwugekwu et al., 2009). Literature reveals 
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that other Vernonia species have been investigated for their antiplasmodial 
activities on other strains of P. falciparum.  Irungu et al., (2007) reported an 
antiplasmodial activity of 4.7 µg/ml against the K1 strain for the 
dichloromethane extract of Vernonia lasiopus.  This correlates well with the 
activity of V. amygdalina with IC50 values of 4.12 µg/ml and 3.98 µg/ml against 
the DD2 and D10 strains, respectively obtained in this study (Table 4.3.2.4). V. 
lasiopus is one of the plants used to treat malaria in Kenya (Muregi et al., 
2003).  The work of Muregi et al., (2003) also recorded similar observations on 
the antiplasmodial activities of Vernonia species investigated.   In the work of 
Pillay et al., (2007) the DCM extract of V. staehelioides showed an IC50 value of 
3.0 µg/ml against the D10 strain and is similar to the activity of the DCM extract 
of V. amygdalina in the present study (3.98 µg/ml) against the chloroquine 
sensitive D10 strain.  Extracts from leaves of V. brasiliana species using n-
hexane fractions also showed antiplasmodial properties (Alves et al., 1997).  V. 
colorata subspecies grandis was active against W2 with an IC50 value of 6 
µg/ml and 10 µg/ml against human monocytic THPI cells. In this study, V. 
amygdalina showed IC50 of 4.12 µg/ml and 38.54 against the DD2 strain and 
the CHO cell line, respectively.  Some Sesquiterpene lactones isolated from V. 
amygdalina such as vernolepin, vernolin, vernolide, vernodalin and 
hydroxyvernodalin have demonstrated antiplasmodial activity with IC50 values 
of <4 µg/ml (Phillipson et al., 1993), however, no cytotoxicity testing was done 
to establish if the recorded activity was due to the cytotoxic effect of the isolated 
sesquiterpene lactone.   Different species of the genus Vernonia have shown 
promising antiplasmodial activities. In addition, in this work, V. amygdalina 
showed a low RI of 1.03 when compared to other extracts indicating good 
activity against the CQ resistant strain.  Work done by Iwalokun (2008) showed 
that V. amygdalina dose dependently enhanced the efficacy of CQ against P. 
berghei.  This suggests that extracts of this species may be good candidates in 
the reversal of chloroquine resistance.  The in vitro antiplasmodial activity of C. 
citratus was not significantly different from C. limon.  Similarly, there was no 
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significant difference between the in vitro antiplasmodial activities of V. 
amygdalina and P. guajava (Fig 4.3.3.1 and fig 4.3.3.2).   
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Key; P52= Psidium guajava dichloromethane extract 
 
Plasmodium falciparum   dd2































Fig 4.3.3.1 The in vitro antiplasmodial dose response curves of the 
representatives of the selected extracts.    
  
Key:                    
            P32= Citrus limon dichloromethane extract 
P63= Carica papaya ethyl acetate crude extract 
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Fig 4.3.3.2 The in vitro antiplasmodial dose response curves of the 
representatives of the selected extracts. 
 
Key: P72= Cymbopogon citratus (DCM extract); P82= Vernonia amygdalina (DCM extract) 
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Fig 4.3.3.3 The in vitro dose response curves of representatives of the 
cytotoxicity experiments of selected extracts 
 
Key: 
Em= Emetine      
P72= Cymbopogon citratus dichloromethane crude extract 
           P82= Vernonia amygdalina dichloromethane crude extract 
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Most of the extracts showed equipotent activity against the sensitive and 
resistant strains of the parasite. However, it was apparent that there were slight 
increases in parasite survival in the DD2 IC50 as compared to the D10 IC50.  
This increase was significant between C. citratus and P. guajava.  
Representatives of the in vitro experiments with the extracts used in this study 
are further shown (figs A1-A3).  The traditional healers in Nigeria use these 
plants in combination in the treatment of malaria (Igoli et al., 2005). It was 
therefore decided to test the active extracts in combination for antiplasmodial 
activity to establish if they act synergistically.   
  
 
4.3.4 In vitro antiplasmodial activity of extracts in combination  
Combination therapy, which has been a strategy approved for other multidrug 
resistance infections such as HIV and tuberculosis, is widely recommended for 
malaria treatment (White, 1998; WHO, 2001).  Over the past decades 
combination therapy has gradually replaced single drug treatment due to the 
rapid spread of drug resistance by Plasmodium parasites globally (Martinelli et 
al., 2008).  Recently, artemisinin combination therapy (ACT) has been the main 
therapeutic treatment for malaria, but has been met with treatment failures in 
some regions.  This emphasizes the urgent need for the development of new 
drugs and combination treatments.  The antiplasmodial properties of the 
extracts from five plants were investigated in combination with each other 
(Table 4.3.4.1).  The combination study was confined to combinations of two 
extracts.  The checkerboard method used in the combination studies in this 
work was adapted from Berenbaum et al., (1978), as described in section 
3.4.1.1.   In this method the concentration of one extract is kept constant while 
in the other it is varied.  The in vitro dose response curves of representative 
extracts in combination using the D10 chloroquine sensitive strain are shown in 
fig 4.3.4.1 and figs A4 -A9. 
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Table 4.3.4.1: IC50 values (µg/ml) of two extracts in combination (a+b) 
when extract a is kept constant while extract b is the variable component 





        + 
50µg/ml b 
50µg/ml a 
        + 
25µg/ml b 
50µg/ml a 
        + 
5µg/ml b 
32+52  3.39 3.91 4.17 
52+32  3.09 4.89 6.76 
32+63  2.73 4.47 4.4 
63+32  0.83 1.65 2.28 
32+72  4.22 5.62 6.02 
72+32  6.6 8.1 11.4 
32+82  24.26 25.17 30.83 
82+32  17.03 13.5 19.01 
52+63  2.72 39.90 48.30 
63+52  2.31 2.59 6.32 
52+72  9.68 10.02 10.23 
72+52  6.08 10.30 13.89 
52+82  >50 >50 >50 
82+52  43.35 44.05 >50 
63+72  3.01 3.8 3.98 
72+63 4.07 4.51 4.46 
63+82  8.87 15.84 16.03 
82+63  4.42 8.74 23.01 
72+82  7.23 6.82 10.37 
82+72  9.1 9.5 11.2 
 
                      Key: P32= Citrus limon dichloromethane extract 
                    P52= Psidium guajava dichloromethane extract 
                    P63= Carica papaya ethyl acetate crude extract 
                    P72= Cymbopogon citratus dichloromethane crude extract 
                                   P82= Vernonia amygdalina dichloromethane crude extract 
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4.3.4.1 Results and discussion 
Results are shown in Table 4.3.4.1.  Some combinations such as that in 63+72 
and 32+52 do not show significant differences in their activity when either 
extract was kept constant and the other varied at different concentrations.  This 
suggests that their activities were not dose dependent. Combinations of 52+82 
showed no enhancement of the activity of either component in combination.  
However significant enhancement of activity was observed between the 
extracts 63+32. This suggests that some of the components in this combination 
may have acted synergistically (Berenbaum, 1978). Combinations with 
activities ≤10µg/ml were chosen and further tested against CQS and CQR 
strain (DD2). The results given are the mean of three independent experiments 
(Table 4.3.4.2).  A cytotoxicity experiment was carried out on selected 
combinations using the CHO cell lines. This was carried out to investigate if the 
activity of the extracts in combination at different concentrations is cytotoxic to 
the CHO cell lines or selective to Plasmodium falciparum.  The combinations 
were not cytotoxic at the concentrations tested (Table 4.3.4.2).  The cytotoxicity 
values of these combined extracts showed higher selectivity for P. falciparum 
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Table 4.3.4.2: In vitro activity of selected combination of crude extracts on  
Plasmodium falciparum D10 and DD2 strains and toxicity towards Chinese 














3.39±1.85  3.78±0.95 82.60 24.32 
63+32  
 
0.83±0.56 0.86±0.62 >100 ND 
63+52  
 
3.71±0.22  4.02±1.12 >100 ND 
63+72  
 
3.01±0.55  2.95±0.78 >100 ND 
32+72 
 
5.01± 1.21 4.98±1.86 >100 ND 
72+52  
 
5.01±0.74  5.28±1.03 >100 ND 
72+82  
 
4.43±0.21  3.82±0.72 >100 ND 
 
 
                      Key: P32= Citrus limon dichloromethane extract 
                    P52= Psidium guajava dichloromethane extract 
                    P63= Carica papaya ethyl acetate crude extract 
                    P72= Cymbopogon citratus dichloromethane crude extract 
                                  P82= Vernonia amygdalina dichloromethane crude extract 
 
a+b=extract a combined with extract b, IC50 values are given as the mean of 3 independent 
experiments.  ND= Not determined  
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Cytotoxicity: CHO cell line
C.citratus
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Fig 4.3.4.1 Dose response curves: The dose response curves of some representatives of 
the extracts in combination 
 
Key: P32= Citrus limon dichloromethane extract, P52= Psidium guajava   
dichloromethane extract,   P63= Carica papaya ethyl acetate crude extract 
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4.3.4.2 Determination of interactions between selected 
combinations   
 
In order to ascertain if the more active combinations were acting synergistically, 
their fractional inhibitory concentrations (FIC) were determined as described by 
Berenbaum (1978). This method has been used by other researchers including 
Canfield et al., (1995) and Fivelman et al., (2004)). CQ IC50= 9.21±3.01ng/ml. 
 
Table 4.3.4.2.1: The selected combinations and their effect when extract a is 
kept constant using the D10 chloroquine sensitive strain 
 
Combination      
a+b 
IC50 of [a] in 
combination 




32+52  3.39 4.97 1.99 
63+32  0.83 2.43 0.76 
63+52  3.71 3.82 2.39 
63+72  3.01 3.87 1.56 
32+72  5.01 5.63 1.85 
72+52  5.01 6.26 2.58 
72+82  4.43 9.61 3.09 
 
Table 4.3.4.2.2: The IC50 values of the individual extract using the CQS D10 
strain values from table 4.3.3.1 
 







           Key:   P32= Citrus limon dichloromethane extract 
          P52= Psidium guajava dichloromethane extract 
          P63= Carica papaya ethyl acetate crude extract 
          P72= Cymbopogon citratus dichloromethane crude extract 
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 The formula used in calculating the sum of the fractional inhibitory concentrations 
(FIC) is given below; 
 
 IC50 (µg/ml) of extract (a) in combination 
IC50 (µg/ml) of extract (a) alone 
                                  + 
IC50 (µg/ml) of extract (b) in combination 
IC50 (µg/ml) of extract (b) alone 
 
When the sum of the FIC values is less than 0.5 this indicates a clear case of 
synergism while values between 1 and 0.5 indicate a low grade synergism 
(Gupta et al., 2002). Values between 0.5 and 2 are generally regarded as 
indeterminate, while those above 2 indicate antagonism (Gupta et al., 2002)..  
FIC values for the five most active combinations are shown in Table 4.3.4.2.1.  
One combination (63+32) is tending towards synergism while the others show 
either an antagonistic or indifferent effect.  
 
Five extracts from different plants were investigated in this study.  Several 
combinations of these plants were tested.  Each combination was tested with 
one component being kept constant while the other is varied and vice versa.    
The combinations with antiplasmodial activity ≤10 µg/ml were shown (Table 
4.3.4.2).  The activities of these combinations showed no significant difference 
in the D10 and DD2 strains of P. falciparum. The extracts whose activity was 
significantly enhanced in the combination experiment showed an FIC value of 
0.76 (Table 4.3.4.2.1).  This was recorded in the combination between the ethyl 
acetate extract of C. papaya and the dichloromethane extract of C. limon.  This 
combination was not cytotoxic to the CHO cell lines and had a high selectivity 
index (Table 4.3.4.2).  An enhancement of activity was also noted whenever C. 
papaya ethyl acetate extract was one of the components used in combination. 
This was noticed whenever the C. papaya ethyl acetate (P63) was kept 
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constant and the other component varied (Table 4.3.4.2.1, Table 4.3.4.1).  Due 
to the good in vitro antiplasmodial activity of C. papaya against both 
chloroquine-sensitive and resistant strains of the parasite, the indication that it 
interacts synergistically with C. limon and its low cytotoxicity, it was selected for 
further investigation.  This was carried out through a bioactivity-guided 
fractionation with the aim of tracing the activity of this extract and isolating the 
compounds responsible for the recorded activity.   
 
4.4 Bioactivity-guided fractionation 
4.4.1 Introduction 
The ethyl acetate extract was investigated through a bioactivity guided 
fractionation and characterization of isolated compounds using the procedures 
























Fig 4.4.1.1 Fractionation procedure of C. papaya ethyl acetate crude 







   Method 
HPLC analysis (Shimadzu 
LC10AS equipped with a 
desktop PC and detector) 
and GC-MS 
NMR spectroscopy. This made use of the 1-D NMR 
and the 2-D NMR techniques.  The 1D NMR; 1H and 
13C were used and the 2-D NMR techniques used 
include HSQC, HMQC, and COSY. 
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4.4.2 Solid phase extraction (SPE)  
 
Solid phase extraction was used to fractionate the ethyl acetate extract of C. 
papaya (3.5.1).  Briefly, SPE involved sequential elution of the extract from an 
isolute C18 cartridge. The extract (10 mg/ml) was dissolved in methanol and 
layered into a pre-wetted and preconditioned cartridge. The unretained materials 
were washed off under vacuum with Millipore water. Different concentrations of 
acetonitrile in millipore water were used in 20% increments to elute the substances 
that were absorbed in the sorbent bed. The fractions were collected, dried and 
tested for antiplasmodial activity against the D10 chloroquine sensitive strain of P 
falciparum. Chloroquine showed an IC50 of 12.13ng/ml. The 100% acetonitrile 
concentration showed an in vitro activity with an IC50 of 2.24µg/ml.  Results are 
shown in Table 4.4.1.1.   
 









20% 142.80 >50 
40% 295.60 16.55 
60% 329.90 2.52 
80% 482.51 2.69 
100% 369.50 2.24 
 
 The 100% ACN fraction was further fractionated using HPLC analytical system 
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5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00
 
Fig 4.4.2.1 HPLC profiles of SPE fraction using C18 column: Agilent XDB C18 
RP analytical: 4.6 x 150mm; 5µ particle size.  (λ = 236.8nm) 
 
HPLC conditions: Mobile phase ACN: H2O using a gradient of 20-100% ACN 
(30 minutes) 100% ACN hold (3 minutes), 100-20%ACN (2 minutes) 20% ACN 
hold (5 minutes) 
Injection volume: 30 µl of 1 mg/ml 
Column temp: 30°C 
Flow rate: 1 ml/min  
 
 
4.4.3 HPLC Results 
The HPLC profile of the C. papaya ethyl acetate SPE fraction (100% ACN) 
showed two major peaks.  These were isolated using semi-preparative and 
analytical columns.  The CQS D10 and CQR DD2 used in this assay showed 
IC50 of 10.83ng/ml and 118.6ng/ml respectively.  Peak1 had IC50s of 3.58 µg/ml 
and 4.40 µg/ml against the CQS D10 and CQR DD2 of P. falciparum, 
respectively, while peak 2 recorded IC50 values of 6.88 µg/ml and 6.80 µg/ml 
against the CQS and CQR strains of P. falciparum, respectively.  These two 
peaks were less active than the SPE fraction (2.2 µg/ml) as well as the ethyl 
acetate extracts which had an IC50 of 2.96 µg/ml against the CQS strain and 
Peak 2 
Peak 1 
100%ACN  SPE 
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3.98 µg/ml against the CQR strain (Table 4.3.3.1).  The in vitro activities of 
these peaks are shown in the dose response curves in Fig 4.4.3.1.  Neither 
peak showed significant cytotoxicity (Table 4.4.3.1). 
Plasmodium falciparum    DD2
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Fig 4.4.3.1 Dose response curves of peaks 1 and 2 
  



















Peak 1 3.58 
 
4.40 54.70 15.27 12.43 0.81 
Peak 2 6.88 
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4.4.4 Nuclear Magnetic Resonance (NMR) 
4.4.4.1 Introduction 
An attempt was made to characterize and elucidate the structures of 
compounds 1 and 2 using the 1D and 2D NMR spectrometric methods.   The 
1H and 13C spectra used in this study are the most widely used 1-D NMR 
techniques.  1H –NMR spectra can identify the protons in molecules.  The 
number of 13C signals identified compounds 1 and 2 as unsaturated aliphatic 
fatty acids.  Generally, 1D NMR helps in identification of aliphatic systems, 
determination of the degree of unsaturation, as well as the identification of 
functional groups.   Further characterization of compounds 1 and 2 using 2-D 
NMR techniques, which included HSQC, HMQC, and gCOSY met with 
difficulties due to the similarity in chemical shift of most of the methylene groups 
and of the olefinic double bonds.   In this study the representative 2D NMR data 
of compounds 1 and 2 using the conventional NMR spectroscopy are shown 
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                     Fig 4.4.4.1.3: A representative of compound 2 gHSQC plot 
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                          Fig 4.4.4.1.4: A representative of compound 2 gCOSY plot 
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                        Fig 4.4.4.1.5: A representative of compound 2 gCOSY plot 
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4.4.4.2 The structural characterization of compounds 1 and 2  
Two groups could be unequivocally identified.  The CH2 at position 2 gave a 
triplet at δ2.30, with a coupling constant of 7.50Hz.  Similarly the CH3 at position 
18 gave a triplet at δ0.90 with a coupling constant 0f 3.6Hz.  The multiple peaks 
for compound 1, which were at 1H 5.27 - 5.38 (9, 12, 15 H) were connected to 
carbon signals at 13C 131.0-127.0 in the HSQC spectrum (Fig 4.4.4.1.2), while 
in compound 2 the multiple peaks at 1H peaks which were at δH 5.30 - 5.39 (9, 
12 H) were linked to the carbon signals at 13C 129.0-130.6 in the HSQC 
spectrum (Fig 4.4.4.1.3).  Due to the complexity of the resonances for the 
olefinic protons we do not believe that it is possible to assign the stereo-
configuration of the double bonds using the conventional NMR spectroscopy.  
The work done by Vatele et al., (1998); Viron et al., (2000); Cao et al., (2006; 
2007), emphasized the difficulties encountered in characterizing this class of 
compounds.  Cao et al., (2007), made a significant input in giving a more 
detailed characterization of the unsaturated fatty acids he studied (ß-
eleostearic, α-eleostearic and punicic acids) by using a derivative which 
converted the acid into a nitrogen containing derivative.  Vatele et al., (1998), 
reported the use of a new 2D NMR technique: SAPHIR-HSQC, in the complete 
assignment of 13 C and elucidation of n-3 polyunsaturated fatty acids.   Cao et 
al., (2006), documented the use of silver ion impregnated high-performance 
liquid chromatography (Ag+-HPLC) in the separation of CLnA methyl ester 
(CLnAMe) mixture while Ying et al., (2007) reported the identification and 
characterization of conjugated linolenic acid isomers by Ag+ -HPLC and NMR.  
Gas chromatography is routinely used to analyze fatty acids due to its high 
resolution, speed and sensitivity (Horning et al.,1964).  It was therefore 
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4.4.5 GC-MS analysis  
The purity of these peaks was further confirmed using the GC-MS spectrometry 
facility available at the University of Stellenbosch GC-MS laboratory.  The 
HPLC samples were analyzed by a Waters GCT premier spectrometer, model 
HP5 (3.6).  The column specification was 30 m, 0.25 mm ID, 0.25 µm film 
thickness.  The carrier gas was helium with a constant flow of 1 ml/min.  The 
injection split was 1:5, the temperature of the injector and the transfer 
temperature were 280ºC.  The EI ionization energy was 70eV, the scanning 
mass range was m/z 40 to 400 (perfluoro-tri-N-butylamine as mass reference), 
with a solvent hold of 6 minutes.  Peaks 1 and 2 were identified as essential 
fatty acids 9,12,15-octadecatrienoic acid (Compound 1: Linolenic acid) and 
9,12-octadecadienoic acid (compound 2: Linoleic acid). These essential fatty 
acids belonging to the C18 fatty acid differ structurally in the position and degree 
of unsaturation.  Compound 1 also known as Linolenic acid has three double 
bonds, while compound two also known as Linoleic acid has two double bonds.  
The GC-MS spectra and structure of Compounds 1 and 2 are shown (Figs 
4.4.5.1- 4.4.5.2 and figs A12-A17).   The spectrum of compound 1 (Fig 4.4.5.1) 
shows the molecular ion at m/z 278.  In compound 1 two losses of CH2 groups 
were evident (m/z 135 - m/z 121; m/z 93 – 79), while in compound 2 (Fig 
4.4.5.2) the molecular ion was shown at m/z 280.  Two losses of CH2 groups 
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Fig 4.4.5.2: GC-MS spectrum showing the structure of compound 2 (9, 12, 
Octadecadienoic acid). 
 
4.4.6 Result and discussion 
Linolenic and linoleic acids belong to the C18 fatty acids.  Linolenic acid 
(compound 1) which has three double bonds, showed a higher antiplasmodial 
activity with a higher selectivity index when compared to linoleic acid (compound 
2) with two double bonds (Table 5.2.1).  Previous work on a C18 fatty acid 
(scleropyric acid) isolated from the twigs of Scleropyrum wallichianum Arn. of the 
family Santalaceae (Suksamrarn et al., 2005) reported antiplasmodial activity 
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to the antiplasmodial activity of linoleic acid with an IC50 of 6.80 μg/ml against the 
DD2 (CQR) strain in this study.  Further study documented the antiplasmodial 
activities with IC50<5µg/ml showed by fatty acids isolated from Croton lobatus 
against Plasmodium falciparum K1 (CQR) strain (Attioua et al., 2007). The fatty 
acids they isolated included (Z.,Z.,Z.)-9,12,15-octadecatrienoic acid methyl ester,    
8,11,17,21-tetramethyl-(E.,E.,E.,E.)-8,10,17,21-tetraentetracosanoic acid, (E.)-3-
(4-methoxy-phenyl)-2-phenyl-acrylic acid and betulinic acid (Attioua et al., 2007). 
 
The antiplasmodial activity of the unsaturated fatty acids has been reported to 
increase as the degree of unsaturation increases (Kumaratilake et al., 1992, 
Kumaratilake et al., 1997).  These researchers reported the marked in vitro 
growth inhibition of P.falciparum by Docosahexaenoic acid (C22-6,n-3), 
docosahexaenoic acid methyl ester (C22-6,n-3 methyl ester), eicosapentaenoic 
acid (C20-5,n-3), arachidoic acid (C20-4,n-6), linoleic acid  (C18-2,n-6).  They reported 
that oleic acid (C18-1,n-9) and docosanoic acid (C22-0) had very little effect on 
parasite growth inhibition (Kumaratilake et al., 1992).  In their work, the 
unsaturated fatty acids C22:6, n-3, and C20:4, n-6 resulted in the death of 
P.falciparum parasites by >90% and 80%, respectively.  However, they stated 
that the effect of C22:0 on parasites was comparable to the parasites which 
received no fatty acid.  The introduction of a single double bond into the mono-
unsaturated fatty acid greatly enhanced the antiplasmodial effects of the 
molecules (Kumaratilake et al., 1992).  It was demonstrated in their study that 
oxidized fatty acids exhibit a stronger antiplasmodial effect than the non-
oxidized fatty acids.  This observation further confirms their previous finding 
since the saturated and mono-unsaturated fatty acids which are resistant to 
oxidation are not as active as the polyunsaturated hydrocarbons with ≥2 double 
bonds.  This may help explain the relative increase in the in vitro activity of 
linolenic acid (3 double bonds) with IC50 value of 4.40 μg/ml compared to 
linoleic acid (2 double bonds) with an IC50 of 6.80 μg/ml against the DD2 strain 
in this study.  Further study reported that the neutrophil-mediated killing of the 
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asexual blood forms of Plasmodium falciparum could be enhanced by fatty 
acids (Kumaratilake et al., 1997).  Previous studies demonstrated other factors 
that could enhance neutrophil-mediated killing of Plasmodium falciparum, such 
as tumor necrosis factor (Kumaratilake et al., 1990) and Lymphotoxin and 






















In vivo antimalarial activity of linolenic and linoleic acids 
and their methyl esters 
 




Polyunsaturated fatty acids especially the essential fatty acids, have medicinal 
properties.  Polyunsaturated fatty acids have been shown to have 
antiplasmodial properties which are traceable to their degree of unsaturation 
(Kumaratilake et. al., 1992).  Compounds 1 and 2 commonly, known as 
linolenic and linoleic acids, respectively are polyunsaturated hydrocarbons that 
belong to the omega 3 and omega 6 fatty acids respectively.  Linolenic and 
linoleic acids are essential fatty acids which belong to the omega 3 and omega 
6 fatty acids.  These essential fatty acids have recently drawn attention and are 
recently marketed as health supplements due to the health benefits associated 
with them (Larsen et al., 2003, Gaullier et al., 2005).  The conjugated forms of 
these essential fatty acids have also shown promising biological activities. They 
are conjugated fatty acids due to the geometric position and configuration of 
their double bonds. Conjugated linoleic acids (CLA) are octadecadienoic acids 
with two conjugated double bonds. CLA have been shown to suppress human 
tumor (Tsuzuki et al., 2004) and were also recorded to reduce metastasis of 
cancers to lung tissue (Cesano et al., 1998).  Other health potentials of CLA are 
antiathergenic, antidiabetogenic and immune modulating properties (Belury, 
2002; McLeod et al., 2004).  They are the only conjugated fatty acids that can 
be prepared in large quantities from natural sources (Tsuzuki, et al., 2006).  
Conjugated linolenic acids (CLnA) are octadecatrienoic acids with three 
conjugated double bonds.  Linolenic and linoleic acids, isolated from C. papaya 
ethyl acetate extract in this study, showed in vitro antiplasmodial activities of 
<10 µg/ml.   They were further investigated in vivo using a mouse model 
infected with P. berghei.   
 
5.2 In vivo activity of linolenic and linoleic acids  
Due to the poor yield of linolenic and linoleic acids from the ethyl acetate 
fraction of C. papaya, more of these compounds were purchased for further 
work (Sigma).    The very lipophilic nature of these compounds meant that they 
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were not readily soluble in an aqueous environment.  When part of a crude 
extract, lipophilic compounds such as artemisinin often demonstrate an 
increased solubility compared to the purified compounds (Mueller et al., 2000).  
This suggests that other components of plant extracts could help make 
compounds lipophilic in aqueous solution. Due to the lipophilic nature of the 
purified fatty acids, DL-α- Dipalmitoylphosphatidylcholine (DPPC) has been 
used as a vehicle to deliver these unsaturated hydrocarbons in in vitro and in 
vivo antimalarial assay (Kumaratilake et al., 1992).  DPPC alone showed no 
activity against plasmodium parasites (Kumaratilake et. al., 1992).  It was 
decided to adopt this approach.  Linolenic and linoleic acids were formulated in 
DPPC micelles according to Kumaratilake et al., (1992).  Details have been 
given in section 3.7.1.2.   Briefly, lipids were dissolved in chloroform (10-50 
mg/5 ml).  A mixture of fatty acids and DPPC micelles were prepared by adding 
DPPC at four-fold the amount of the fatty acid.  Solvents were evaporated 
under nitrogen.  A volume of 1 ml complete medium (RPMI 1640) was added to 
the mixture.  The mixture was sonicated for 2 minutes and thereafter used for 
the assay.   The activity of the purchased compounds (99% pure) were tested 
in vitro and correlated well with the activity of the isolated compounds (Table 
5.2.1). 
 
Table 5.2.1: In vitro activity of linolenic and linoleic acids isolated and 
purchased against the CQR DD2 strain of P. falciparum 
Compound  IC50 DD2 (µg/ml) 
Linolenic acid (Isolated) 4.40 
Linolenic acid (Sigma) 5.04 
Linoleic acid (Isolated) 6.80 
Linoleic acid (Sigma) 7.56 
  
Mice infected with P. berghei were dosed orally with linolenic and linoleic acids 
singly and in combination.  In the single treatment each compound was 
administered at a dose of 100 mg/kg using the 4-day suppressive test of Peters 
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et al. (1993). Linolenic acid significantly inhibited the growth of parasites 
compared to linoleic acid.  The suppressive effect of the free acids when 
combined together (at a dose of 50 mg/kg each) proved to be more potent than 
the individual compounds alone (100 mg/kg) (Fig 5.2.1).   
 
 
In vivo experiment with Plasmodium berghei







linoleic free acid 100mg/kg
linolenic free acid 100mg/kg












 Fig 5.2.1 In vivo activity of linolenic and linoleic acids in combination 
compared with the compounds alone in a 4-day suppressive test using oral 
administration.  
 
Key: cq = Chloroquine (10 mg/kg), mH2O = Millipore water 
 
The percentage growth inhibition of the parasites by the free acids, singly and 
in combination is shown (Table 5.2.2).  The untreated control group, which is 
necessary to determine parasite growth inhibition, could not survive longer, 
thus day four post treatments was therefore chosen since it gives a good 
indication, of the rate of parasite suppression, induced by drug in a 4-day 









Table 5.2.2:  Percentage growth inhibition of compounds 1 and 2 individually 
and in combination on day 4 of treatment 
Compound %parasitemia % growth inhibited 
Millipore water 12%  Untreated negative control 
Chloroquine 3.7% 69% 
Linolenic free acid 3.6% 70% 
Linoleic free acid 4.3% 64% 





Parasite growth inhibition was calculated using the formula below: 
 
% growth inhibition =   Parasitemia of negative control- Parasitemia of test sample X 100 
                                                    Parasitemia of negative control                                             
 
 
5.2.1 Results and discussion 
The in vivo result from this study demonstrated that linolenic acid was more 
potent than linoleic acid (Fig 5.2.1).  This correlates well with the observations 
of Kumaratilake et al. (1992) which showed that fatty acids vary in their ability to 
inhibit the growth of parasites.  Their work demonstrated that this variation in 
fatty acid antiplasmodial activity is partly dependent on the degree of 
unsaturation.  The polyunsaturated compounds they investigated: C22:6,n=3, 
C20:5,n-3, C20:4,n-6 and C18:2,n-6  markedly inhibited the growth of the  parasites, 
while the mono-unsaturated fatty acid C18:1,n-9 and the saturated fatty acid 
C22:0 showed little effect. Kumaratilake et al. (1992) further reported that the 
growth inhibition of parasites by the 22-C fatty acid significantly increased 
several-fold by increasing the degree of unsaturation of the molecule by six. 
Similarly, when they introduced a single double bond to the mono-unsaturated 
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fatty acid, the antiplasmodial effect of the molecule was more than tripled.  
These researchers concluded that the polyunsaturated fatty acids were more 
effective against P. berghei in mice when compared to the saturated fatty acids 
which had no effect.   Fatty acids were reported to cause degeneration in the 
intra erythrocytic stages of P. falciparum in vitro (Kumaratilake et al., 1992).   In 
the present work, compounds linolenic and linoleic acids inhibited the growth of 
parasites by 70% and 64%, respectively on day 4 of treatment.  There was 
marked inhibition of parasite growth by a 1:1 combination of linolenic and 
linoleic acids.  The growth inhibition of compounds linolenic and linoleic acids in 
combination was 96% on day 4 of treatment. This suggests a possible 
synergistic effect.  The figures are slides from the untreated control group (Fig 
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Fig 5.2.3: Combined effect of linolenic and linoleic acids on P. berqhei on day 
4 of treatment using the 4-day suppressive treatment  
 
After the final dose on day 4, parasite growth remained suppressed until day 10 
but by day 15 significant recrudescence was observed for the compounds 
administered singly, while the result for the mixture suggested that the two 
compounds were acting synergistically, and were as potent as the chloroquine 
control by day 15 (Fig 5.2.1).  In order to ascertain the reason for the observed 
recrudescence post treatment using the compounds singly, it was decided to 
investigate the bioavailability of the more active linolenic acid, so as to establish 
its absorption and elimination rate from plasma, and the possible reasons for 
the recorded recrudescence. 
 
5. 3 Bioavailability study of linolenic acid methyl ester  
 A bioavailability study of linolenic acid requires its extraction from plasma.  The 
bioavailability study was carried out using an Agilent 1200 series HPLC coupled 
to an API 3200 Applied Biosystems Mass Spectrometer (LC-MS/MS).  The 
standards of linolenic acid were prepared at various concentrations necessary 
for method development and optimization using the LC-MS/MS spectrometer 
(3.7.1.4).  However, linolenic acid which is a free acid, was not efficiently 
detected by the mass spectrometer.  Previous studies have shown that fatty 
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acid methyl esters are more stable and show good chromatographic properties 
compared to the free acids (Viron et al., 2000) and would be expected to be 
more readily detected by mass spectrometry.  The methyl esters of linolenic 
and linoleic acids were therefore purchased from Sigma (purity ≥ 99%).  To 
determine if their antiplasmodial activity was the same as the free acids, the 
linolenic and linoleic acid methyl esters were tested for antimalarial activity in 
vitro and in vivo. The in vitro activity was similar for the free acids and their 
methyl esters.  Similarly, no significant difference was shown for the in vivo 
antiplasmodial activity of the two free acids and their methyl esters using the 
oral administration (Figs. 5.3.1-5.3.2 and fig A11).   These findings were similar 
to those of Kumaratilake et al., (1992) who reported similar antiplasmodial 
activity of a range of free acids and their methyl esters.  The dose response 
curves of the in vivo schizontocidal activity of the free acids and their methyl 
esters are shown below. 
 
Both the in vivo and in vitro antimalarial activities of linolenic and linoleic acids 
compares well with their methyl esters.  Representative mass spectra of 
linolenic and linoleic acids are shown in figs A24-A29. The methyl ester of 
linolenic acid which showed the greatest activity was therefore used for the 
bioavailability study. 
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In vivo experiment with Plasmodium berghei




















Fig 5.3.1: The in vivo activity of linoleic acid and the its methyl ester in a 
4-day suppressive test using the oral route of administration  
 
In vivo experiment with Plasmodium berghei






















Fig 5.3.2: The in vivo activity of linolenic acid and its methyl ester in a 4-
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5.4 Bioavailability study of linolenic acid methyl ester in 
plasma 
The bioavailability study of linolenic acid methyl ester was carried out in a 
mouse model using different routes of administration (oral, intravenous and 
subcutaneous routes).  A sensitive and selective method was developed for 
compound analysis using the LC-MS/MS.  
 
5.4.1 Mass spectrometry method development  
Prior to the bioavailability study, the detection, stability and ionization of the 
compound was established using the LC-MS/MS tandem mass spectrometer.  
 
5.4.2 Optimisation of mass spectrometry conditions 
The LC-system (Agilent 1200 series HPLC) was connected with an API 3200 
quadrupole mass spectrometer (Applied Biosystems) in the ESI positive 
ionization mode and multi-reaction monitoring (MRM) was used for this 
analysis.  The optimized mass spectrometry conditions are summarized in 
Tables 5.4.2.1 and 5.4.2.2. 
 
Table 5.4.2.1 ESI settings 
Curtain gas (psi) 20 
Collision gas (psi) 5 
Ionspray  voltage (V) 5500 
Source temperature (˚C) 500 
Gas 1 (psi) 20 
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Table 5.4.2.2 MS/MS settings 
Specification linolenic methyl ester 
Linolenic acid methyl ester mass [M+H]+ 
(mass filter 1) 
293.2 
Q3 mass(mass filter 2) 67.1 
Dwell time (ms) 150 
Declustering potential (V) 31 
Entrance potential (V) 5 
Collision cell entrance potential (V) 20 
Collision energy (v) 47 
Collision cell exit potential (V) 4 
Scan type MRM 
Polarity Positive 
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 +Q1: 0.480 min from Sample 1 (TuneSampleID) of MT20090528142247.wiff (Turbo Spray) Max. 3.9e5 cps.







































277.2 290.8 323.3 331.3283.0 303.1 329.1245.2 284.5 332.8294.7265.2 313.2296.1274.7 321.4304.3270.3 341.3251.1
309.9 325.6259.8 287.3290.3276.1 335.6319.8
 
Fig 5.4.2.1 Shows the mass spectrum of lionlenic acid methyl ester with 
molecular ion of 293.1 [M+H] + 
 
The molecular ion [M+H]+ 293.1 amu is shown in the MS/MS spectrum of 
linolenic acid methyl ester (Fig. 5.4.2.1). The molecular ion, which was selected 
in the first mass filter, was subsequently fragmented in the collision cell to give 
rise to product ions.  The mass of linolenic acid methyl ester and the sodium 
adduct, which usually comes from glass, was shown at m/z  315.3 (Fig 5.4.2.1).  
The most abundant product ion was at m/z 67.2, while the protonated 
molecular ion was m/z 293.2 (Fig 5.4.2.2).  The product ions at m/z 123, m/z 
94.8, m/z 81.2, and m/z 67.2 all arise from sequential loss of CH2 groups (Fig 
5.4.2.2).  In this experiment the protonated molecular ion m/z 293.2 and not the 
sodium adduct at m/z 315.3 has been used to form product ions. 
 
 




 +MS2 (293.22) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Methyl linoleate B_InitProduct_Pos.wiff (Turbo Spray) Max. 9.2e4 cps.

















































191.0 214.8161.4 251.2 275.2
 
Fig 5.4.2.2 Mass spectrum of linolenic acid methyl ester showing the most 




The chromatography was determined using the LC-system (Agilent 1200 series 
HPLC) equipped with an API 3200 quadrupole mass spectrometer detector 
(Applied Biosystems) coupled with an ESI positive ionization and multi-reaction 
monitoring (MRM).  This was carried out by direct injection of 2µl at a flow rate 
of 0.5 ml/min.  The system is equipped with a flush port wash station which 
automatically rinses the injection needle with the mobile phase before each 
injection.  The mobile phase (MP) was acetonitrile: 0.1% formic acid (50:50) 
which was ran isocratically for 1.9 minutes.  The stability of the eluent system 
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was efficient for identifying the retention times of compounds.  A representative 
chromatogram of linolenic acid methyl ester at 1 µg/ml is shown in Fig 5.5.1.1. 
 
XIC of +MRM (4 pairs): 293.2/67.1 amu from Sample 1 (1 ug/ml) of 1001.wiff (Turbo Spray), Smoothed Max. 4971.3 cps.








































Fig 5.5.1.1 A representative chromatogram of linolenic acid methyl ester 
at a concentration of 1 µg/ml in the mobile phase using the LC/MS/MS. 
MRM:293.2-67.1 amu. 
 
5.6 Extraction of linolenic acid methyl ester from plasma 
The extraction process was performed on the test samples and the standards 
(STDI-STD7) which served as controls. Stock solutions of seven standards with 
known concentrations were prepared in plasma (20 µg/ml-0.3125 µg/ml). 
Initially, the extraction of linolenic acid methyl ester from red blood cells in pH 
buffers ranging from pH 2-12 (prepared with Britton Robinson Universal buffers) 
did not prove very sensitive. Extraction was therefore attempted using the 
modified method of Aleryani et al., (2005) as described in section 3.7.1.5.  
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Briefly, a volume of 100 µl of acetone was added into 20µl of spiked plasma (20 
µg/ml) in labeled Eppendorfs (Group B).  Acetone was added to precipitate 
protein.  The solution was vortexed for a minute and placed in ice for ten 
minutes.  It was thereafter centrifuged at 1200 rcf for 5 minutes.  The resultant 
supernatant was transferred to labeled Eppendorfs (Group C).  Hexane (150 µl) 
was added to group C Eppendorfs, vortexed for a minute, placed in ice for ten 
minutes, and centrifuged at 200 rcf for 5 minutes.  The hexane layer was 
transferred to group D eppendorfs and dried under nitrogen.  After drying was 
completed, 100µl of mobile phase (ACN: 0.1% formic acid; 50:50) was added 
to these Eppendorfs.  The mixture was vortexed for 30 seconds and transferred 
into LC/MS/MS vials for injection.  This method proved sensitive and effective, 
and was used in all of the extraction procedures in this work.   
 
5.7 Mass spectrometry method validation 
A pilot study was carried out using the mass spectrometer to evaluate the 
concentrations of the linolenic acid methyl ester in plasma, as well as the 
stability and sensitivity of the different concentrations in plasma.  These 
concentrations were prepared as different standards (STD1-STD 9).  The initial 
and highest concentration (STD 1 = 25 µg/ml) was diluted in plasma to 0.097 
g/ml (STD 9).  The intensity of the chromatogram of the lowest standard (STD 
9), and the low concentrations observed in mouse plasma prompted another 
evaluation.  This time a starting concentration STD 1 of 6.25 µg/ml and a final 
concentration STD 7 of 0.098 µg/ml was used (Fig 5.7.1.1).  
 
5.7.1 Preparation of calibration standards 
An initial stock solution (SS1) of 1 mg/ml concentration of linolenic acid methyl 
ester was prepared in methanol. Seven standards (STD 1-7) from the initial 
stock solution (SS1) of linolenic acid methyl ester were prepared by two-fold 
serial dilution in plasma with a starting concentration of 6.25 g/ml to 0.098 
g/ml.   Standard 1 had the highest concentration (STD 1 =6.25 g/ml) while 
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standard 7 showed the lowest concentration (STD 7 = 0.098 g/ml). Blank 
plasma was also included to serve as an internal check.  Samples were 
vortexed briefly and stored at -20ºC for short term storage and at -80ºC for 
longer durations.  A representative calibration curve of linolenic acid methyl 
ester is shown in Fig. 5.7.1.1. 
 
5.7.1.1 Calibration curve 
190609.rdb (293): "Quadratic" Regression ("1 / x" weighting): y = -2.38 x̂ 2 + 2.19e+003 x + -184 (r = 0.9990)
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5.8 Effect of route of administration on the bioavailability of 
linolenic acid methyl ester  
 
The bioavailability of compounds and their activity in vivo are partly influenced 
by parameters such as the route of administration (Peters et al., 2002), as well 
as the elimination rate of the compound from plasma.  Three routes of drug 
administration, including the oral, subcutaneous and the intravenous routes 
were analyzed to evaluate the bioavailability of linolenic acid methyl ester in a 
mouse model.   Groups of five male mice were used for each route of 
administration, as the bioavailability of linolenic acid methyl ester in each 
mouse is likely to differ, due to different physiological changes in different 
animals. Samples were taken from each mouse at four time points (T1 - T4) 
which were the same for all the mice in the three routes of drug administration.  
The standards shown were run before and after the time points of a particular 
mouse (T1 - T4).  The lower limit of quantification (LLOQ) in this experiment 
was at a concentration of 0.195 µg/ml. Further use of STD 7 (0.098 µg/ml) was 
discontinued since it was below the limit of quantification (BLQ).  A tabular 
representation of STD1- STD 6 is shown (Table 5.8.1). 
 
Table 5.8.1:   Representative standards showing their percentage accuracy 






Standard 6 0.195 0.2 102 
Standard 5 0.39 0.289 74 
Standard 4 0.78 0.775 99.4 
Standard 3 1.56 1.49 95.3 
Standard 2 3.13 3.61 115 















Table 5.8.2: Plasma concentrations of linolenic acid methyl ester extractions 
in the oral route of administration 
 










Mouse 1 T1 358 0.082 
Mouse 1 T2 350 0.0813 
Mouse 1 T3 313 0.0777 
Mouse 1 T4 0 No Peak 
Mouse 2 T1 211 0.068 
Mouse 2 T2 70 0.0546 
Mouse 2 T3 105 0.058 
Mouse 2 T4 259 0.0726 
Mouse 3 T1 0 No Peak 
Mouse 3 T2 0 No Peak 
Mouse 3 T3 0 No Peak 
Mouse 3 T4 186 0.0657 
Mouse 4 T1 101 0.0576 
Mouse 4 T2 192 0.0663 
Mouse 4 T3 54.4 0.0531 
Mouse 4 T4 0 No Peak 
Mouse 5 T1 0 No Peak 
Mouse 5 T2 0 No Peak 
Mouse 5 T3 246 0.0714 
Mouse 5 T4 0 No Peak 
 
The first time point T1 was 30 minutes post treatment, the second (T2), third 
(T3) and fourth (T4) time points were 2, 4 and 6 hours post treatment, 
respectively.  The results of the oral and subcutaneous administrations are 
shown in Tables 5.8.2 and 5.8.3 respectively.  The concentrations of linolenic 
acid methyl ester in the oral and subcutaneous route were below the limit of 
quantification (BLQ) for all the time points tested in all mice.  However, the 
intravenous route of administration showed good concentrations of linolenic 










Table 5.8.3 Plasma concentrations of linolenic acid methyl ester extractions 











Mouse 1 T1 
TTTtTTTT1 
72.6 0.0646 
Mouse 1 T2 
rrTTtT2 
138 0.0706 
Mouse 1 T3 
1 T3 
210 0.0772 
Mouse 1 T4 
1 T4 
0 No Peak 
Mouse 2 T1 
2  T1 
0 No Peak 
Mouse 2 T2 
2 T2 
77.4 0.0651 
Mouse 2 T3 
2 T3 
41.4 0.0618 
Mouse 2 T4 
2 T4 
0 No Peak 
Mouse 3 T1 
3  T1 
68.2 0.0642 
Mouse 3 T2  
T2 
0 No Peak 
Mouse 3 T3  
T3 
80.5 0.0654 
Mouse 3 T4  
T4 
161 0.0727 
Mouse 4 T1  
T1 
0 No Peak 
Mouse 4 T2  
T2 
0 No Peak 
Mouse 4 T3  
T3 
54 0.0629 
Mouse 4 T4  
T4 
0 No Peak 
Mouse 5 T1  
T1 
253 0.0811 
Mouse 5 T2  
T2 
161 0.0727 
Mouse 5 T3  
T3 
0 No Peak 
Mouse 5 T4  
T4 
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Table 5.8.4 Plasma concentrations of linolenic acid methyl ester extractions 
in the intravenous route of administration 










Mouse 1 T1 112000 14.2 
Mouse 1 T2 16100 2.64 
Mouse 1 T3 8720 1.42 
Mouse 1 T4 1040 0.0527 
Mouse 2 T1 126000 15.6 
Mouse 2 T2 27700 4.4 
Mouse 2 T3 9760 1.6 
Mouse 2 T4 2380 0.3 
Mouse 3 T1 216000 23.1 
Mouse 3 T2 102000 13.3 
Mouse 3 T3 1800 0.194 
Mouse 3 T4 81.9 < 0 
Mouse 4 T1 34900 5.42 
Mouse 4 T2 4520 0.687 
Mouse 4 T3 751 < 0 
Mouse 4 T4 180 < 0 
Mouse 5 T1 171000 19.5 
Mouse 5 T2 6630 1.06 
Mouse 5 T3 1020 0.0503 




5.9   Results and Discussion 
The method achieved a lower limit of quantification (LLOQ) of 0.195 µg/ml.   
The fact that no plasma concentrations above the LLOQ were seen in mice 
receiving oral and subcutaneous doses suggests that the compound was either 
very poorly absorbed or may have been metabolized.  Previous work reported 
the low levels of 18:3n-3 fatty acids, and further pointed out the differences 
between their metabolism and that of 18:2n-6 which is usually more abundant 
(Pawlosky et al., 1996).  Oxidation of the methyl ester to its active metabolites 
could explain the in vivo activity recorded when this compound was 
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administered orally. Fatty acid methyl esters are metabolized as would be other 
dietary fats.  Higher molecular weight aliphatic esters are readily hydrolyzed to 
the corresponding alcohol and acid.  These are subsequently oxidized to 
carbon dioxide and water through an established mechanism of metabolic 
breakdown into two-carbon fragments. These fragments are utilized by the 
body for energy and serves as building blocks for synthesis.  During digestion 
they are hydrolyzed to the free fatty acids for absorption from the intestine into 
the blood stream aided by lipase enzymes and bile salts. Once formed, the free 
acid is metabolized by known oxidative processes or are reconstituted into 
glyceride esters and stored in the fat depots in the body.   Further work by 
Kumaratilake et al. (1997) confirms the oxidation of this class of compounds.  
This suggests that the in vivo activity recorded when this compound was 
administered orally could be traceable to the active metabolites.  Rapid 
metabolic conversion of linolenic acid to linoleic acid isomers in the oral 
administration, has been reported by other researchers (Tsuzuki et al., 2004).   
The relatively high levels of the linolenic acid methyl ester, achieved after the 
intravenous injection, allowed determination of the elimination rate of the 
linolenic acid methyl ester from plasma.  The result showed the highest 
concentration at T1 (30 minutes post dosing) and the lowest at T4 (6 hours post 
dosing) (Figs 5.9.1, 5.9.2, and 5.9.3).  This decrease in concentration as the 
time after dosing increases, coupled with the very low concentration at 6 hours 
post-dosing, shows a fast elimination rate from plasma within 6 hours of 
administration.   
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Fig 5.9.1 Concentrations of linolenic acid methyl ester between 0.5-6 
hr in mouse 2 following i.v. dosing    

























Fig 5.9.2 Concentrations of linolenic acid methyl ester 
between 2-6 hr in mouse 2  following i.v. dosing                          
 

























Fig 5.9.3 Concentrations of linolenic acid methyl ester between 4-6 hr in 
mouse 2 following i.v. dosing                          
                                
       
The formula below was used to calculate the half life (t1/2) and to evaluate the 





/ K, t½ =0.693/ K  
Mouse two was chosen for this evaluation since it recorded no value below the 
limit of quantification (BLQ).  The other mice all had some data values below the 
lower limit of quantification of the assay which did not allow data to be used for 
half life determination.  The first group in this evaluation is 0.5-6 hrs using the 
formula above =0.693/0.694 equals -0.99856 hr.  The second and the third 
groups (2-6 hrs) and (4-6 hrs) had K values of -1.032217 hr and -1.066156 hr, 
respectively. The standard deviation of the elimination rate constant was 
calculated as -0.6718 and this gave rise to the mean K =0.693/-0.6718 = -
1.03156 hrs.  This value represents the estimated half life of linolenic acid methyl 
ester in plasma between 0.5-6 hrs. It correlates well to the calculated value in 
mouse 1 between 0.5-6 hrs (Fig 5.9.4), suggesting that the longer range 0.5-6 
hrs could be the best fit for this evaluation.  The bioavailability evaluations of 
linolenic acid methyl ester in mouse are shown in Figs 5.9.4 and 5.9.5.  
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The formula used in evaluating the half life of linolenic acid methyl ester in 







      K=0.693/-0.617 






















Fig 5.9.4 Concentrations of linolenic acid methyl ester between 0-6 
hr in mouse 1 
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Fig 5.9.5 Concentrations of linolenic acid methyl ester between 2-6  
hr in mouse 1 
 
5.9.1 Mean elimination rate  
The mean value of the elimination rate constant (K) in mouse 1 was calculated 
to be -1.123 hours.  This value did not differ significantly with the value 
calculated for mouse 2 with a mean value of K= -1.0322 hours.  Two mice were 
used to evaluate and compare the elimination rate of linolenic acid methyl ester 
from plasma, since there may be slight variations due to physiological 
differences.  The remaining two mice showed values that were below the limit 
of quantification (BLQ) which may be due to technical errors and thus were not 
used in this evaluation.  The highest concentration recorded at 0.5 hrs (30 
minutes) and the significant decrease in concentration recorded 2 hours post 
treatment could be traceable to its half-life, which showed a fast elimination 
from plasma after 1 hour of treatment.  
 
5.10 In vivo schizontocidal experiment using the intravenous 
route of administration 
As linolenic acid methyl ester showed relatively good concentrations in the 
intravenous route of administration, as compared to the oral and subcutaneous 
routes, it was decided to check the schizontocidal effect of the compound after 
intravenous administration.  A group of mice were infected with P. berghei and 
 
Chapter 5 – In vivo Anti-malarial Activity of Compounds 1 and 2 and their Methyl Esters 
 
 144 
treated intravenously with linolenic acid methyl ester (100 mg/kg) once a day 
for four days.  The positive control compound is Cq at a dose of 10mg/kg as 
used in the previous in vivo experiments in this study.  Results are shown in fig 
5.10.1.  
 
         
 
Fig 5.10.1 Percentage parastemia post-infection using a 4-day 
suppressive treatment against P. berghei 
 
 
5.11 Results and Discussion 
Parasites were markedly suppressed during the 4-day treatment, but a rapid 
recrudescence with parasitemia of >50% was recorded on day 10 post 
treatment (Fig 5.10.1).  The fast recrudescence observed during the in vivo 
antiplasmodial study of this compound intravenously could be attributed to its 
short half-life.  Chemical modification of this compound to increase its solubility 
could help it to be a better pharmacokinetic match with other compounds 
having similar half-life, like the artemisinin derivatives since this class of 
compounds seem to have a different mechanism of action.   Previous studies 
reported that the biosynthesis of type II fatty acid synthase  (FAS II) which 
takes place in the apicoplast of P. falciparum could be altered by fatty acids 
Intravenous dosage of linolenic acid methyl ester  








2 4 7 10 
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(Carballeira, 2008).  The type II FAS II system is vital to these apicomplexan 
parasites and is also found in bacteria and algae.  The fatty acid biosynthesis of 
parasites differs from that of humans or higher eukaryotes and this makes it 
possible for the parasite to be destroyed without harming the host (Carballeira, 
2008).  .  The type normally found in higher eukaryotes is the type I fatty acid 
synthase (FASI) system (Carballeira, 2008).  .   
 
Linolenic and linoleic acids isolated from the ethyl acetate fraction showed 
synergistic properties when combined.  It is possible that these compounds and 
other numerous components in the crude extract may have added to the 
relatively increased activity observed in the ethyl acetate extract. Researchers 
have shown that plants contain complex mixtures of chemical agents, and the 
possibility of synergism existing between the various compounds may not be 
ruled out (Kirby, 1996).  Such complex interactions may help fight 
recrudescence but may also help delay or prevent the onset of resistance. It 
was therefore decided to investigate the in vivo activity of the crude extracts 
from the five selected plants.  The objective here is to investigate the activity of 
each crude extract as an entity alone, or in combination with another extract, 


















In vivo antiplasmodial activity of crude extracts 








6.1 Antiplasmodial activity 
6.1.1 Introduction 
The five plants investigated in this study are used to treat malaria by traditional 
medical practitioners in Nigeria.  These plants include Citrus limon, Psidium 
guajava, Carica papaya, Cymbopogon citratus, and Vernonia amygdalina. 
Herbal remedies from these plants are prepared singly and in combination as 
decoctions, infusions or macerations.  An attempt has been made in this study 
to scientifically evaluate the in vitro antiplasmodial efficacy of these plants 
singly and in combination.  A bioassay-guided fractionation of the most active 
plant extract (C. papaya ethyl acetate fraction) in this study yielded two 
compounds with in vitro activity less than that of the crude extract (IC50=2.96 
µg/ml).  The activity of C. papaya ethyl acetate fraction could be due to the 
synergistic activity of mixtures of several compounds present in the extract. The 
extracts of Citrus limon (DCM), Psidium guajava (DCM), Carica papaya (EA), 
Cymbopogon citratus (DCM), and Vernonia amygdalina (DCM) investigated in 
this study showed good to moderate in vitro antiplasmodial activity (IC50 values 
between 2-10 µg/ml) and were not cytotoxic to the Chinese Hamster Ovarian 
(CHO) cell line at the concentrations tested.  However, since in vitro results are 
not necessarily predictive of in vivo activity, this chapter describes the in vivo 
schizontocidal activity of these extracts singly or in combination using the 4-day 
suppressive test.    
 
 
6.2 In vivo schizontocidal activity of extracts singly  
The crude extracts of these plants were tested in mice infected intraperitoneally 
with Plasmodium berghei, using the 4-day suppressive test of Peters et al. 
(1993).  The extracts were dissolved in SMEDDS formulation (solution of 200 µl 
ethanol, 20 µl Tween 80 and 780 µl PBS), and showed no in vivo toxicity when 
tested at doses >1000 mg/kg.  Each extract was administered orally at a dose 
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of 800 mg/kg.  The SMEDDS formulation when tested alone had no effect on 
parasitemia.   The extracts dissolved well in the SMEDDS formulation (solution 
of 200 µl ethanol, 20 µl Tween 80 and 780 µl PBS). The composition of the 
formulation includes a test sample, lipids, surfactants and co-surfactants which 
when exposed to the aqueous environment in the gastrointestinal tract form a 
fine emulsion of oil in water (Wu et al., 2006).  The extracts were dissolved first 
in ethanol followed by PBS and Tween 80 was added last.  This was done to 
give room for optimal solubility. A volume of 200 µl of each extract formulation 
was administered orally to the test animals 24 hours post infection. The positive 
control group received CQ at a dose of 10 mg/kg while the negative control 
group received millipore water only since the formulation alone had no effect on 
parasitemia.   The number of cells/ml was calculated using a haemocytometer 
and was diluted to a suspension of 5 x 106 cells/mlusing phosphate buffered 
saline (PBS).   There were five test groups for the five extracts, with each group 
comprising of five mice.  The positive and negative control groups had three 























Fig 6.2.1: Percentage parasitemia of C. limon DCM extract (P32) 
during and post treatment.   
 
























Fig 6.2.2: Percentage parasitemia of P. guajava DCM extract (P52) 
during and post treatment.   
 
 



















Fig 6.2.3: Percentage parasitemia of C. papaya ethyl acetate extract        






























Fig 6.2.4: Percentage parasitemia of C. citratus DCM extract (P72) 















Fig 6.2.5: Percentage parasitemia of V. amygdalina DCM extract 
(P82) during and post treatment.   
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The antiplasmodial activities of the five extracts and the control groups on day 4 
of treatment against P. berghei are shown in Fig 6.2.6, and Table 6.2.1. 
Percentage parasitemia of representative extracts in the in vivo experiments 
are futher shown in fig A10. 
 
In vivo  experiment with extracts against 
























             
Fig 6.2.6 The mean parasitemia of each group on day 4 of treatment            
 
                Key: P32= Citrus limon dichlromethane extract 
                                    P52= Psidium guajava dichloromethane extract 
             P63= Carica papaya ethyl acetate crude extract 
             P72= Cymbopogon citratus dichloromethane crude extract 
             P82= Vernonia amygdalina dichloromethane crude extract 
 
Table 6.2.1: Percentage growth inhibition against P. berghei on day 4 of 







on day 4 of 
treatment (%) 
Percentage growth 
inhibition on day 4 of 
treatment  
Chloroquine(+control) CQ 4.50±2.00 70.5% 
Milliporewater(-ve control) mH2O 15.27±1.96  
C. limon (DCM) P32 3.87±1.16 74.7% 
P. guajava (DCM) P52 2.92±1.45 80.9% 
C. papaya (EA) P63 2.14±0.83 86.0% 
C. citratus (DCM) P72 1.96±0.71 87.2% 
V.amygdalina (DCM)                              P82 0.64±0.39 95.8% 
 
 




The percentage growth inhibition of each extracts and control on day 4 of the 
treatment was calculated using the formula below: 
 
% growth inhibition=   Parasitemia of negative control- Parasitemia of test sample  X 100 
                                                    Parasitemia of negative control                                             
 
 
6.2.1   Results and Discussion 
 
Treatment lasted for four days and thereafter mice were monitored and 
parasitemia checked regularly.  Percentage parasite suppressions of 74.7%, 
80.9%, 86.0%, 87.2% and 95.8% were recorded by C. limon, P. guajava, C. 
papaya, C. citrates, and V. amygdalina respectively on day 4 of treatment. The 
extracts of four plants (P. guajava (DCM), C. papaya (EA) C. citratus (DCM) 
and V. amygdalina (DCM) significantly inhibited the growth of the parasites. 
The percentage inhibition of of C.limon extracts compares well with that of 
chloroquine in this study (Table 6.2.1).  These extracts showed no indication of 
toxicity in rats.  There was a marked suppression of parasites by the 
dichloromethane extracts of C. citratus and V. amygdalina with growth inhibition 
of 87.2% and 95.8%, respectively (Table 6.2.1).  Previous work with the 
essential oils of C. citratus in mouse models showed a dose dependent activity 
with 86.6% parasite suppression at a dose of 500 mg/kg (Tchoumbougnang et 
al. (2005).  This is similar to the growth inhibition of C. citratus DCM extract 
(87.2%) at a dose of 800 mg/kg demonstrated in this work.  Abosi and 
Raseroka (2003) demonstrated a dose-dependent in vivo antimalarial activity of 
ethanol extracts of V. amygdalina leaf with chemo suppression of 41.5% and 
67% at doses of 250 mg/kg and 500 mg/kg, respectively using P. berghei.  A 
previous study reported that extracts from the leaves of Vernonia species have 
shown good hepatoprotective effects in mice models at doses of 500 mg/kg 
(Roy et al., 2006).   In the present work, however, there was an increase in 
parasitemia post treatment due to recrudescence. The rate at which 
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recrudescence occurred could be shown by the increase in the parasitemia of 
































Fig 6.2.7: The mean parasitemia of each group on day 7 post-treatment. 
 
        Key: P32= Citrus limon dichlromethane extract 
                            P52= Psidium guajava dichloromethane extract 
     P63= Carica papaya ethyl acetate crude extract 
     P72= Cymbopogon citratus dichloromethane crude extract 
     P82= Vernonia amygdalina dichloromethane crude extract 
 
The parasitemia of the groups treated with the dichloromethane extracts of C. 
citratus or V. amygdalina on day 7 post-treatment was lower compared to C. 
limon (DCM) and C. papaya (EA) extracts (Fig 6.2.7). C. limon demonstrated 
an increase in parasitemia comparable to that of C. papaya at 7 days post 
treatment.  Similarly, growth inhibition of P. guajava (DCM) extract compares 
well to that C. citratus and V. amygdalina (DCM) extract.  The growth of the 
surviving parasites treated with C. citratus and V. amygdalina was markedly 
restricted and most of them appeared as “dots” during the course of treatment 
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(Figs 6.2.8 and 6.2.9).  The untreated control and CQ treated mouse are shown 




Fig 6.2.8:  Thin blood smear of an infected mouse treated with V. 
amygdalina in vivo 
 
 









Fig 6.2.10:  Thin blood smear of an untreated mouse  
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The weight of the mice during the experiment was monitored and the values 
are shown in Table 6.2.2.    
 
 
Table 6.2.2: Average weight (g) of mice using the 4-day suppressive test 






Cq control mH2O P32 P52 P63 P72 P82 
0 19.84±2.06 
 
18.97±0.39 17.76±1.24 19.29±1.19 18.07±1.68 18.03±0.76 18.68±1.62 
2 19.82±2.59 
 
18.27±0.84 17.81±1.59 19.20±2.01 17.57±1.74 17.38±1.14 18.91±1.88 
4 19.68±2.92 
 
18.60±0.65 17.71±1.61 18.90±1.32 17.62±1.81 17.88±1.21 18.52±2.26 
6 20.11±3.1 
 
17.75±0.22 17.40±1.62 18.68±2.30 16.97±1.50 17.02±1.21 18.13±1.52 
8 20.99±3.14 
 
16.72±0.74 17.88±1.69 17.85±3.09 17.06±1.44 17.24±1.19 18.08±1.63 
10 20.13±2.52 
 
14.70±0.02 17.50±1.56 18.68±1.42 16.57±1.40 17.09±1.15 17.03±2.39 
14  
 
------------- 17.02±1.14 18.10±1.28 16.35±1.10 16.71±0.58 16.47±3.34 
 
 
The weights of the mice treated with C. limon appeared to be stable, however, 
parasitemia was increasing post-treatment.  This may help explain that stability 
in weight does not rule out an increase in parasitemia. The mean parasitemia of 
the groups treated with either C. papaya or C. limon was higher compared to 
the groups treated with either P. guajava, C. citratus or V. amygdalina. The 
groups treated with extracts of C. citratus or V. amygdalina appeared healthier 
than the others.  In India, the leaves of Vernonia species are traditionally used 
to treat cough.  Traditionally, V. amygdalina is used alone in the form of 
decoctions, however, other plants may be added to reduce the side effect of 
nausea which often occurs due to the characteristic bitter taste of this species 
(Ohigashi et al., 1991).  A further investigation was carried out to demonstrate 
the schizontocidal activities of C. citratus and V. amygdalina in combination 
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6.3 In vivo antiplasmodial activities of extracts in combination 
This study investigated the antiplasmodial activities of combinations of plant 
extracts such as C. papaya and C. limon, C. citratus and Vernonia amygdalina 
using P. berghei.  These plants were chosen for this combination experiment 
due to their observed activity when used singly in this study. Having 
investigated the toxicity of these plants in mice model at higher doses 
>800mg/kg, the extracts from these plants were tested in combinations, at two 
different doses (600 mg/kg and 400 mg/kg).  The first combination comprised 
600 mg/kg of each extract and the second combination was dosed at 400 
mg/kg of each extract.  The first group of extracts was the two extracts that 
gave the best in vitro activity (C. papaya (EA) + C. limon (DCM)), while the 
second group of extracts (C. citratus (DCM) + V. amygdalina (DCM)) was the 
two extracts that gave the best in vivo activity in this study.  These two groups 
were tested in combination at two different doses (600 mg/kg and 400 mg/kg), 
which were administered to the mice orally.  This was done to maintain the 
same route of administration used for the extracts singly, for a good 
comparison. The drug formulation and volume given to the test group remained 
the same as in the previous experiment with crude extracts administered singly.  
In these combinations, the group which received 600 mg/kg of each extract 
inhibited the growth of parasites more than the group which received 400mg/kg 
showing a dose dependent activity (Fig 6.3.1).  However, recrudescence 














Fig 6.3.1 In vivo slide of an infected mouse treated with C. papaya (EA) + 
C. limon (DCM) (each 600 mg/kg) on day 1 post treatment 
 
 
6.3.1 Results and Discussion 
The first group of extracts was a combination of the two extracts that gave the 
best in vitro activity (C. papaya (EA) + C. limon (DCM)).  The group which was 
dosed with 400mg/kg inhibited the growth of parasites by 59% and the group 
which received 600mg/kg inhibited parasite growth by 76% on day three of 
treatment.  The second group of extracts (C. citratus (DCM) + V. amygdalina 
(DCM)) was the two extracts that gave the best in vivo activity.  These extracts 
were combined at two different doses (600 mg/kg and 400 mg/kg).  The group 
which received 400 mg/kg showed growth inhibition of 85% on day 3 of 
treatment, while the group treated with 600 mg/kg inhibited the growth of the 
parasite by 95% (Table 6.3.1).  In the group treated with 400 mg/kg of the 
mixed extracts, it was observed that one mouse which received 300 µl instead 
of 200 µl of the dosage recorded a lower parasitemia than all others in the 
group. This suggests that the activity of the extracts is dose dependent. The 
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dose dependent antimalarial activity of C. citratus essential oil was shown in a 
previous study (Tchoumbougnang et al. (2005).   The combinations which were 
tested at a dose of 600 mg/kg of each extract showed good in vivo 
antiplasmodial activity. The mice treated with this combination showed no 
parasites after the 4 days of treatment.  On day 1 post treatment there was a 
100% growth inhibition of parasites in the group treated with C. citratus and V. 
amygdalina (600 mg/kg each), while the group that received 400 mg/kg 
recorded 87% growth inhibition (Table 6.3.1).  This shows a dose-dependent 
activity of the extracts.  The significant difference recorded by this group called 
for a repeat experiment using the same dosage and experimental conditions.   
The repeat experiment recorded 100% parasite inhibition day 1 post treatment 
as was observed in the first experiment.   Mice were monitored for >30 days. 
No recrudescence was seen in any of the mice in that group (Fig 6.3.2).  
According to WHO guidelines mice are considered cured if no parasites are 
seen ≥ 28 days of treatment (WHO, 2006).   
 
 




Table 6.3.1: Percentage parasite inhibition of the combinations in vivo  
 
Extract a+b (dose 
mg/kg) 
Parasite growth 
inhibition on Day 3 of 
treatment (%) 
Parasite growth 
inhibition on day 1 post 
treatment (%) 
Chloroquine(10 mg/kg) 71 70 
63+32 (400 mg/kg) 59 69 
63+32 (600 mg/kg) 79 76 
72+82 (400 mg/kg) 85 87 
72+82 (600 mg/kg) 95 100 
  Key: 63+32 = C. papaya (EA) combined with C. limon (DCM) 





In vivo experiment with Plasmodium berghei






63+32 (600 mg/kg each)
72+82 (600 mg/kg each)











Fig 6.3.2: The schizontocidal activity of C. papaya + C. limon and that 
between C. citratus and V. amygdalina in combination. 
Key: 63+32=C. papaya (EA) combined with C. limon (DCM) 
         72+82=C. citratus (DCM) combined with V. amygdalina (DCM) 
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Figs 6.3.3 and 6.3.4 show the slides of mouse treated with a combination of C. 





Fig 6.3.3: Thin blood smear from an infected mouse treated with P72+82 
(600mg/kg) showing no parasites >30 days post treatment. 
 












Fig 6.3.4: Thin blood smear of untreated control mouse at 7 days post 
infection 
 
The mice treated with a combination of C. citratus (DCM) and V. amydalina 
(DCM) at a dose of 600 mg/kg increased in weight by about 13% compared to 
their original weight before infection.  The weights of the group that was cured 
were monitored for 37 days post-infection to establish cure of infected mice 
according to WHO guidelines (WHO, 2006).    The rest of the other groups died 
due to increased parasitemia, including the CQ group which recorded a high 
recrudescence post treatment (Fig 6.3.2).  The only surviving group after 
eleven days post-treatment was the group treated with a combination of C. 
citratus (DCM) and V. amydalina (DCM) at a dose of 600 mg/kg.  The weight 
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Key: 63+32=C. papaya (EA)combined with C. limon (DCM) 






infection CQ mH2O 
63+32 (600 
mg//kg) 






0 22.01±1.71 23.50±1.31 25.79±0.22 24.49±1.41 23.65±1.81 24.15±1.87 
1 21.98±1.24 22.39±0.73 26.06±0.68 25.23±0.96 24.60±1.73 24.94±1.68 
2 21.88±0.73 21.91±1.26 25.77±0.83 25.05±1.01 24.47±1.55 24.64±1.79 
3 20.87±0.50 21.87±0.84 25.98±0.82 24.88±0.95 24.28±1.54 24.64±1.65 
4 21.03±1.30 22.12±0.86 24.04±0.63 24.63±0.66 22.28±0.91 23.77±1.33 
5 20.93±1.80 21.23±0.59 22.38±0.75 23.12±1.09 21.6±1.46 22.92±1.40 
8 18.47±1.18 19.7±0.87 19.28±0.91 19.28±1.06 20.95±2.14 19.36±2.41 
10 18.35±0.64  --------- 18.75±0.72 18.02±1.44 22.9±1.63 18.73±2.35 
11 17.8  ---------- 18.6±0.78 17.73±1.60 23.23±1.61 18.3±2.61 
14 ---------   ----------  ---------  ----------- 22.89±1.11 -----------  
16  ---------  ---------  ---------  --------- 23.59±0.99  --------- 
18 ---------  ---------  ---------  --------- 23.01±0.81  --------- 
23  ----------  ---------  ---------  --------- 24.11±0.86  --------- 
28  ----------  ---------  ---------  --------- 25.17±0.69  --------- 
32  ---------  ----------  ---------  --------- 25.91±0.56  --------- 
35  ----------  --------  ---------  --------- 25.86±0.82  --------- 
38  -----------  ----------  ---------  --------- 25.87±0.48  --------- 
37  ----------  ----------  ---------  --------- 26.62±0.55  --------- 
 































 Fig 6.3.5 Trend in weight of the various groups of mice post infection 
 
Key: 63+32=C. papaya (EA) combined with C. limon (DCM) 



















Discussion, Recommendations and Conclusions 
 





The traditional medicinal use of the seven plants M. sapientum, M. indica, C. 
papaya, C. limon, P. guajava, C. citratus and V. amygdalina in the treatment of 
malaria and febrile illnesses in Nigeria initiated this scientific investigation.  In 
Nigerian folk medicine, the traditional healers prepare aqueous decoctions, 
infusions, or macerations using these plants singly or in combination.  These 
plants were investigated singly in an in vitro system to determine their 
antiplasmodial activities. Antiplasmodial activities of ≤10 µg/ml were regarded 
as active in this study. Gessler et al. (1994) recommended that very good 
extracts should display IC50s of ≤10 µg/ml.   Extracts of C. papaya, C. limon, P. 
guajava, C. citratus and V. amygdalina showed activities in this range and were 
selected for further investigation.  These plants were investigated singly and in 
combination using in vitro and in vivo systems to establish their potential 
therapeutic effectiveness.   
 
7.1.1 In vitro antiplasmodial activity 
The five extracts selected after screening were chosen out of the seven plants 
collected because they showed promising in vitro antiplasmodial activities with 
IC50 ≤ 10 µg/ml, against the chloroquine sensitive (D10) and chloroquine 
resistant strains (DD2) of Plasmodium falciparum.  There was no significant 
difference in the activity of each extract against the CQS (D10) and CQR (DD2) 
of P. falciparum. Of the seven plants investigated, Musa sapientum and 
Mangifera indica were not selected for further work because of their weak in 
vitro activity. These two plants, however, have gained popularity and wide 
application in the traditional treatment of malaria and febrile illnesses in Nigeria.  
The absence of good in vitro activity could possibly mean that these plants may 
be acting as antipyretics or immune stimulants which perform better in relieving 
the symptoms rather than a direct parasiticidal activity against P. falciparum 
(Phillipson et al., 1993).  Some plants which have shown no in vitro activity 
could be active in vivo.  Some chemical compounds in plants may require being 
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modified in vivo before activity is exhibited.  Several other environmental 
factors, as well as harvesting and storage conditions, geographical location of 
plant species could also influence the secondary metabolites, thus affecting the 
bioactivity of the plants. Leaves of Carica papaya are used in the traditional 
treatment of febrile illnesses in Nigeria. This may help explain the traditional 
use of the fruits in the treatment of anaemia which could also be caused by 
malaria.  However, there is scanty data regarding the antiplasmodial properties 
of plants in this family.  
 
The investigation of these extracts singly revealed that the ethyl acetate fraction 
of C. papaya was the most active extract in vitro.  This extract recorded an IC50 
of 2.96 µg/ml and 3.98 µg/ml against the CQS (D10) and CQR (DD2) of P. 
falciparum.  C. papaya crude extract showed a high selectivity index of 249.25 
and 185.37 against the D10 and DD2 strains respectively, which indicates good 
specificity against P. falciparum.  It also shows that the recorded activity of the 
C. papaya extract was not due to cytotoxicity to the CHO cell lines. The in vitro 
antiplasmodial activity of the petroleum ether extract of Carica papaya pulp and 
rind have been reported to show IC50 values of 18.09 µg/ml and 15.19 µg/ml, 
respectively (Bhat and Surolia, 2001) against FCK 2 strain of Plasmodium 
falciparum.  Interestingly, this correlates well with the IC50 value of petroleum 
ether extract of the leaves (16.36 µg/ml) demonstrated in the present study 
against the Plasmodium falciparum D10 strain (Table 4.3.2.1).  The methanol 
and water extracts showed activities >100 µg/ml (Bhat and Surolia, 2001) which 
was similar to that observed in this study.  This is due to the inability of these 
solvents to effectively extract the active lipophilic constituents from these 
plants. 
 
 The sequential extraction carried out in all the extractions in the present study 
enabled the identification of greater antiplasmodial activity in the ethyl acetate 
fraction with IC50 value of 2.63 µg/ml when compared to other solvents. I am yet 
to come across literature data on the antiplasmodial properties of C.limon. 
 






Vernonia amygdalina in this study showed IC50 values of 3.98 µg/ml and 4.12 
µg/ml against the D10 and DD2 strains, respectively in the dichloromethane 
(DCM) extracts.  This correlates well with the activity of V. colorata Drake, V. 
myriantha Hook.f. and V. oligocephala Gardner naturalized in South Africa 
which showed IC50 values of  4.7 µg/ml, 3.0 µg/ml and 3.5 µg/ml, respectively 
against D10 (Clarkson et al., 2004).  Vernonia amygdalina leaves have 
previously been reported to show in vitro antiplasmodial activity (Masaba et al., 
2000; Alawa et al., 2003; Tona et al., 2004). Several classes of compounds 
have been isolated from these species; flavonoids, sesquiterpenes, 
triterpenoids, alkaloids, and steroids, and the triterpenes have been implicated 
in the antiplasmodial activity of this plant (Alves et al., 1997).   Vernonia 
colorata DCM root extract showed an IC50 of 6 µg/ml against the W2 strain of P. 
falciparum.  Vernolide and vernoladin isolated from the leaf extract of Vernonia 
colorata were shown to be responsible for the recorded activity in the acetone 
fraction (Chukwujekwu et al., 2009).  Vernonia species have shown antipyretic, 
analgesic, and anti-inflammatory properties (Valverde et al., 2001; Iwalewa et 
al., 2003; Mazumder et al., 2003; Cioffi et al., 2004).   They have shown 
antitumoral (Jisaka et al., 1993), antibacterial (Reid et al., 2001; Rabe et al., 
2002; Erasto et al., 2006), anti-inflammatory (Cioffi et al., 2004) and antioxidant 
activities (Erasto et al., 2007).  In vitro growth inhibition of malaria parasites 
with a value of 57.9% was recorded for the chloroform/ethanol extract (Bidla et 
al., 2004). These reports further emphasize the antimalarial potential of 
Vernonia species.  
 
 Psidium guajava is commonly used to treat malaria and diarrhea in Nigeria.  
The aqueous stem bark of this plant showed IC50 values of 10-20 µg/ml against 
the D10 strain of P. falciparum (Nundkumar and Ojewole, 2002).  In the present 
study, the activity of this plant in the petroleum ether, dichloromethane and 
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ethyl acetate extracts were found to be 15.45 µg/ml, 5.95 µg/ml, and 21.62 
µg/ml, respectively (Table 4.3.2.1).  Psidium guajava had a selectivity index (SI) 
of 25.33 and 18.61 against the D10 and DD2 strains, respectively.  The greater 
activity in the dichloromethane extract suggests the presence of active lipophilic 
agents.  The essential oils from C. citratus have demonstrated antioxidant and 
radical scavenger properties (Menut et al., 2000).   
 
7.1.2 In vitro study of extracts in combination 
Combination therapies are a vital strategy to prevent or delay resistance of 
parasites and have been approved for other multidrug resistant infections, such 
as HIV and tuberculosis.  Although the combination of compounds for the 
treatment of malaria has been recommended (White, 1998; WHO, 2001), this 
study explored the in vitro and in vivo activity of plant extracts investigated 
when combined.  Several combinations of these plant extracts were tested.  
The combination that recorded a significant enhancement in its activity in vitro 
was between the ethyl acetate extract of C. papaya and the DCM extract of C. 
limon with an IC50 of 0.83 µg/ml.  This combination was not cytotoxic to the 
CHO cell line as evidenced by a selectivity index >100.  Ngemenye et al. 
(2006) recorded the use of Carica papaya leaves in combination with 
Turraeanthus africanus (Welw.) Pellegr. belonging to the family Meliaceae, lime 
and Aframomum melegueta K. Schum. of the family Zingiberaceae in the 
traditional treatment of malaria in Cameroon.  In this study, C. papaya extract 
was demonstrated to enhance the activities of other extracts in combination.  
The dominant effect of C. papaya activity could be traceable to its high 
selectivity index for the sensitive and the resistant strain of the parasites (Table 
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7.1.3 Bioactivity guided fractionation of C. papaya ethyl acetate 
Fractionation of the ethyl acetate fraction of C. papaya by solid phase 
extraction was carried out to isolate and identify the active components.  The 
SPE extraction of the ethyl acetate fraction of C. papaya revealed the greatest 
activity in the 100% ACN concentration with an IC50 of 2.2 µg/ml.  This activity 
was very close to the activity of the parent ethyl acetate crude extract of 2.96 
µg/ml against P. falciparum.  Further purification of the 100% ACN fraction by 
HPLC yielded two peaks.  Identification and characterization of these 
compounds was accomplished using NMR and GC-MS which identified the 
compounds as two essential fatty acids namely 9,12,15- octadecatrienoic acid 
(Compound 1) and 9,12- octadecadienoic acid (Compound 2).  Compound 1 
(linolenic acid) and compound 2 (linoleic acid) with IC50 values of 3.58 µg/ml 
and 6.88 µg/ml, respectively were not as active as the ethyl acetate SPE (100% 
ACN, IC50 2.2 µg/ml) fraction or its crude extract.  This may suggest an 
enhancement of activity by other chemical constituents present in the extract. 
These essential fatty acids are very useful in the body, but cannot be 
synthesized in the body.  Essential fatty acids (EFAs) and their polyunsaturated 
metabolites are major lipid components of all tissues and they play a vital role 
in modulating the fluidity and function of cell membranes (Minich et al., 2000).  
They can be acquired through diet or dietary supplements, however, the 
quantity needed for a therapeutic dose may not be obtained in a normal diet 
due to poor yield, and low concentrations of these lipophilic compounds in an 
aqueous or similar environment.  This class of compounds has various related 
health benefits and can be prepared in large quantities from natural resources 
(Tsuzuki et al., 2004). They are also commercially available. The activity of 
linolenic acid, which is a polyunsaturated fatty acid with three double bonds, 
was higher and more selective for P. falciparum compared to linoleic acid which 
has two double bonds.  Previous work by Kumaratilake et al., (1992) 
demonstrated that the antiplasmodial activity of the fatty acids is influenced by 
the degree of unsaturation.  The work done by this group of researchers using 
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varying degrees of unsaturated fatty acids demonstrated that the 
polyunsaturated fatty acids significantly inhibited parasite growth when 
compared to the saturated fatty acids (Kumaratilake et al., 1992).  The free 
acids and their methyl esters in the present study were equipotent in their 
activity against P. falciparum and the data compare well with the observations 
of Kumaratilake et al., (1992). Since the antiplasmodial activities of this class of 
compounds are dependent on the degree of unsaturation; (Kumaratilake et al., 
1992, Kumaratilake et al., 1997), chemical modification of these compounds by 
the introduction of two or three more double bonds could be of immense help in 
increasing its activity.  Furthermore, long chain fatty acids with >18 carbon 
atoms, such as arachidonic acid [20:4(n-6)] are vital ingredients in infant 
nutrition and they serve as precursors for eicosanoids which mediate immune 
and vascular functions (Decsi and Koletzko, 1994). 
 
Further investigation of the in vivo schizontocidal activity of both compounds 
was carried out to evaluate their efficacy in a mouse model using a 4-day 
suppressive test.  The results of the in vivo experiments further demonstrate 
the antiplasmodial properties of polyunsaturated fatty acids singly and in 
combination.  The in vivo antiplasmodial activities of linolenic acid and linoleic 
acid in combination were significantly higher than those of the individual 
compounds.  This observation suggests a possible synergistic effect.  Linolenic 
acid and its methyl ester significantly suppressed the growth of parasites during 
the course of treatment with percentage growth inhibition of 70% and 76%, 
respectively.  However, there was a rapid recrudescence post-treatment.  The 
rate at which recrudescence occurred in mice dosed with linolenic acid methyl 
ester led to an investigation of its pharmacokinetic properties in a mouse 
model.  This study was aimed at evaluating its absorption, elimination rate and 








7.1.4 Bioavailability study of linolenic acid methyl ester  
Linolenic acid methyl ester was preferred to its free acid for the bioavailability 
study using the LC-MS/MS because it was readily detected by mass 
spectrometry. Previous studies have shown that the methyl esters of fatty acids 
have preferential chromatographic qualities compared to the free acids (Viron 
et al., 2000).  The molecular ion of linolenic acid methyl ester was recorded as 
293.1 [M+H]+. Linolenic acid methyl ester was extracted from plasma using the 
method adapted from Aleryani et al., (2005).  The limit of quantification (LOQ) 
was 0.132 µg/ml.  The bioavailability of linolenic acid methyl ester was 
assessed through three routes of drug administration: oral, subcutaneous and 
intravenous routes.  The compound achieved good plasma concentrations 
through the intravenous route only.  The oral and subcutaneous routes showed 
concentrations that were below the limits of quantification (BLQ), and as such 
were not used to determine its elimination rate from plasma. This suggests that 
the compound could have been metabolized or have been poorly absorbed 
(Minich et al., 1999).  Though the traditional use of the plants is by the oral 
route, the claim of therapeutic efficacy of these plants may be traceable to the 
activity of the various compounds in the mixture which may have acted 
synergistically and such interactions between extracts could help keep lipophilic 
compounds in aqueous solution.  However, the recorded lower limits of linolenic 
acid methyl ester in plasma could be due to malabsorption, oxidation, 
desaturation and elongation, which are all the end products of increased 
metabolism.   This may further indicate the need to establish the dosage used 
by the traditional healers, route of administration and possibly the optimal 
conditions necessary for effective use of these plants.  A previous study 
reported that patients with cholestatic liver disease were noted to have a 
compromised bile secretion into the intestinal lumen which negatively affects 
the absorption of adequate amount of their dietary lipids (Minich et al., 2000). 
Kobayashi et al. (1983) further pointed out that lipid absorption was reduced by 
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30% in patients with biliary atresia.   Rats with permanent biliary drainage 
showed decreased percentages in the concentrations of linoleic acid absorbed 
(Minich et al., 1999).  Cholestatic liver disease in infants alters the efficiency of 
hepatic elongation and denaturation (Socha et al., 1997; Socha et al., 1998). 
 
 These observations may help explain that the physiological state and health 
status of any experimental model could influence the experimental results. The 
intestines are the first recipients of nutrients, and microbial hydrogenation of 
these acids takes place in the lumen before they are subsequently delivered to 
other body tissues (Garton, 1961).  By virtue of their strategic position, they 
may modulate the bioavailability and biological activity of the fatty acids 
(Tsuzuki and Ikeda, 2007).  The oxidized form of these fatty acids showed 
increased antimalarial activity (Kumaratilake et al., 1997).  This may help 
explain that the in vivo activity observed after the oral administration of this 
compound may be traceable to the active oxidation products of these fatty 
acids investigated in the present study.  The presence of vitamin E, which is an 
anti-oxidant, suppresses the antiparasitic activities of this class of compounds 
(Kumaratilake et al., 1992).  This suggests that diets rich in antioxidants such 
as vitamin E could counteract the antiplasmodial effect of these fatty acids.  
This may also indicate that using this class of compounds as antimalarials will 
require that diets of experimental animals should contain no antioxidants.  
However, since antioxidants are present in most diet, eliminating them is almost 
impossible hence fatty acids are not likely to be good antimalarials.  
Kumaratilake et al. (1997) further demonstrated the significant structural 
differences between the fatty acids which induced killing by acting directly on 
the parasites, and those whose antimalarial activity are products of neutrophil 
priming.  The mechanism of parasite adherence to the neutrophils, and how 
this can result in the death of parasites, is not known.   
 
When infected mice were treated intravenously with linolenic acid methyl ester, 
parasite growth was restricted by 97%, with a 69% recrudescence 3 days post-
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treatment. A bioavailability study to determine the elimination rate of the 
compound from plasma revealed that linolenic acid methyl ester is quickly 
eliminated from plasma, with an estimated half life of 1 hour 18 minutes.  In this 
study, the highest concentrations were recorded at 1 hr post-administration 
(T1), and this concentration continuously decreased, with very low 
concentrations at T4, which was at 6 hours post administration.  This indicates 
fast elimination from plasma within the first 6 hours of administration.  A 
previous study demonstrated that the absorption of conjugated linolenic acid 
(CLnA) is slow in the rat intestine and is rapidly converted to conjugated linoleic 
acid (Tsuzuki et al., 2006).  Their report, which was based on the CLA isomers 
investigated, α-eleostearic acid (9Z,11E,13E-18:3) and punicic acid 
(9Z,11E,13Z-18:3) showed that after 1 hour of administration, the lymphatic 
recovery of the conjugated fatty acids with three double bonds was significantly 
lower compared with the conjugated linoleic acid (CLA) with two double bonds 
and they recorded that this observation persisted for 8 hours (Tsuzuki et. al., 
2006).    
 
Their study suggested that this difference in absorption of CLA and conjugated 
triene fatty acids could be due to the rapid conversion of conjugated triene fatty 
acids to CLA.  This, they further explained, was due to ∆13-saturation enzyme 
reaction which the conjugated triene fatty acids undergo as a result of their slow 
secretion from the intestine.  The study recorded a lymphatic recovery ≥ 90% 
for the most conjugated triene fatty acids investigated 24 hours after 
administration (Tsuzuki et al., 2006).  This slow absorption and rapid 
conversion to CLA could possibly be responsible for the very low 
concentrations (BLQ) of linolenic acid methyl ester in the oral and 
subcutaneous routes observed in this study.  This may also help explain the 
high rate of recrudescence observed soon after the intravenous treatment with 
linolenic acid methyl ester was completed.  In other words, the parasites gather 
more momentum even before good concentrations of the compounds are 
achieved.   
 




Another study demonstrated that deuterium-labeled ethyl linolenate (2H5-
17,17,18,18,18-18:3n-3) and deuterium-labeled ethyl linoleate (2H5-
17,17,18,18,18-18:2n-6) after oral administration in rats reached maximum 
concentrations in plasma, stomach and spleen at the time points before 8 
hours, while in the red blood cells and other internal organs, maximum 
concentration was reached at 8 hours  (Yu Hong and Norman, 2007). Similar 
observations were reported in a study with linoleic acid and palmitic acid where 
maximum concentrations were achieved at 6 and 4, hours respectively after 
bolus administration orally (Minich et al., 2000).  This may help explain that 
absorption of CLA by the oral administration is significantly different from the 
absorption of conjugated triene fatty acids, due to the fast conversion of 
conjugated triene fatty acids to CLA. It is therefore very likely that linolenic acid 
methyl ester (linolenic acid methyl ester) investigated in this study may have 
been rapidly converted to CLA (Minich et al., 2000).  In the present study with 
linolenic acid methyl ester, the maximum concentration was reached 1 hour 
post administration within 6 hours using the intravenous route. The high rate at 
which recrudescence occurred could be due to the short half life of this 
compound, and this could be averted by increasing the duration of treatment or 
by administering them 2 to 3 times a day using the four-day suppressive 
treatment.  During the in vitro combination of extracts in this study, C. papaya 
ethyl acetate fraction, from which linolenic and linoleic acids were isolated, 
acted synergistically and influenced the activity of the components in 
combination.   In the in vivo experiments with linolenic and linoleic acids, it was 
observed that suppression of parasites when the two compounds were 
combined was greater than that observed with the individual compounds. The 
in vitro antiplasmodial activity of the ethyl acetate (EA) extract may be traceable 
to the combination effect of linolenic and linoleic acids, which was relatively 
stronger than the activities of the individual compounds.  However, the 
pharmacokinetic study of linolenic acid methyl ester revealed a short half life, 
and since its fatty acid appears to be the dominant compound in the EA fraction 
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its short half life could possibly be responsible for the rapid recrudescence 
observed during the in vivo test with the parent ethyl acetate extract of linolenic 
acid.  It was also evident in this study that linolenic acid methyl ester was poorly 
absorbed in the oral and subcutaneous route of administration.  The 
recrudescence recorded in the in vivo combination study of C. papaya and C. 
limon extracts which acted synergistically in the in vitro experiment could 
therefore be attributed to the rapid elimination of linolenic acid methyl ester 
present in C. papaya ethyl acetate extract.   Poor absorbtion of this compound 
in the oral route of administration is another factor that could be responsible for 
the observed recrudescence in the oral administration of the parent ethyl 
acetate extract.  
 
                        
7.1.5 In vivo antiplasmodial investigation of extracts singly 
                       The extracts of four plants, P. guajava (DCM), C. papaya (EA), C. citratus 
(DCM) and V. amygdalina (DCM), significantly inhibited the growth of the 
parasites with percentage growth inhibition of 80.9%, 86.0%, 87.2% and 95.8%, 
respectively in a 4-day suppressive test.  The least growth inhibition was 
recorded by C. limon (DCM) 74.7% and this was close to that recorded in the 
group treated with chloroquine (10 mg/kg) with a growth inhibition of 70.5%.   
Mice treated with these extracts showed no obvious signs of toxicity at the 
concentrations tested during the course of the experiment. V. amygdalina 
extracts have been reported to act dose dependently (Anoka et al., 2008).    In 
a 4-day suppressive test, the ethanol leaf extracts and root bark of V. 
amygdalina suppressed parasites by 67% and 53.5%, respectively (Abosi and 
Raseroka, 2003), at a dose of 500 mg/kg and 250 mg/kg.   In the present study, 
there was a marked growth inhibition of parasites with values of 87.2% and 
95.8% by the dichloromethane extracts of C. citratus and V. amygdalina, 
respectively at a dose of 800 mg/kg.  This suggests that these extracts could be 
acting in a dose-dependent manner.  The growth of the parasites treated with 
C. citratus and V. amygdalina was highly restricted, and most of them appeared 
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as “dots” during the course of treatment.  The two groups of test animals 
treated with either of these two extracts outlived all others, including the group 
which received chloroquine.  Recrudescence was delayed in the groups treated 
with C. citratus or V. amygdalina when compared to other groups.  The in vivo 
activity of C. citratus has been reported to show IC50s from 6-9.5 µg/ml with a 
20 µg/ml chloroform/ ethanol extract (Tchoumbougnang et al., 2005).   
 
7.1.6 In vivo study of extracts in combination 
7.1.6.1 Combination of C. papaya and C. limon 
The extracts investigated in combination were in two groups.  The first group 
(C. papaya + C. limon) was selected based on their activity in vitro with an IC50 
of 0.83 µl/ml, and the second group was a combination of the best extracts in 
vivo (C. citratus + V. amygdalina).  Two groups of mice were treated with each 
combination at two different doses (400 mg/kg and 600 mg/kg).  These plant 
extracts were not cytotoxic at the concentrations tested, rather, they showed a 
dose-dependent activity.  The combination of C. papaya + C. limon recorded a 
significant suppression of parasites at a dose of 600 mg/kg each (76%) but was 
met with recrudescence on day 1 post-treatment.  This result may help explain 
why the in vitro activity does not mean that the chemical compound is equally 
active in vivo (Phillipson et al., 1993).  This is because some physiological 
factors and immune response that are inevitable in an in vivo system are not 
applicable in the in vitro experiment.  In the in vivo system, the effectiveness of 
the extracts is partly influenced by factors such as the gastrointestinal uptake, 
oxidation of active compounds and half-life in plasma (Franssen et al., 1997).  
The in vivo activity to a large extent is influenced by pharmacokinetic, as well 
as pharmacodynamic, properties of the chemical compounds.   The aqueous 
decoctions from these plants used in the traditional treatment of malaria have 
not been reported to show cytotoxic activities.  Aqueous decoctions may 
contain low concentrations of active constituents which could account for the 
reduced toxicity (Kirby et al., 1996).   In this study, these plants showed no 
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toxicity to mice, however, the evaluation approach used here is likely to 
demonstrate acute toxicity and not chronic effects of the extracts on vital 
organs in the body such as the brain, liver, kidney, or even the central nervous 
system.  Assessment of the functional state of these organs, size and shape, 
as well as full blood count, may offer a better and more reliable assessment of 
in vivo toxicity. 
 
7.1.6.2 Combination of C. citratus and V. amygdalina extracts 
An exciting result was recorded in the combination between C. citratus + V. 
amygdalina at a dose of 600 mg/kg each.  The mice treated with this 
combination showed no parasitemia after treatment in the 4-day suppressive 
test.  The animals were monitored for >30 days and no recrudescence was 
observed in any of the mice.  Their weight also increased by 13% of the original 
weight before infection.  A repeat experiment recorded the same result.  WHO 
recommended that treated mice should be considered cured if no parasites are 
seen after ≥28 days of treatment (WHO, 2006).  This result shows that the 
combination of C. citratus + V. amygdalina DCM extracts cured mice infected 
with P. berghei using a 4-day suppressive test. V. amygdalina has also been 
shown to enhance the in vivo activity of chloroquine (Iwalokun, 2008).  The 
plants investigated in this study are traditionally prepared as aqueous 
decoctions which involve boiling the plant and drinking the extract. Moreso, the 
traditional healers make use of these plants in their fresh state.  Poor activity of 
the water extract from plants has been shown in several studies (Francois et 
al., 1996, Clarkson et al., 2004).   The water extracts of plants investigated in 
this study showed very weak in vitro activities with IC50 values >50 µg/ml (Table 
4.3.2.1). It could be possible that preparing these plants in their fresh state, 
following the traditional recipe which involves boiling for several hours may 
have increased their activities. However there is a possibility of denaturing 
some active components in the crude extracts since their heat tolerance has 
not been established. Stronger antiplasmodial activities were mostly displayed 
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by the dichloromethane extract, with the exception of C. papaya, where activity 
was shown in the ethyl acetate fraction.  This may help explain why the 
aqueous extracts showed no activity since the active lipophilic components 
from these plants were extracted with the non-polar solvents.  This could 
suggest that the claim of therapeutic efficacy of these plants may be traceable 
to the activity of the various compounds in the mixture which may have acted 
synergistically and such interactions between compounds could increase their 
solubility in an aqueous environment.  The ideal animal model that could 
display precise clinical characteristics of human malaria is not yet available.  
However, the murine model of PbA in (BALB/C x 57BL/6) has shown several 
features in common with human cerebral malaria (Hearn et al., 2000).  Results 
from the use of these models may not be directly extrapolated to humans. They 
can only be predictive since major differences exist between the small 
mammals and humans. 
 





The primary objective of investigating the chemotherapeutic effectiveness of 
these extracts in the treatment of malaria was achieved in this study.  Out of the 
seven extracts investigated in an in vitro system, M. sapientum and M. indica 
were inactive with IC50 >50 µg/ml and further work with them was discontinued. 
The active five extracts tested in the in vitro experiment as single entities 
exhibited antiplasmodial activities with IC50 <10 µg/ml against the sensitive 
(D10) and resistant (DD2) of P. falciparum.  The extracts were not cytotoxic 
with CHO cell line at the concentrations tested.  C. papaya ethyl acetate 
showed good antiplasmodial activity of 2.96 µg/ml and a high selectivity (>100) 
to Plasmodium falciparum.  In vitro testing of these extracts in combination 
revealed a combination of the extracts of C. papaya and C. limon with an IC50 
of 0.83 µg/ml.   The potency of these extracts was enhanced by combining 
them.  It is therefore recommended that researchers should exhaustively 
explore the in vitro properties of extracts in combination before considering 
them inactive.  A follow up investigation of the ethyl acetate extract of C. 
papaya revealed that the long chain polyunsaturated hydrocarbons that were 
responsible for the recorded activity are the essential fatty acids (linolenic and 
linoleic acids).  
 
The linolenic acid methyl ester showed an IC50 of 3.58 µg/ml and 4.40 µg/ml 
with a selectivity index greater >10.  The activity of this class of compound is 
partly influenced by the degree of unsaturation (Kumaratilake et al., 1992).  
Chemical modification of this compound by the introduction of additional double 
bonds could enhance its activity. The oxidized form of these fatty acids showed 
increased activity (Kumaratilake et al., 1997). Therefore chemical oxidation of 
this class of compounds could also enhance efficacy.  Recently, researchers 
have reported the medicinal properties of this class of compounds (Sala-vila et 
al., 2006; Ren-Wang Jiang et al., 2008), therefore a thorough investigation of 
their biological activities is recommended.  Some of these polyunsaturated fatty 
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acids could be obtained naturally in diets, natural products or food 
supplements. However, the quantity may be grossly insufficient for therapeutic 
doses and effort to reduce the lipophilic properties of this class is necessary.  
The linolenic and linoleic acid and their methyl esters investigated are 
equipotent and are commercially available.  The linolenic acid methyl ester has 
better chromatographic behaviour than the free acid, and thus was used for the 
bioavailability study. The bioavailability study of linolenic acid methyl ester 
showed that it is best administered intravenously and showed good 
concentrations in plasma.  However, due to its short half- life as revealed in the 
pharmacokinetic study, recrudescence occurred rapidly in mice after a 4-day 
suppressive treatment.  It is recommended that treatment with this compound 
be given 2 to 3 times a day and for a longer duration, and possibly be evaluated 
in combination with existing antimalarials.  This is necessary because in 
addition to acting directly on the parasites, these fatty acids and their methyl 
esters could activate the neutrophils and their effector cells thereby enhancing 
their antimalarial properties (Poulos et al., 1991).  Combinations of this nature 
with a different mechanism of action and similar half-life are vital tools 
necessary to fight, prevent or delay resistance, as well as to augment cure 
rates.  Artemisinin combination therapies have been highly recommended by 
WHO in the treatment of malaria (WHO, 2001). 
 
It would be necessary to use animal models to validate the therapeutic efficacy 
of extracts or chemical agents.  In this study, the combination that cured mice 
infected with P. berghei was not the combination which gave the best activity in 
vitro.  This research could help to justify that in vitro antiplasmodial activity 
should be confirmed by in vivo studies in experimental models.  The 
extrapolation of in vitro results to in vivo efficacy is not encouraged.  This is 
because the in vivo system is more complex than the in vitro system which is 
closely controlled.  Traditional remedies which have been the source of 
antimalarial agents are prepared mostly in aqueous environment.  They have 
played indispensable roles in drug discovery and have been readily accessible 
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where pharmaceuticals are unavailable, inaccessible, or expensive. However, 
in this study, these plants were extracted using different solvents with varied 
polarities.  The strong activity of the DCM extract shows that the active 
components are lipophilic and may not be extracted by water.  The hot water 
treatment of these extracts could extract lower concentrations of these active 
lipophilic components, but may not be available at therapeutic doses.   This 
result may help explain the increase in parasite survival despite continuous 
treatment with herbal remedies. The number of existing antimalarials is still 
inadequate especially in the face of parasite resistance.  It is therefore highly 
recommended that researchers should explore more of the antiplasmodial 
properties of extracts in vivo for more potent antimalarial remedies.  Good ideas 
of plants to explore could be obtained from the traditional healers who use them 
locally to prepare herbal remedies.  It is therefore necessary for the traditional 
healers and the scientific community to work in collaboration.  Since the 
traditional healers are patronized by the majority of the populace in developing 
countries, such a relationship will help the traditional healers to know the 
dosage and duration of treatment that could be toxic to humans, and also the 




This study has demonstrated that the extracts from the leaves of these Nigerian 
plants investigated are potential sources of antimalarial compounds.  That the 
activities of these plants investigated were seen in the leaves is also of interest 
since it does not endanger the plants species.  This work has revealed a 
combination of two extracts from Nigerian plants that cured mice infected with 
P. berghei.   To the best of our knowledge this is the first study which has 
shown that mice infected with P. berghei could be cured by a combination of 
the two Nigerian plants C. citratus (DCM) and V. amygdalina (DCM) at a dose 
of 600 mg/kg using a 4-day suppressive treatment.  Nigeria has a rich flora and 
fauna which are yet to be explored.  Exhaustive exploration of the combination 
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potentials of plant extracts should form part of any drug development program.  
Such extracts with curative potentials could be further investigated and clinically 
tried in a controlled study. The results of this study could help encourage more 
identification and validation of natural products which has shown antiparasitic 
properties thus facilitating the development of a new generation of 
antimalarials.  Quinine and artemisinin are products based on the documented 
use of medicinal plants in treating malaria.   However, that the disease is still 
endemic in Nigeria where the majority of the populace patronize traditional 
healers could suggest the possibility that these healers may not have 
administered the right dosage (since they could be dose dependent as 
observed in this study).  It also could be that the right combinations were not 
given.  The presence of active lipophilic compounds which may not be 
extracted in water as practiced traditionally is another hindrance to its 
antimalarial activity.  Very importantly also, the duration of the treatment could 
play a vital role.  Collaboration between the natural product scientists and the 
traditional healers could be of immense help and that could assist traditional 
healers to administer the right doses to avoid the risk of toxicity that may result 
from these herbal remedies.  This active combination is a product of this study, 
and since it has not been proven clinically, the observed efficacy in a mouse 
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Drug -Parasite interaction of P72
during and post treatment


















Drug -parasite interaction of P82
 during and post treatment






















Drug -parasite interaction of P32
during and post treatment


















































Drug-parasite interaction of P52















Drug -Parasite interaction of P72
during and post treatment

























In vivo experiment with Plasmodium berghei



















In vivo experiment with Plasmodium berghei






































































































































































































































































































































































                       



























Mass spectrometry data of linolenic 










Sample Name: "STD 1"    Sample ID: ""    File: "1033.wiff"
Peak Name: "293"    Mass(es): "293.2/67.1 amu"
Comment: ""    Annotation: ""
Sample Index:       1     
Sample Type:     Standard  
Concentration:      6.25    ng/mL  
Calculated Conc:    6.72    ng/mL  
Acq. Date:       10/17/2009  
Acq. Time:       2:40:02 PM  
 
Modified:           No    
Proc. Algorithm: Analyst Classic  
Bunching Factor:    1     
Noise Threshold:    4.25   cps
Area Threshold:   21.23   cps
Num. Smooths:       5     
Sep. Width:         0.20  
Sep. Height:        0.01  
Exp. Peak Ratio:    5.00  
Exp. Adj. Ratio:    4.00  
Exp. Val. Ratio:    3.00  
RT Window:         30.0    sec
Expected RT:        1.26   min
Use Relative RT:    No    
 
Int. Type:       Base To Base  
Retention Time:     1.27   min
Area:         101000.   counts
Height:          14500.  cps
Start Time:         1.09   min
End Time:           1.58   min























































 +Q1: 0.480 min from Sample 1 (TuneSampleID) of MT20090528142247.wiff (Turbo Spray) Max. 3.9e5 cps.







































277.2 290.8 323.3 331.3283.0 303.1 329.1245.2 284.5 332.8294.7265.2 313.2296.1274.7 321.4304.3270.3 341.3251.1




 Fig A25 Q1 mass spectrum of linolenic acid methyl ester showing 
























 +MS2 (293.22) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Methyl linoleate B_InitProduct_Pos.wiff (Turbo Spray) Max. 9.2e4 cps.

















































191.0 214.8161.4 251.2 275.2
 
 
Fig A26: Product ion mass spectrum of linolenic acid methyl ester showing 





























 +Q1: 0.468 min from Sample 1 (TuneSampleID) of MT20090528140459.wiff (Heated Nebulizer) Max. 5.9e5 cps.


































285.2 291.2 312.2273.1 290.2
277.1 299.2272.1 309.2298.2293.1 313.2
280.1 282.1 319.3305.2270.6 287.2
307.2273.7 289.2




























 +Q1: 0.553 min from Sample 1 (TuneSampleID) of MT20090528140020.wiff (Turbo Spray) Max. 6.1e5 cps.





























301.1263.3 314.2252.9 285.0 333.3
342.4294.7266.9 304.8245.2 323.0 331.1271.0 319.1277.0265.0259.0255.7 306.1 311.3281.0 293.3 297.3289.1254.4 334.8 341.0
 
 
Fig A28 Q1 mass spectrum of linoleic acid methyl ester showing 



























 +MS2 (295.15) CE (50): 26 MCA scans from Sample 1 (TuneSampleName) of Methyl linoleate A_InitProduct_Pos.wiff (Turbo Spray) Max. 7.2e4 cps.


































139.2 163.2 171.2 193.0 199.0 219.0228.4 249.0160.8
 
 
Fig A29: Product ion mass spectrum of linoleic acid methyl ester 
showing the   most abundant product ion at m/z 57.0 
Most abundant product ion 
